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1
GeNerAL INTrODuCTION AND OuTLINe Of THe STuDIeS
Chronic obstructive pulmonary disease (COPD) is a very common chronic 
disease in developed western countries where it reaches an estimated prevalence 
of 2 - 4 % of the population. In other countries spread over all continents, COPD 
is prevalent also in high numbers. Exact figures are lacking because large epide-
miological studies often use self-reporting of a doctors diagnosis, which may set 
back their reliability compared to the identification of cases performed by 
clinicians. The latter ones are based upon spirometric evidence, although 
definitely not always when general practices are concerned. Moreover, 
underdiagnosis, mainly through motivational factors in individuals at risk is 
another common problem in estimating true prevalence rates. Eventually, the 
aetiology of steady, long-lasting inhalational exposure to noxious gases, 
especially tobacco smoke, means that nearly all populations in the modern world 
are threatened of getting affected.
 COPD is a complex disease in that it starts insidiously, alerting the patient 
with bothering symptoms late in its course. In early stages the affected 
individuals usually think that mild manifestations are caused by other, more 
common, temporary illnesses such as common colds or attacks of influenza or 
pneumonia. Not rarely they even neglect the link with disease by blaming their 
smoking habit for coughing and/or phlegm production. Because these symptoms 
are not considered seriously threatening, the progression of COPD often is not 
halted by change in lifestyle or avoidance of occupational exposure which 
nowadays also includes motor vehicle exhaust.
 So to say, the early phases of COPD development are characterized by an 
asynchrony of components: on the one hand the gradual pulmonary impairment, 
and on the other the course of cognitive, emotional and behavioural processes. 
The former, developing steadily from the early beginnings onward, is dominated 
by slowly increasing airflow obstruction and, in its wake, gas exchange 
abnormalities with, in the end, cor pulmonale. This has been conceptualized 
visually by Decramer in a simple but clear diagram with an emphasis on the 
early pathways. It supposes the onset of symptoms at the very end of the disease 
history. According to previous work on the subject of Health Related Quality of 
Life/ Health Status in COPD, it can be questioned whether subjective complaints 
should not be situated earlier on this time line, instead of after the radiologic and 
lungfunctional abnormalities have been manifested. Many clinicians and 
researchers noticed that some people suffer a substantial burden of complaints 
or impairments in the presence of only mild lungfunctional disturbances. Even 
more surprising is the recognition of the reverse: little discomfort in the 
presence of severe lung function impairment. So, in fact, there is no simple linear 
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relationship between disease progression and the onset, time course and 
severity of its manifestations.
Fortunately some of the persons at risk, when still asymptomatic, are diagnosed 
early by attending a spirometry test administered for various possible reasons, 
which illustrates nicely this disparity. Hence the disease is above the subclinical 
level of experience, psychological mechanisms enter the scene evolving various 
emotional and behavioural features. Depending on how these factors interact 
with the physiological impairment and with each other in the individual patient, 
the clinical presentation is formed. By this interaction the clinical picture reveals 
its unique composition of complaints, disabilities and quality of life. These may 
emerge, in a variety of single severities, early as well as later on in the course of 
COPD. Most typically such manifestations are seen rather late relative to 
reduction in lung function, due to the late appearance of the key symptoms 
cough, dyspnoea and sputum expectoration. Because it has been shown that 
physiological impairment in the lungs correlates only weakly with complaints, 
disabilities and quality of life no characteristic pattern of sequences exists. 
The early pathophysiological signs of COPD and its progression have been 
studied extensively during the last 4 decades. The cognitive, emotional and 
behavioural aspects drew attention only about the last 2 decades by scientific 
From Decramer and Cooper, Thorax, 2010 65: 837-841. Conceptual diagram of disease progression 
in chronic obstructive pulmonary disease (COPD).
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research, and are now more and more considered important outcomes. It should 
not wonder that these aspects have an origin of their own when the weak 
correlation between these aspects and lung function are memorized. Studies not 
involving data about quality of life aspects are becoming rare in COPD as well in 
other illnesses. This is due to the growing awareness among clinicians that at 
last, people with complaints about their health ask their doctors to do and feel 
better. To that goal their bio-psychosocial context should be taken into account. 
With an emphasis on pathophysiological aspects only, chest physicians do not 
sufficiently meet the needs of patients. In recent years it was increasingly 
recognised that quality of life as an additional outcome parameter should be 
incorporated in clinical studies which evaluate therapeutic interventions. Since 
this understanding had emerged, several instruments to assess quality of life 
have been developed. Remarkably, there is very little uniformity in the domains 
of health that are covered by these instruments, and as a consequence, a variety 
of health domains are represented by the different measurement tools now 
available (1) (2). In a rather random series of 4 studies on exercise capacity and 
health status for instance, already 9 different instruments are encountered  (3) 
(4) (5) (6), not to mention the additional subscales for evaluation of specific 
aspects of psychological or social functioning. 
 So there are two main reasons to improve assessment of health in COPD. 
First, the variety of actual instruments do not cover all important aspects of 
what has to be considered health status, and secondly, patients health should be 
described in terms of both physiological and psychosocial terms. Therefore an 
integration of existing tools must be accomplished. These considerations were 
at the cradle of developing such an assessment method. For the studies that 
compose this thesis, health status was redefined in an original way in an attempt 
to delineate which aspects of health are most relevant for patients with COPD. 
This was achieved by theoretical as well as empirical means. Thereafter, in this 
thesis, study questions were addressed regarding the relationships of important 
clinical topics in COPD with that broad concept of health status.
 In the next paragraph first a brief summary is given of the historical path 
that the term health status has gone through.
Health Status: history, meaning and validation of its assessment
From a historic viewpoint health status is only recently introduced in the area of 
pulmonary medicine. In other fields of medicine, in general practice in particular, 
it has a longer history, somewhere originating after the second world war. A 
WHO (World Health Organization) definition of health, taking back to 1948, 
defines health not merely as the absence of disease, but broadens its concept to 
the complete physical, mental and social wellbeing. This now seems rather 
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idealistic and may be too far to be in reach, but as an official statement still holds 
into the present time. Attempts to define health in a more appropriate way take 
into account the changed profile of diseases and demographic features since the 
approval of that health definition long ago. With the ever enhancing availability 
of high-tech diagnostic tools to detect pathophysiological, morphological, 
biochemical or molecular and genetic changes in early-phase bio-medical 
processes, there may rise a serious threat by labelling people ill who would be 
healthy if not (yet) tested by the high-performing detection methods of our days 
(7). In other words, people may be marked ill, before relevant clinical 
manifestations have emerged. Also, the large amount of people with chronic 
illnesses are treated as patients irrespective of the degree in which they are 
adapted to their physical impairments. This is of special interest in people of 
older age, who are still increasing in number.
 The WHO definition encompasses at least three domains of life: the physical, 
mental and social domain. This construct of health status, in spite of criticism of 
its further implications, has in fact not been doubted over the years. In clinical 
research however, the focus often lies at issues that are popular from the 
perspective of the medical model, i.e. attention to diagnosis, medical treatment 
and prognosis, and so is disease-centered. These aspects of health are all within 
the boundaries of the domain physical. Results frequently, if not always, are 
described as statistically significant changes or differences, but individual 
patients do not perceive mathematical parameters. It is not long ago that a 
‘clinically meaningful change’ was introduced in medical research, to pursue 
positive effects of therapeutic interventions that are thought important in the 
lives of individual patients. Gradually, the attention is turned towards ‘patient-
centered outcomes’.
 Until the early 80-ties of the previous century the broader concept of health 
status, rooted in the WHO definition, is hardly encountered in clinical medicine. 
From that time on terms like health related quality of life and quality of life 
begin to take their place in pulmonary medicine and other medical disciplines. 
One dedicated pioneer should be mentioned here: P.W. Jones, who was one of the 
first to develop concepts regarding health status in respiratory medicine, and 
proposed an instrument that is known as the Saint Georges Respiratory 
Questionnaire. In his opinion health status measurement should offer a 
quantitative, objective and standardized manner of evaluating “the impact of 
the disease on patient’s daily life, health and wellbeing” (8). Probably the 
collaboration with researchers from the social sciences such as psychologists, 
have paved the way to develop a broader concept in clinical medicine, generally 
indicated by the bio-psycho-social model.
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 Health status is a term now commonly used in respiratory medicine, in 
which it has been introduced without a clear definition of what it means and so 
deserves some explication here. To this aim two other terms from which it 
should be discriminated, and are already mentioned above, are outlined 
concurrently. Quality of life (QoL), to begin with, refers to the feeling of wellbeing 
or satisfaction with life in general. The second, Health related quality of life 
(HRQL) is part of QoL, and therefore smaller in range, in that it accounts for 
satisfaction with health, being just one aspect of quality of life in general. 
Because these are different concepts, they are rated independently. As a 
consequence, any patient has his own unique profile of these different health 
domains. For example, low HRQL may combine with good QoL, and the reverse, 
among other possibilities, may be presented too. Health status, lastly, is a much 
broader concept than QoL and HRQL, and comprises the degree of physiological 
impairment, and its expressions leading to bothering the patient by symptoms, 
functional impairments (for instance not being able to continue going out for 
shopping because of limited exercise capacity) and diminished QoL ( based on 
Wilson and Cleary (9) and (10). In this concept, evidently, also patient-oriented 
aspects are represented and to this extent it resembles the WHO definition of 
health. The three concepts mentioned should not be confused since they are 
conceptually different and so they mean different things. This is not the same as 
saying that scientific reports on the matter excel in consensus regarding these 
terms. Quite the opposite. Anyone who is a faithful follower of biomedical 
literature is rapidly overwhelmed by the multiplicity of methods to assess health 
status, or Health Related Quality of Life as it is more often designated. Not 
surprisingly, the view on the distinguished concepts of these terms is foggy. As 
they are designed basically by putting a list of questions at patients and asking 
them to answer, the variety in psychometric properties can be expected to be 
high, not in the least because many examples of previously used questionnaires 
are translated for application in other language areas than in which they were 
conceived. However, a small number of these have gained appreciation sufficiently 
to be applied frequently in international scientific reports. Silently, and unofficially, 
they have reached the status of standard instrument. That is not to say that the 
validation process is far beyond criticism in all instances. Rather it seems that 
feasibility in clinical studies, attraction, and familiarity with presentation 
helped to select them by fellow researchers. 
 Various examples are met in the literature, that illustrate the simple borrowing 
of validation of one questionnaire from a somewhat older, already accepted 
instrument (11) (12) (13). When two such instruments correlate with a coefficient 
≥ 0,7 the proposed new instrument is presented as validated (14). However, 
instruments to measure quality of life or health status still are devoid a true gold 
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standard. Therefore the range of instruments whose application one has seen 
coming forth in recent years is hard to approve or disapprove. Besides, even 
lower correlations then 0,7 are used to prove new instruments valid. Whatever 
is the height of the correlation, validation also depends heavily on conceptual 
similarity, and this aspect is often missing.
In this thesis the broader and comprehensive concept of health status is in the 
spotlight of several studies, in order to explore the interrelationships with 
common clinical aspects of COPD. To that purpose a new assessment method 
was introduced that promised to cover many important aspect of health status, 
springing from the concept proposed by Wilson & Cleary, and Taillefer.
empowering the studies on health status. review of the 
development of a new assessment method
Some years before the start of this thesis initiatives were taken to develop an 
instrument that could represent both the well-known pathophysiological 
condition of patients with COPD, and other domains of health status, in line with 
the bio-psycho-social model. It started with a working group ‘assessment’, 
recruited from all disciplines of a pulmonary rehabilitation centre associated 
with Radboud University Nijmegen. This was composed of nurses, some of them 
specialized in respiratory care, physiotherapists, psychomotor therapist, 
psychologist, a social worker, chest physician, respiratory physiologist and a 
dietician. The working group provided information from clinical practice and 
empirically derived knowledge that was used to define preliminary sub-domains 
within main domains physiological functioning, complaints, functional 
impairments, and quality of life. These domains are based on a theoretical 
framework of health status (9) (15). 
 After discussing the preliminary sub-domains of health status in the working 
group, existing instruments were selected to measure the proposed sub-domains. 
Common pulmonary function tests were chosen including exercise testing, 
muscle strength, and measurement of fat free mass to compose the main domain 
Physiological Functioning (10). In a stepwise approach all variables that should 
hypothetically be attributed to the sub-domains, were subjected to factor 
analysis. This method played a major role in constructing an assessment model 
of health status. In addition, several statistical methods were used to ensure the 
best possible reliability and validation (10).
 
Essentially, factor analysis puts together in one (main) domain or, at another 
level, in one sub-domain, what is conceptually alike, and separates what is 
apparently different. The resulting framework of health status aspects was 
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named the Nijmegen Integral Assessment Framework (NIAF). This is 
characterized by 4 main domains and 15 relative independent sub-domains. 
This implies that each sub-domain represents a unique aspect of a patient’s 
health status. Main domains are Physiological Functioning, Complaints, 
Functional Impairments and Quality of Life (10). In the finishing phase of the 
NIAF Fatigue was appended as additional unique sub-domain in main domain 
Complaints, resulting in 16 sub-domains in total.
STuDy OuTLINe
In the first study (chapter two) it was evaluated, using the NIAF as an assessment 
instrument, to what extent the Global initiative for chronic Obstructive Lung 
Disease (GOLD) classification is discriminating differences in health status. 
GOLD classes were recommended lately to create some global standard frame, 
by which patients with varying stages and severity of health problems can be 
easily clustered, based on a simple measurement available to any physician at 
any place in the world. The underlying meaning was to collect clinical data from 
studies all over the world, divided into one of four ranges of the FEV1 %predicted, 
so as to accelerate useful knowledge about the increasing burden of COPD 
victims. Because clinical experience withstands the idea that much differentia-
tion in severity or clinical presentation can be foreseen by FEV1 category, the 
value of the GOLD principle was tested by means of the newly developed 
assessment tool of Health Status. For it is reminded that the NIAF covers many 
more health aspects than spirometric values alone. 
In chapter three the NIAF was used to examine the value of maximal oxygen 
consumption at Cardio Pulmonary Exercise testing with respect to all health 
aspects that it contains. In this study 129 patients with COPD were recruited 
who fulfilled the criteria of inclusion. An important criterion was the 
uninterrupted cycle ergometry till maximum exercise. Such an incremental 
exercise test with VO2 max as the key parameter, is generally considered to have 
much value in reflecting health status (HS). Moderate to strong correlations (up 
till 0.60) with varying measures of health status are reported in the literature, 
like subscales of the SGRQ instrument, measures of daily activity or Chronic 
Respiratory Questionnaire. Other HS aspects, except physiological correlates 
such as FEV1, show lower correlations with exercise capacity. Because health 
status was rarely assessed in a comprehensive way similar to the NIAF concept, 
it was thought necessary to delineate the value of VO2 max within the full array 
of health status sub-domains.
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Chapter four deals with the commonly seen loss of muscle mass in patients with 
severe forms of COPD. Weight loss is a hallmark of this subgroup. It is estimated 
that some 15 to 30% of patients may present with weight loss at some time point 
of their disease. Not necessarily this is restricted to the severe and very severe 
stages of COPD. Mechanisms of this manifestation has been tried to describe, but 
still there is considerable debate whether it should be regarded as a consequence 
of systemic inflammation affecting the protein synthesis/breakdown ratio 
together with imbalance of caloric intake, or as a result of atrophy of muscle 
tissue due to inactivity. Consequences of muscle depletion with respect to 
muscle strength and endurance of exercise are well documented and are not 
doubted. Less evident is the question whether muscle depleted patients 
experience lower levels of health status. Some reports seem to favour this 
viewpoint, but recent studies found no such associations. The large diversity 
and apparent random use of HS instruments, claiming to measure health related 
quality of life and/or quality of life, furthermore, is drawing clouds over this 
issue. We tried therefore to clarify the question whether decreased muscle mass 
is correlated with low HS sub-domains. It was postulated that it is correlated 
with some physiological parameters as part of the main domain Physiological 
Functioning, not with non-physiological sub-domains belonging to the other 
three main domains. In addition, further attention was paid to gender as a 
possible determinant of muscle wasting, as former studies reported significant 
higher prevalence rates for women. Details are given in chapter four.
In chapter five the focus lies on the clinical importance of acute exacerbations 
of COPD (AECOPD), especially with respect to the frequently stated negative 
effect it has on HS. The question leading to this study was: can AECOPD worsen 
the HS, when using a comprehensive HS instrument. Studies up till now have but 
one conclusion regarding the impact of exacerbations of COPD on HS: it gets 
worse, especially in frequent exacerbators. When studying the literature on this 
subject several issues draw  attention.
 First, reliable scientific evaluation of effects of therapy and of health in 
general, is greatly challenged by the definition of an exacerbation, whether the 
effect parameter may be mortality or lung function deterioration, or more 
specific areas of health status like perceived impairments. Not any satisfactory 
definition has been put forward that meets objective criteria, obviously because 
there is no single laboratory test to detect and identify exacerbations. Neither a 
combination of test results can be collected which fulfils the criteria for 
sensitivity and specificity. One still has to rely on criteria dependent on clinical 
judgment, either by the physician or the patient himself, in the lack of a diagnostic 
gold standard.
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Second, as holds for other areas of research on Health Status issues, the field of 
exacerbations has been flood with many different instruments to measure it 
(16), (17), (18), (19), (20). This should make one reluctant to draw conclusions all 
too quickly. Moreover, deserving a third comment, some studies, if read with care, 
provide data that suggest that some Health Status parameters do even ameliorate 
over time (17), (18).
 Because our data set was expanded with a longitudinal follow up with 
regular administered questionnaires concerning complaints and therapy, we 
were able to design a study that might give more firm answers than hitherto. 
The recordings by the patients included short term changes in severity and 
resulting therapeutic decisions. These questionnaires were designed to provide 
data sufficient to study exacerbations by a symptom-based definition, derived 
from the classical work of Anthonisen  (21) as well as an event-based definition. 
The difference between the two was first outlined and labelled by Pauwels et al. 
(22). During evaluation of the results the event-based definition was chosen for 
analyses because of its advantage being more objective than the symptom-based 
ones. In the first draft of this study, it even was concluded that the symptom-based 
definition had hardly nothing to add to a description of the state of health 
captured in merely subjective terms. Therefore the event-based definition, 
sustained by an evaluating physician with clear therapeutic decision, was 
selected for answering our questions. Subsequent to the question in the study 
above, we hypothesized that some Health Status aspects would show 
deterioration along with exacerbation frequency. The study details are 
elaborated in chapter five.
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ABSTrACT 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) serves as a 
guide to treat and manage different severity classes of patients with COPD. It 
was suggested that the five categories of FEV1 % predicted (GOLD 0–4), can be 
applied for selecting different therapeutic approaches. However, validation of 
these selective properties is very poor. To determine the relevance of the GOLD 
staging system for estimating the severity of clinical problems, GOLD 2 (n=70) 
and GOLD 3 (n=65) patients were drawn from a prospective cohort of patients 
with COPD and evaluated cross-sectionally by a newly developed Nijmegen 
Integral Assessment Framework (NIAF). The NIAF is a detailed assessment of a 
wide range of aspects of health status (HS). Significant, though small, differences 
were found in Static lung volumes, Exercise Capacity, Subjective Pulmonary 
Complaints, Subjective Impairment, and Health-Related QoL, besides Airflow of 
course. Moreover, overlap between scores of these five HS sub-domains was 
substantial, indicating small clinical relevance for discernment. No significant 
differences were found in nine other aspects of HS. It is concluded that GOLD 
stages do not discriminate in any aspect of HS other than airflow obstruction, 
and therefore do not help the clinician in deciding which treatment modalities 
are appropriate.
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INTrODuCTION
The GOLD classification for chronic obstructive pulmonary disease (COPD) has 
been introduced in order to facilitate comparability of clinical studies, by 
stratifying patients according to severity of airflow limitation, measured as 
forced expiratory volume in 1 second as percentage of predicted (FEV1%)(1) 
[1;2]. Severity classes of COPD can be used to tailor diagnostic and therapeutic 
interventions in the management of this large patient group.
Clearly, airflow obstruction is only one aspect of COPD. Other key pathophysio-
logical aspects include hyperinflation, diminished exercise capacity, malnourishment, 
and decreased muscle strength. In addition, there are clinical manifestations 
such as dyspnoea, functional impairment in daily life, and quality of life. All 
these aspects are key components of health status (HS) [3-5](3-5). 
It is unclear to what extent GOLD stages discriminate in aspects of health status, 
other than airflow obstruction. One study showed a statistically significant 
difference only in St. George’s Respiratory Questionnaire (SGRQ) section impact 
and total score between GOLD 2 and 3 (previously designated as stages 2a and 
2b), but not in the sections symptoms and activities [6]. Another study found 
higher exacerbation rates with increasing COPD severity stage (0-IV), but the 
correlation was weak (r=0.29) [7]. Other relationships between GOLD stages 
and aspects of health status have not been reported.
In studies on the relationship between health status and GOLD staging, to date, 
only few aspects of health status were measured. The SGRQ is most frequently 
used, but as this instrument contains only three sections, at best three aspects 
of health status are measured. In a previous study we have developed and 
validated a conceptual framework of health status, the Nijmegen Integral Assessment 
Framework (NIAF) [8]. This framework provides a much more detailed definition 
of health status, and is much more formulated in terms of empirical observations 
than definitions found in the literature. The NIAF covers the following main 
domains of health status: Physiological Functioning, Complaints, Functional 
Impairment, and Quality of Life. These four main domains were found to be 
subdivided into 15 more concrete and relatively independent sub-domains. In 
addition, the NIAF provides an integration of many existing tests and instruments, 
by indicating which aspect of health status is measured by each instrument. 
The purpose of the present study was to evaluate the relevance of the GOLD 
classification in COPD to a broad spectrum of aspects of health status, as measured 
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by the NIAF. We focused on GOLD stages 2 and 3, as these stages make up the 
major part of patients seen in primary and secondary care, and because previous 
studies have shown that GOLD stages discriminated in aspects of health status 
between these two stages, and not between other consecutive stages.
MeTHODS
Study Design and recruitment of patients
Cross-sectional data were collected from a prospective cohort of patients with 
COPD, who visited three outpatient pulmonary clinics for respiratory complaints. 
The clinics consisted of one University Hospital (Radboud University Nijmegen 
Medical Centre, location Dekkerswald), a non-academic teaching hospital 
(Rijnstate Hospital), and a smaller city-hospital (Maas Hospital). Patients were 
seen by pulmonologists, whether for reasons of follow-up or new referrals. All 
patients with an established diagnosis of COPD within GOLD stages 2 and 3 
(FEV1 post-bronchodilation between 30-80% predicted), and in a stable 
condition, were selected by examination of the medical records by one of the 
authors (JM). Exclusion criteria were: co-morbidity (e.g. cardial, neurological, 
oncological, or diabetes mellitus), acute exacerbation of COPD within six weeks 
before enrolment, participation in a pulmonary rehabilitation program within 
the last six months, or inability to speak Dutch. 
The recruitment procedure resulted in 361 eligible patients (see Figure 1). Of 
them, 316 (88%) gave permission for a telephone call by one of the investigators 
(LD). One-hundred-and-forty-eight patients did not consent with the study 
protocol for a variety of reasons, e.g. refusing cycle ergometry, travel problems, 
being too busy at work or at home, feeling too old. Of the remaining 168 patients, 
all of whom had given written informed consent, 156 belonged to GOLD stages 2 
and 3. Twelve patients had to be classified into GOLD 1 or 4 on the basis of their 
baseline post-bronchodilator spirometry (shortly after enrolment), which 
differed slightly from spirometric values observed during the recruitment 
procedure. Finally, 21 non-smokers, all with a clear history of asthma extending 
from childhood, were excluded, resulting in 135 smoking-related COPD patients. 
Subgroup analysis of these never smoking chronic asthmatics revealed neither 
significant differences in scores of the sub-domains of health status, nor in 
demographic variables, as compared to the total group (results not shown).
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Measurements
Health Status was assessed by the Nijmegen Integral Assessment Framework, 
developed and validated in a previous study of our research group [8]. This 
framework covers the following main domains of Health Status: (I) Physiological 
functioning, (II) Complaints, (III) Functional Impairment and (IV) Quality of 
Life. These main domains were shown to be subdivided into 15 different 
sub-domains. Each sub-domain is measured by different existing tests and 
instruments, and for each sub-domain a Sub-domainTotalScore was calculated. 
Reliability of the different sub-domains of the framework was adequate to 
excellent. See Appendix for details on instruments used for each sub-domain.
I: Main domain Physiological functioning 
Routine pulmonary function tests were performed including transfer capacity 
for carbon monoxide (CO), maximal exercise capacity, respiratory and skeletal 
figure 1  Flow chart of the patient inclusion procedure
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
361 eligible   
316 informed about study 45 not willing further study-information  
168 informed  
consent 
148 not consented with study  
protocol 
156 GOLD 2&3  12 GOLD 1 & 4  
21 never smokers  135 current or ex-
smokers 
   Flow chart of inclusion procedure 
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muscle function, and indices of body composition. Various parameters were 
incorporated into one of the following six sub-domains: Airflow, Static lung 
volumes, Exercise capacity, Gas Exchange, Muscle Force, and Body Composition. 
Maximal ergometry consisted of a symptom limited, incremental bicycle test. 
Patients cycled at a rate of 60 rpm. After a 3 minute reference phase, workload 
was increased each minute by 10% of estimated maximum work capacity. 
Whenever major abnormalities developed during the test in ECG or O2 saturations 
at pulse-oxymetry, the test was ended by the attending physician. The quadriceps 
leg pressure dynamometer was used to measure quadriceps force. Fat free mass 
index (FFMI) was derived from the standard formula using bioelectrical 
impedance measurement (Bodystat 1997). 
II: Main domain Complaints 
The sub-domains were measured by specific subscales of the following self- 
reported questionnaires: Physical Activity Rating Scale-Dyspnoea (PARS-D) [9], 
Dyspnoea Emotions Questionnaire (DEQ) [8], and Quality of Life for Respiratory 
Illness Questionnaire (QoLRIQ) [10].
III: Main domain functional impairment
The following questionnaires were used: Sickness Impact Profile (SIP) [11; 
12], Global Impairment (measuring general subjective experienced functional 
impairment) [9], and Quality of Life for Respiratory Illness Questionnaire (QoLRIQ). 
In addition, an accelerometer was used to measure actual physical activity level 
in daily life [9]. This small electronic device is worn at the ankle for 10 consecutive 
days, 24 hours per day (except when taking a bath or when swimming).
IV: Main domain Quality of Life 
The Satisfaction with Life Scale (SWLS) [13;14], Symptom Check List (SCL) [15], 
Beck Depression Inventory (BDI) [16], and specific questions concerning satisfaction 
with physical functioning, future, spouse, and social functioning [8] were used.
Statistical Analyses
Differences between GOLD 2 and 3 with respect to nominal variables were 
tested by χ² test. Differences in the Sub-domainTotalScores of the Nijmegen 
Integral Assessment Framework between GOLD stages 2 and 3 were analyzed 
by t-tests. To avoid Type I error due to the large number of tests, the p-value 
was set at < 0.01 for all analyses. For Sub-domainTotalScores that reached 
significance, box-plots were produced to test the clinical relevance of the 
statistical difference found between GOLD stages 2 and 3. The larger the overlap 
between both stages, the less the clinical relevance. As the GOLD classification 
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represents a categorical system, with relatively arbitrary boundaries, additional 
analyses were performed using the non-categorized FEV1% predicted. For this 
purpose, Pearson correlation coefficients of FEV1% predicted with the Sub-do-
mainTotalScores were calculated.
reSuLTS
Patient characteristics
The main characteristics describing the patient sample are presented in Table 1. 
No significant differences were found between patients in GOLD 2 and 3 
concerning age, sex, body mass index (BMI), smoking status, and duration of a 
Table 1   Anthropometric, basic pulmonary function, and demographic data 
of the study sample
Variable GOLD  2
(N=70)
GOLD 3
(N=65)
Sex    Male                                                     57 54
Age    yrs                               64.3     (10.2)                64.7     (8.3)
BMI    kg/m²                           26.5     (3.8)                 24.8     (4.0)
IVC %pred                             94.5     (15.2)                90.1     (14.2)
FEV1 %pred                           61.0     (7.1)                  40.9     (5.2)
Tiffeneau %pred                    50.0     (8.0)                  35.0     (8.0)
TLC %pred      100.9   (16.6)                106.0   (14.7)
TLCO %pred                           73.7     (21.5)                59.4     (22.3)
PaO2 rest, kPa                        11.1     (1.3)                  10.6     (1.3)
PaCO2rest, kPa                 5.1       (0.5)                  5.2       (0.5)
Smoking status     
    current smoking                 
    quit 
22
48
18
47
Self-reported COPD diagnosis, yrs.
   < 1yr.                                                                 
   1 – 10 yrs.                                                          
    > 10 yrs.                                                            
12
28
30
5
30
30
Note: BMI= body mass index; IVC %pred= inspiratory vital capacity as percentage of predicted; 
FEV1 %pred= forced expiratory volume in one second as percentage of predicted; Tiffeneau 
%pred= FEV1/IVC as percentage of predicted. TLC %pred= total lung capacity as percentage of 
predicted; TLCO %pred= lung transfer capacity for carbon monoxide as percentage of predicted. 
Data are presented as N, or mean (SD).
28 | Chapter 2
self-reported diagnosis of COPD. The same was true for inspiratory vital capacity 
(IVC)% predicted, TLC% predicted, and PaCO2% predicted. TLCO% predicted 
was significantly different between the two GOLD stages. Obviously, FEV1% 
predicted and Tiffeneau index were significantly different, because the division 
Table 2   Health Status main domain  (I) Physiological Functioning. 
Sub-domainTotalScores (Mean (SD)) are presented with p-values 
for difference between GOLD stage 2 and 3 and values of  
individual parameters composing each sub-domain. Higher scores 
of Sub-domainTotalScores indicate worse condition.
GOLD 2 GOLD 3 p-value
T-test
Mean (SD) Mean (SD)
Air�low
FEV1 %pred
MEF50 %pred
VE max %pred
762.7 (22.8)
61.0   (7.1)
24.7   (9.7)
 80.0 (15.7)
812.7 (21.8) 
40.9   (5.2) 
13.1   (5.2) 
93.2 (22.1) 
     < .001  
Static lung volumes
TLC %pred
RV %pred
145.6 (28.4)
100.9 (16.6)
120.3 (33.0)
159.8 (26.3) 
106.0 (14.7) 
142.6 (33.2) 
        .003 
Exercise Capacity
HRmax %pred
VO2max%pred
TLCO %pred
Delta BE (kPa)
444.5 (42.7)
86.2 (13.8)
77.9 (19.1)
73.7 (21.5)
-7.0   (2.8)
478.5 (34.2) 
82.0 (11.9) 
63.2 (13.0) 
59.4 (22.3) 
- 5.5   (2.2) 
     < .001
Gas Exchange:
Δ (A-a)DO2 (kPa)
Δ PaCO2   (kPa)
0.96 (1.4)
0.32 (0.5)
1.14  (1.2) 
0.52  (0.5) 
       .417
       .017
Muscle Force
Pi  max %pred
Pe max %pred
Leg force %pred
208.2 (34.0)
114.9 (35.6)
79.1 (23.2)
83.4 (23.4)
210.6 (33.7) 
107.9 (32.0) 
80.2 (23.8) 
83.2 (24.5) 
       .675
Body Composition
BMI (kg/m²)
FFMI (kg/m ²)
males 
females
861.9 (27.2)
26.5 (3.8)
18.29 (1.8)
15.88 (1.9)
872.2 (28.0)
24.8   (4.0)
17.69 (1.8)
15.08 (1.5)
       .032
Note: Delta BE= change in Base Excess during exercise test; Δ (A-a)DO2 (kPa)= change in (A-a)DO2 
during exercise test; ΔPaCO2 (kPa): change in PaCO2 during exercise test calculated as value at 
maximum exercise minus value at rest; FFMI : fat free mass index; values for males and females 
separately, taking into account different lower limits of normal. p < .01 is considered statistically 
significant and is displayed in bold. 
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into different GOLD stages is based on FEV1% predicted. The number of patients 
in each group was equally distributed.
Sub-domains of Health Status in relation to GOLD 2 and 3
Data of pulmonary function at rest and during maximal cycle ergometry, muscle 
function, and body composition are summarized by the six sub-domains of 
Physiological Functioning, and are shown in Table 2. Regarding FFMI, all values 
were in the normal range ( > 16 kg/m² for males and > 15 kg/m² for females), 
although the mean value of females in GOLD 3 hardly exceeded the lower limit of 
normal. Results on the sub-domains of the main domains Complaints, Functional 
Impairment, and Quality of Life are presented in Table 3.
Though a clear difference existed between GOLD 2 and 3 regarding the sub- 
domain Airflow, differences in the other Sub-domainTotalScores were small or 
absent. Statistical significant differences were only found in five out of the other 
14 sub-domains: Static lung volumes, Exercise capacity, Subjective Pulmonary 
Complaints, Subjective Impairment, and Health-Related QoL. The sub-domain 
Table 3   Health Status (HS) main domains II Complaints, III Functional 
Impairment and IV Quality of Life. Sub-domainTotalScores mean 
(SD) for GOLD 2 and 3 and p-values for differences from T-tests. 
Detailed information on the instruments that constitute these 
sub-domains is available in appendix 1.
GOLD 2 GOLD 3 diff. GOLD 2 vs3.
(T-test)
Mean  (SD) Mean  (SD) p value
II   Complaints
       subjective pulmonary complaints
       dyspnoea emotions
       dyspnoea expected
  
  57.3 (19.2)
  40.1 (13.2)
    2.1   (0.9
69.2 (20.5)
45.2 (12.1)
2.5     (1.0)
   .001
   .023
   .032
III Functional Impairment
      actual physical activity
      behavioural impairment
      subjective impairment
177.3 (27.1)
  21.3 (16.2)
  98.3 (22.9)
182.4 (30.3)
  27.8 (16.4)
111.4 (24.7)
   .305
   .023
   .002
IV Quality of Life
     general wellbeing
     Health-Related QoL
     satisfaction in social relations
 53.7  (12.1)
 19.1    (8.0)
   9.6    (8.1)
 56.4  (11.7)
 23.2    (9.1)
 10.1    (8.9)
   .190
   .006
   .703
Note: Significant p-values are depicted in bold.
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Gas Exchange (Table 2) lacks a Sub-domainTotalScore, as the two composing 
variables were not linear in distribution. Box-plots (Figure 2) show that considerable 
overlap existed between GOLD stage 2 and 3 for all five sub-domains that 
reached statistical significance.
figure 2   Box plots of Sub-domainTotalScores (y-axis) which were significant 
in t-test, split by GOLD stage (x-axis)
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Sub-domains of Health Status in relation to feV1%predicted
Correlations between Sub-domainTotalScores and FEV1% predicted are presented 
in Table 4. Significant correlations were found only for Airflow, Exercise capacity, 
and an index of Gas Exchange (Δ PaCO2 ).
DISCuSSION 
This is the first study that evaluated the relevance of the GOLD classification in 
relation to a broad range of aspects of health status in COPD. In the present study 
it was shown that the GOLD classification has no clinical relevance in aspects of 
health status other than airway obstruction.
Table 4   Pearson correlations of subdomains of Health Status (HS) main 
domains Physiological Functioning, Complaints, Functional 
Impairment, and Quality of Life (QoL) with FEV1% predicted and 
p-value.
Sub-domains of main domains Pearson corr. with
 feV1 %pred.
p-value
Main domain Physiological Functioning
    Airflow
    Static Lung Volumes
    Exercise Capacity
    Gas Exchange:
        Δ (A-a)DO2
        Δ PaCO2
    Muscle Strength
    Body Composition
- .88
- .22
- .41
- .16
- .27
-.03
-.20
<0.001
.011
<.001
.068
.002
.755
.018
Main domain Complaints
    Subjective 
    Dyspnoea Emotions
    Dyspnoea Expected
-.20
-.05
-.13
.019
.607
.144
Main domain Functional Impairment
    Actual Physical Activity
    Behavioural
    Subjective
-.08
-.16
-.19
.371
.065
.032
Main domain Quality of Life
    General Quality of Life
    Health-Related QoL
    Satisfaction with relationships
-.02
-.18
  .02
.835
.042
.850
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The relevance of GOLD stages with respect to different aspects of health status 
(HS) was evaluated using the recently developed Nijmegen Integral Assessment 
Framework (NIAF) of health status in COPD [8]. Most existing instruments 
contain only three to five subscales, and thus measure only some aspects of HS. 
An integral assessment of HS therefore requires the use of multiple instruments. 
However, an evidence-based integration of existing instruments is lacking [17]. 
The NIAF covers the main domains Physiological Functioning, Complaints, 
Functional Impairment, and Quality of Life. We found that these four main 
domains were conceptually distinct, and were shown to be further subdivided 
into 15 more concrete and homogeneous sub-domains. The NIAF has four key 
characteristics. First, it covers a broad range of aspects of health status relevant 
to COPD. Second, it integrates existing instruments by indicating which 
instruments measure the same sub-domain of HS, and it provides information 
on the validity of these instruments by indicating which sub-domain is actually 
measured. Third, all 15 sub-domains were shown to be relatively independent, 
which means that each sub-domain represents a unique aspect of the patient’s 
health status. Fourth, the sub-domains are measured by existing tests and 
instruments and for each sub-domain a single score is calculated. Taken together, 
the NIAF provides an empirical and detailed definition of health status, and 
allows a valid and integral assessment of 15 relatively unrelated and therefore 
unique aspects of health status in COPD, expressed in only 15 scores. 
We found significant differences between GOLD stage 2 and stage 3 in only five 
of 15 sub-domains, other than airway obstruction. These were Static lung 
volumes, Exercise Capacity, Subjective Pulmonary Complaints, Subjective 
Impairment, and Health-Related QoL. Considering the large overlap in the scores 
of these five sub-domains between both stages, the clinical relevance of these 
differences is small. With respect to the sub-domain Exercise Capacity, 
significant but minor correlations with FEV1% predicted were reported by 
several authors, based mostly on maximal oxygen consumption (VO2max), 
varying between .22 and .44 [18-20]. In the present study the sub-domain 
Exercise Capacity contained three other factors in addition to VO2max, but we 
found a similar correlation with FEV1% predicted (r= .38). Hyperinflation 
commonly occurs in conjunction with decreasing FEV1, but empirical studies on 
this issue are lacking. The correlation of the sub-domains Static lung volumes 
and FEV1% predicted was low (r=-.22) and not statistically significant, indicating 
low shared variance. With respect to the main domain Complaints, there was a 
significant difference between both stages in sub-domain Subjective Pulmonary 
Complaints, but not in the sub-domains Dyspnoea Emotions and Dyspnoea 
Expected. With respect to the main domain Functional Impairment, GOLD 
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discriminated in the sub-domain Subjective Impairment, but not in the 
sub-domains Behavioural Impairment and Actual Physical Activity. Concerning 
the main domain Quality of Life, GOLD stages discriminated only in the 
sub-domain Health-Related QoL.
Poor associations between airflow obstruction and other pathophysiological 
parameters, complaints, functional impairment, and quality of life have been 
reported by many studies [17;20-27], but little research has been done on the 
clinical relevance of the GOLD classification system in relation to these different 
aspects of health status. A low correlation (r=0.29) was reported between GOLD 
staging and number of hospital readmissions for exacerbations [7]. Antonelli-
Incalzi et al. [6] found significant differences between GOLD stages regarding 
the St. George’s Respiratory Questionnaire (SGRQ). However, no significant 
differences were found for the 6-minute walk distance, quality of sleep, and 
cognitive and affective status. Also, the differences in the SGRQ scores were only 
found for some subscales of the SGRQ, and only between stages 2 and 3 
(previously stages 2a and 2b). Similar to the present study, the authors found 
large variability within all GOLD stages, resulting in major overlap in scores 
between consecutive stages. Strikingly, this study also demonstrated substantial 
problems in health status in patients with COPD with GOLD stage 0 and stage 1. 
The authors concluded that health status cannot be inferred from GOLD stage. 
Two studies used criteria for disease staging similar to GOLD. Ferrer and 
colleagues [28] found low to moderate correlations of the SGRQ subscales with 
COPD stages according to the American Thoracic Society (ATS) guidelines (r=.27 
to .51). This relationship was stronger in patients without co-morbidity, as 
compared to patients with co-morbidity (r=.68 versus .40, respectively). These 
authors also reported a large overlap in scores between the ATS stages and 
substantial health status problems in patients with mild disease severity. Hajiro 
et al. used British Thoracic Society (BTS) staging criteria [29]. They found 
significant differences between moderate and severe COPD on all subscales of 
the SGRQ and VO2max. Between mild and moderate COPD they only found 
significant differences on the subscale activity and the total score of the SGRQ. 
Several pulmonary function parameters, dyspnoea, anxiety, and depression 
were not significantly different between any stage.
Results of the present study and previous studies show that a classification 
system based on the severity of airflow obstruction has no relevance with 
respect to aspects of health status other than airflow obstruction. In only a few 
aspects of health status significant relationships were found, but considering 
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the major overlap in scores between consecutive stages these differences have 
little clinical relevance. We explicitly would discard staging systems based on 
only one aspect of health status in favour of assessment incorporating multiple 
aspects of health status.
This conclusion is not surprising, because many studies have shown that airflow 
obstruction (the parameter on which the GOLD stages are based) is poorly 
related to other pathophysiological processes, functional impairment, 
complaints, and quality of life. In addition, previously, we found that the 15 
sub-domains of HS represented by the NIAF are relatively independent [8]. This 
means that scores on a particular sub-domain, such as airflow, do not predict 
scores on other sub-domains.
Some methodological considerations should be discussed. First, we focused on 
patients with GOLD stages 2 and 3, as these patients constitute the most part of 
patients seen in medical care, and because in a previous study it was shown that 
GOLD stages discriminated in aspects of health status between these stages, 
and not between other consecutive stages [6]. Second, we excluded primary 
co-morbidity to exclude its confounding effect, which was reported in a study on 
the relation between ATS classification and health status [28]. In that study, also 
a relationship between disease stage and the SGRQ has been demonstrated. This 
relationship was most pronounced in patients without co-morbidity. Thus, if any 
differences between GOLD stages are present, these would have been found in 
the present sample where co-morbidity was excluded.
The present findings have important implications for clinical practice and 
research. The GOLD classification was designed to create more homogeneous 
subgroups for research purposes, and it was expected that this classification 
could guide diagnosis and treatment of COPD [1;2]. Our findings show that GOLD 
staging is only clinically meaningful with respect to airway obstruction, but not 
to any other aspect of health status, such as other physiological processes, 
complaints, functional impairment in daily life, and quality of life. The relative 
independence of the different sub-domains of health status implies that 
treatment directed at only one aspect of HS, for example airflow obstruction, 
does not result in improvement in other aspects. Integral diagnosis, treatment, 
and management of COPD therefore should go beyond staging and management 
of airway obstruction alone, and should include additional and specific 
interventions aimed at improving other aspects of health status as well. In order 
to tailor treatment to the needs of an individual patient, GOLD staging proves to 
be inadequate. What is needed is an integral assessment of all aspects of health 
status. 
Significance of GOLD for Health Status domains | 35
2
The key characteristic of the NIAF is that multiple, and relatively unique aspects 
of health status are integrated, which produces a more complete picture of the 
patient with COPD. The recently developed BODE index also is an approach in 
which different aspects of COPD are combined to yield a more complete picture 
of the patient. The BODE index (Body Mass Index, airway obstruction, dyspnoea, 
and exercise capacity) significantly better predicted mortality [30] and hospi-
talization [31], as compared to FEV1 alone. The difference between the BODE 
index and the NIAF is, that the former combines the different aspects into a 
single parameter. The NIAF, in contrast, produces 15 different scores. In clinical 
practice, this has the advantage of obtaining a detailed picture of an individual 
patient, with respect to which aspects of health status are problematic, and 
which aspects are not. This enables the clinician to fine-tune treatment to the 
needs of an individual patient. 
In conclusion, GOLD staging only has clinical relevance with respect to airflow 
obstruction, and not to any other sub-domain of HS. Therefore, the GOLD 
classification system is not useful in guiding treatment and management of 
COPD. Integral assessment of different aspects of health status is needed. The 
NIAF provides clinicians with a detailed picture of the patient’s health status, 
and therefore a guide to tailor treatment to the needs of the individual patient.
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Appendix 1   List of instruments used to measure the HS main domains and 
sub-domains with description of included subscales.
Main domains (bold text)
      Sub-domains (plain text)
Parameters
Physiological functioning
     Airflow
     Static lung volumes
     Exercise capacity
     Gas Exchange
     Muscle Force
     Body Composition
FEV1%, MEF50%, VE%
TLC%, RV%
VO2%, TLCO%, BE-Delta, 
HRmax%
Δ (A-a) DO2
Δ PaCO2
Pi  max %, Pe max %, Leg force %
BMI  kg/m², FFMI  kg/m ²
Instrument Subscale
Complaints
     Subjective Pulmonary
     Complaints
Physical Activity Rating Scale-
Dyspnoea
Dyspnoea Emotions 
Questionnaire
Quality of Life for Respiratory 
Illness questionnaire
global activities
global burden
specific activities
dyspnoea 
subjective
breathing 
problems
     Dyspnoea Emotions Dyspnoea Emotions 
Questionnaire
frustration
mood
anxiety
     Expected Dyspnoea Physical Activity Rating Scale-
Dyspnoea
expected dyspnoea
functional Impairment
     Actual physical activity Accelerometer 
     Behavioural impairment Sickness impact profile body care & 
movements 
home management 
mobility 
ambulation 
     Subjective impairment Quality of Life for Respiratory 
Illness questionnaire
Global Impairment
Sickness impact profile
general activities
social activities
total
burden
social interaction
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Appendix 1   Continued.
Main domains (bold text)
      Sub-domains (plain text)
Parameters
Quality of life
     General QoL Satisfaction With Life Scale
Symptom Checklist
Beck Depression Inventory
total
anxiety
primary care
     Health-Related QoL Satisfaction-Physical
Satisfaction-Future
     Satisfaction Relations Satisfaction-Spouse
Satisfaction-Social
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ABSTrACT
Background: Dyspnoea and diminished functional status are pivotal features of 
the health status (HS) in chronic obstructive pulmonary disease (COPD). Still it 
is not fully understood how pulmonary function tests and cardio-pulmonary 
exercise testing relate to these aspects. This may be due to incomplete assessment 
and/or deficient definitions of HS. Especially regarding peak oxygen consumption 
inconsistent results are reported. 
Objectives: What is the value of maximal cycle ergometry  in relation to a broad 
spectrum of aspects of HS? 
Methods: 129 patients with COPD, stage II and III according to the GOLD 
classification, performed a cardio-pulmonary exercise test. Sixteen independent 
sub-domains of HS were assessed according to the Nijmegen Integral Assessment 
Framework, covering Physiological Functioning, Complaints, Functional Impairments 
and Quality of Life as main domains. O2  max and HS sub-domains were correlated 
by bivariate analysis.
Results: Weak correlations of O2  max with most sub-domains were found, except 
for exercise capacity; the other 5 sub-domains of Physiological Functioning did 
not correlate. Between different types of exercise limitation (5 types were 
differentiated) no significant differences were noted in the scores of 13 out of 16 
HS sub-domains.
Conclusions: O2  max indeed is correlated with most aspects of HS, except for 
physiological variables, but associations are weak. No single exercise limitation 
type is associated with specific HS problems. Thus separate assessment of all 
HS sub-domains is advocated to ensure adequate planning of therapeutic 
interventions.
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INTrODuCTION
Airflow obstruction and impaired exercise capacity are the main clinical charac-
teristics of COPD and are measured by pulmonary function tests and by cardio-
pulmonary exercise testing (CPET) respectively. Hitherto, CPET is considered to 
be a better tool to assess overall health status (HS) than resting pulmonary 
function tests [1]. General theories define HS to include not merely physiological 
functioning, but also complaints, functional impairment and quality of life (QoL) 
as main domains [ 2,3].
 Our recent study [4] confirmed this theoretical definition of HS empirically. 
In that study we developed and validated a conceptual framework of HS in COPD, 
the Nijmegen Integral Assessment Framework (NIAF), which shows that these 4 
main domains are conceptually distinct. Moreover, we found that these main 
domains were subdivided into 15 relatively independent sub-domains, each 
representing a unique aspect of HS. In another, yet unpublished study, the 
sub-domain Fatigue was added, thus resulting in 16 sub-domains. The definition 
of HS provided by the NIAF is both detailed and based on empirical observations, 
far more than the definitions found in the literature. 
With respect to airflow limitation, we showed in a previous paper that the severity 
of airflow limitation classified according to the Global initiative for Chronic 
Obstructive Lung Diseases (GOLD), hardly relates to Complaints, Functional 
Impairment or QoL [5].  Several previous studies already provided substantial 
evidence for such a conclusion [6-17], yielding weak correlations between forced 
expiratory volume in 1 second (FEV1), and components of the other 3 domains of HS.
 With respect to CPET, it is unclear whether physiological impairments are 
reflected by functional impairments in daily life or other aspects of HS. Similar 
to the correlations with airflow, exercise capacity and HS aspects correlate 
weakly [6-17]. Moreover, the corresponding literature lacks clear definitions of 
HS, QoL and health-related QoL (HRQL). As a consequence these terms are 
frequently used interchangeably, which is a setback in comparing the results 
between studies. Also, most of these studies were restricted to only one or a few 
aspects of HS. Only 2 studies in COPD evaluated exercise capacity in relation to a 
greater number of HS aspects, using a range of questionnaires [12,13]. However, 
both studies selected different instruments, thus hampering comparability. 
Also, the way of exercise testing differed in both reports. One study reported a 
wide range of strengths of correlation of the six minute walk distance (6-MWD) 
with various HS aspects: dyspnoea (r = 0.35), measures of functional status and 
self-efficacy walking (r = 0.34 and 0.68 respectively) [12]. The correlation 
between 6-MWD and the Chronic Respiratory Questionnaire total score was 
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weak (r = 0.28). The other study used the disease-specific questionnaire (St. 
George’s Respiratory Questionnaire, SGRQ) and the generic SF-36 [13]. Exercise 
capacity measured as peak oxygen consumption ( O2 max) on treadmill was 
found to correlate rather strongly with SGRQ total score (r = 0.58) and less 
strong with some domains of the SF-36 (general health: r = 0.48, social 
functioning: r = 0.58, and mental health: r = 0.53). 
 Common to all these studies is the paucity and variability in HS aspects that 
were measured.  
 Starting from the NIAF as a much more detailed and comprehensive assessment 
of HS we hypothesized that maximal exercise capacity would show less strong 
correlations with other physiological aspects of COPD than generally reported, 
and low or non-significant correlations with the other sub-domains of Health 
Status.  Therefore, this study explored correlations between maximal exercise 
capacity performed on a cycle ergometer and the 16 sub-domains composing the 
NIAF HS assessment. Besides maximal O2 max, different types of exercise 
limitations were also evaluated with respect to HS. 
MATerIALS AND MeTHODS
Study design 
A cross-sectional cohort of patients with COPD was selected from the outpatient 
department of three different hospitals. The in– and exclusion criteria were 
published elsewhere [3]. In brief, inclusion of patients followed if: their COPD fell 
within GOLD stages II and III, (FEV1/FVC < 70 % and FEV1 between 30 %  80% 
after bronchodilatation), they were current or ex- smokers, and were in stable 
clinical condition without exacerbation in the last 6 weeks before enrolment, 
and did not participate in a pulmonary rehabilitation program within the last 6 
months, and asthma was excluded (defined as a long history of dyspnoea attacks 
and reversible airflow obstruction dating from childhood, with persistent 
airflow obstruction later on).
The study has been approved by the local ethics committee.
MeTHODS
Health Status
Health Status was measured by NIAF, which provides an empirical definition of 
HS and covers the domains Physiological Functioning, Complaints, Functional 
Impairment and QoL. These four domains of HS were found to be subdivided into 
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16 distinct sub-domains. In this process factor analyses were used to identify 
underlying concepts in the data. The sub-domains are measured by different 
existing tests and instruments, and for each sub-domain a Sub-domain Total 
Score (STS) was calculated. Higher scores indicate worse clinical condition. For 
detailed description of the validation of the NIAF and the calculation of the STS 
is reported elsewhere [4]. The Appendix provides details on instruments for 
each sub-domain. 
Physiological functioning
CPET
All subjects performed an incremental maximal CPET on a bicycle, according to 
the criteria of the American Thoracic Society on CPET [18]. Subjects cycled on an 
electrically braked cycle ergometer (Masterlab®, Jaeger, Würzburg, Germany) at 
a pedaling rate of 60 rotations×min-1 breathing room air. After unloaded 
pedaling for three minutes, the workload was increased every minute by 5-20W. 
During exercise, ventilation ( E), O2 and carbon dioxide production ( CO2) 
were measured breath-by-breath (Vmax 29 Sensor Medics, Bilthoven, the 
Netherlands). Electrocardiography was conducted, and saturation was 
measured using a pulse-oxymeter (Datex, Helsinki, Finland). Additionally, blood 
pressure was measured every three minutes during the test and Borg scores 
(0-10) for dyspnoea and leg fatigue were obtained before and at maximal 
exercise. Arterial blood gasses (PaO2, PaCO2, and base excess) were obtained 
from a cannula in the radial or brachial artery before exercise, every 3 min 
during exercise, at maximal exercise and 3 minutes after the end of exercise and 
stored in heparinized syringes (Bayer®, East Walpole, Mass., USA). Predicted 
O2 was derived according to the recommendation by Wasserman et al. [19].
Description of exercise limitation
An integrated approach to the interpretation of exercise data was used, with 
special reference to the 9 panel plots proposed by Wasserman [20]. Key 
parameters such as E, heart rate (HR), blood gases and anaerobic threshold 
were evaluated compared to their respective predicted values. Hereby, 
physiological impairments that lead to exercise limitation can be determined, 
providing 4 main types discerned in this paper (1 – 4). Although there is no 
scientific consensus on the distinct types of exercise limitation in COPD, these 
descriptions are frequently used in the literature. Quantitative criteria were 
chosen as much in line with physiological boundaries as possible.
Based on the physiological data during exercise, exercise limitation of a patient 
was attributed to one of the following causes: 
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1. Ventilatory limitation [breathing reserve (maximal voluntary ventilation - 
E ) of < than 11 L/min or < 15% of pred. (% pred.)] and/or increasing PaCO2, 
and/or decreasing PaO2 without signs of oxygen uptake limitation.
2. Oxygen uptake limitation [increased alveolar-arterial oxygen pressure 
difference, P(A-a)O2 ≥ 4.6 kPa during exercise in combination with a PaO2 ≤ 
8 kPa].
3. Cardio-circulatory limitation, divided into cardiovascular disease or 
decreased physical condition (the subject reached his or her predicted 
maximal heart rate (HR) or heart rate reserve <15 beats/min) and acidosis 
(D base Excess > 8 meq/l) at maximal workload).
4. Symptom limitation (no maximal exercise based on physiological data, but 
patient stopped because of symptoms).
5. Combined limitations (ventilatory and cardio-circulatory limitation, or 
ventilatory and oxygen uptake limitation). This group was chosen if no 
selection between two concurrent causes could be made.  
Other physiological measurements
Spirometry, diffusion capacity for carbon monoxide (TLco), skeletal and 
respiratory muscle force and fat free mass (FFM) were measured according to 
current international guidelines. 
Complaints, functional Impairment and Quality of Life
They were measured according to the NIAF. The appendix provides details on 
instruments and subscales composing the NIAF.
Analysis
Correlations between O2  max (%pred.) and STS of the NIAF were calculated by 
Pearson’s correlation coefficients. To test differences in STS between the distinct 
types of exercise limitation, ANOVA was used. A Post Hoc analysis to correct for 
multiple comparisons (Bonferoni) was applied to identify between which types 
significances existed. In the same manner, ANOVA and post hoc tests were 
carried out to test differences in O2  max between the types of exercise 
limitation. 
A p <  0.01 was taken as significant to avoid Type I error due to multiple testing.
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reSuLTS
From 361 eligible patients 135 fulfilled the inclusion criteria. They all gave 
written informed consent to the study protocol. For this study, however, 6 
patients had to be excluded because of interruption of their cycle ergometry test 
due to cardiac arrhythmias. Table 1 shows the characteristics of the 129 patients 
involved.
Table 1   Anthropometric, spirometric and CPET results.
variable N = 129
Mean (SD) or numbers (%)
age 64.5     (9.2)
sex M/F 106/23   (82.2 / 17.8 %)
smoking status
  current    
  quit 
38          (29.5 %)
91          (70.5 %)
self reported history of COPD a 
   < 1 years
   1-10 years
   >10 years
15          (12.3 %)
55          (45.1 %)
52          (42.6 %)
BMI  (kg/m²) 25.7    (3.9)
IVC % pred 92.3   (15.0)
FEV1 % pred 51.1  (11.8)
FEV1/IVC  (%) 42.9   (10.9)
RV  % pred 131.3 (35.1)
TLC %pred 103.3 (16.0)
TLCO %pred 66.8   (23.3)
PaO2 (kPa) rest
PaO2 (mmHg)
10.9     (1.3)  
81.8     (9.8)
PaCO2 (kPa)  rest
PaCO2 (mmHg)
5.2       (0.5) 
39        (3.8)
O2  max  % pred 71.2   (18.1)
Borg score at max workload 
       Breathing effort
       Leg effort
5.8       (2.1)
6.0       (2.4)
Legend: values are presented as means  (SD) except for sex, smoking status and history of COPD 
(n). IVC: inspiratory vital capacity. RV: residual volume. TLC: total lung capacity.
 a Refers to 122 patients due to 7 missing values.
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 Anthropometric data together with spirometry and ergometry results of 
the 129 patients are displayed in Table 1. The study sample consisted of mainly 
elderly patients, predominantly men, with slightly raised body mass index, 
moderate decrease in TLco and signs of hyperinflation. Mean resting values of 
PaO2 and PaCO2 were within normal limits. Mean O2  max (%pred.) was clearly 
below normal.
As shown in Table 2 O2 max (%pred.) was associated with  many sub-domains 
of HS, but the observed correlations were weak (highest r = 0.36 for Subjective 
Impairments). With respect to the main domain Physiological Functioning, the 
correlation with the sub-domain Exercise Capacity was very strong, as expected. 
No significant correlations were found between O2 max and the other 
physiological sub-domains. With respect to the other main domains the highest 
correlations were found between O2 max and the three sub-domains of 
Functional Impairment (Subjective Impairment, Behavioral Impairment and 
Actual Physical Activity). However, correlations still were weak.
The interpretation of causes of exercise limitation at cycle ergometry led to 5 
categories (see Methods) with rather unequal group sizes. The ventilatory limited- 
group contained 54 patients, the oxygen uptake-limited group 7 patients, the 
cardio-circulatory-limited group 28 patients, the symptom-limited group 17 
patients and the group of combined causes 23 patients.
 Variation in O2 max for each type of exercise limitation is shown in Figure 1. 
O2 max (%pred.) appeared different only between the oxygen uptake-limited 
group (the most impaired group) and those limited by physical condition, which 
had the best median O2  max (%pred.).
ANOVA with type of exercise limitation as the dependent variable and 
sub-domains of the NIAF as independent variable (Table 3) demonstrated some 
significant differences between types of exercise limitation within the main 
domain Physiological Functioning. This concerned Airflow, Exercise Capacity 
and change in alveolar-arterial oxygen gradient and in PaCO2 during exercise. 
Box plots of these sub-domains are shown in figures 2, in which the significant 
between-group differences are drawn. Differences are most marked in 
comparisons in which the type of exercise limitation is closely linked to the 
sub-domain involved, like the oxygen uptake-limited group concerning change 
in  (A-a)DO2 (figure 2C).
 No significant differences were observed in any sub-domain of the other 3 
main domains.
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Table 2   Correlation between O2 max %predicted and the NIAF sub-
domains of Health Status.
Correlation sub-domains with VO2 max  %pred. Pearson 
correlation
p value
Physiological functioning
  Airflow - .208    .018
  Hyperinflation - .070    .429
  Exercise Capacity - .799 < .001
  Gas Exchange
      Δ (A-a)DO2
      Δ PaCO2
- .025
  .148 
   .776
   .095
  Muscle Force - .193    .028
  Body Composition   .133    .134
Complaints
  Subjective Pulmonary Complaints - .290    .001
  Dyspnoea Emotions - .208    .018
  Dyspnoea Expected - .252    .004
  Fatigue - .248    .005
functional Impairment
  Actual Physical Activity - .303 < .001
  Behavioural Impairments - .339 < .001
  Subjective Impairments - .361 < .001
Quality of Life
  General QoL - .240    .006
  Satisfaction Health - .310 < .001
  Satisfaction Relations - .011    .903
Legend:  Sub-domains are grouped into four main domains. N=129. Negative signs indicate worse 
scores of sub-domains with lower O2  max % pred. because Sub-domain Total Scores were 
mirrored. Δ (A-a)DO2:  change in alveolar-arterial oxygen difference during exercise test. Δ 
PaCO2: change in arterial carbon monoxide tension during exercise test. Significant correlations 
in bold.
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figure 1   Box plot representing  O2 max %predicted in 5 groups with 
different causes of exercise limitation during cycle ergometry. 
Boxes define 25 th and 75 th percentile with median depicted as 
horizontal bar.  Significant between-group difference is based 
on Post Hoc analysis. * between-group difference with p= 0.021. 
Outliers are also shown (o).
Table 3   ANOVA of sub-domains of the NIAF with exercise limitation type 
as dependent variable. 
NIAf sub-domains f ratio        p
Physiological functioning
  Airflow 9.55 < .001
  Hyperinflation 0.85    .495
  Exercise Capacity 9.67 < .001
  Gas Exchange 
      Δ (A-a) DO2
      Δ PaCO2                                                                                    
9.31   
6.13           
< .001
< .001
  Muscle force 2.56    .042
  Body composition 1.19    .317
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Table 3   Continued. 
NIAf sub-domains f ratio        p
Complaints
  Subjective Pulmonary Complaints 2.56    .042
  Dyspnoea emotions 0.90    .468
  Dyspnoea expected 2.93    .024
  Fatigue 1.24    .298
functional Impairment
  Actual physical activity 0.28    .889
  Behavioral impairments 2.07    .089
  Subjective impairments 2.62    .038
Quality of Life
  General QoL 1.82    .130
  Satisfaction Health 2.65    .036
  Satisfaction Relations 2.51    .045
Legend: NIAF: Nijmegen Integral Assessment Framework; F ratio: ratio of mean squares between 
groups and within groups of different type of exercise limitation. 5 types were distinguished: 
ventilatory limited, limitation in oxygen uptake, limited by physical condition, symptom limited 
and combined causes. Sub-domains are grouped into four main domains. N= 129.
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figure 2   STS box plots. Significant between-group differences, based on 
Post Hoc analyses are indicated. A and B: STS Airflow (A) and STS 
Exercise Capacity (B) according to type of exercise limitation. 
Higher scores mark worse clinical parameters. Outliers are also 
shown (o).
A
B
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figure 2   Continued. C and D: Box plots of NIAF Sub-domain Gas Exchange 
with Δ (A-a) DO2 (C) and Δ PaCO2 (D) during cycle ergometry (kPa) 
according to the type of exercise limitation. Positive values mean 
rise in alveolar-arterial oxygen gradient or PaCO2 during exercise.
C
D
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DISCuSSION
The present study shows that maximal exercise capacity as expressed by O2 
max is correlated with many aspects of complaints, impairments and QoL in 
patients with COPD, in particular with measures of functional impairment in 
daily life. However, it must be noted that correlations were weak. Remarkably, it 
was found that exercise capacity, measured during incremental bicycle 
ergometry, was not associated with any of the other physiological variables 
representing airflow limitation, hyperinflation, gas exchange or systemic effects 
of COPD. Also, the physiological causes of exercise limitation derived from 
standard CPET did not appear to be related to problems in the different aspects 
of HS. These results strongly favor a clinical approach of patients with COPD of 
all severity stages to be assessed for their health status in a comprehensive and 
detailed manner (i.e. assessment of all sub-domains). This enables chest 
physicians to focus therapeutic efforts on the most affected (sub-)domains and 
in this way treatment can be tailored to the specific needs of the individual 
patient. Then it may be expected that patients will benefit more in their 
functional status and/or QoL.
Comparing our results with current literature revealed rather good agreement, 
but looking in more detail, it became evident that the literature is far from 
unambiguous. This is mainly due to methodological problems in HS assessment. 
First, studies to date measure HS in many different ways selecting different 
instruments from the available abundance of tools. Second, current instruments 
measure only few aspects of HS, and, third, do not always measure what can be 
expected at face-value [4]. Fourth, because of the lack of clear definitions, terms 
as HS, health-related QL and QoL are used interchangeably, posing further 
difficulty in interpretation of instruments presumed to assess those concepts [4]. 
 NIAF provides a definition of HS that is much more detailed and more 
formulated in terms of empirical observations than definitions found in the 
literature. In addition, the NIAF integrates many existing instruments in such a 
way that a detailed assessment of HS is warranted. 
I relation of O2 max %predicted with Physiological sub-domains
With respect to significant correlations between O2 max and other physiological 
parameters, the literature provided evidence for a role of FEV1, TLco, respiratory 
muscle force and FFM. However, the magnitude of those individual correlations 
varied greatly. Concerning FEV1, weak- moderate and even strong correlations 
can be found [21-24], proving that O2 max is not determined by a few fixed 
variables. This study exhibits no relationship between O2 max and the 
Maximal Exercise Capacity and its Relevance for Health Status | 55
3
sub-domain Airflow, composed of FEV1 (%pred.), E (%pred.) and maximal 
expiratory flow at 50%, although FEV1 (%pred.) alone did show a significant 
correlation (r = 0.46, result not shown). An effect of units can not be ruled out as 
a cause of the difference with some studies. Various studies used FEV1 expressed 
in liters, others as percent of predicted, but mostly not both. We preferred to use 
FEV1 %pred. values to eliminate variance based on height, age and sex. 
 O2 max neither demonstrated a significant correlation with Muscle Force, 
nor with any of the composing parameters maximal inspiratory and expiratory 
pressure or leg force, %pred. (results not shown). The lack of a significant 
association of sub-domain Body Composition, comprising BMI and FFM index, 
with O2 max, is probably explained by the small numbers of patients with  low 
BMI (≤ 21 kg/m²) or low FFM index (men < 16, women <15) in our sample (16 and 
21 respectively).
 Exercise capacity, as it is captured in the composite NIAF sub-domain, 
though remotely associated with some physiological variables such as FEV1, 
TLco and inspiratory muscle strength, must be considered to be a different 
aspect in the disease presentation of COPD, and therefore warrants separate 
assessment. This view is supported by two other studies that were based on 
principal component analysis, the method also involved in this study [25,26]. 
These studies, although not using identical variables, concluded that walking 
distance belonged to a separate factor than airway obstruction or spirometric 
variables, and hyperinflation.
II relation of O2 max %predicted with Complaints
The relation of O2 max or walking distance, with dyspnoea is variable according 
to the literature. Most studies [10-12;16;17;27] used different instruments to 
measure dyspnoea. In two studies examining this relationship, the symptom 
subscale of the SGRQ, which can be considered to fall into the domain Complaints, 
showed quite contrasting results, varying from a moderate to no significant 
correlation with O2 max [10;13]. With regard to fatigue, weak correlations (up 
to 0.36) were reported in some studies [10;12;17]. As for the main domain 
Complaints there may be some weak correlations with O2 max, in agreement 
with our results, but the disease aspects within this domain can by far not be 
replaced by the outcome of a CPET. 
  
III relation of O2 max with functional Impairment
Maximal exercise capacity can be measured either by incremental or constant 
loading tests. Walk tests now seem to have advantages over cycle ergometry in 
that they better represent someone’s functional capacity and disability (the 
6-MWD especially) and better respond to changes during rehabilitation 
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programs (more particular the shuttle walk test) [28]. Nevertheless, we would 
not credit these tests with enough accuracy to substitute for the validated and 
far more detailed HS assessment of the NIAF, as is our main conclusion (see at 
the head of this section).
Some studies investigated the relationship between measures of exercise 
capacity and aspects of the domain Functional Impairments using for example 
the SGRQ subscales Activity and Impact or Chronic Respiratory Questionnaire 
[10;17]. Also generic questionnaires inquiring physical functioning or 
accelerometer data reflecting actual daily activity, were applied [12,13]. Overall 
correlations between O2 max and indices of Functional Impairment were 
moderate to strong (r = 0.35 to 0.59), whereas the present study only found weak 
correlations, the highest being r = 0.36.
 One study [12] presented data on actual daily activity as measured by 
multi-axis accelerometer in correlation with exercise parameters, and showed a 
strong correlation (r = 0.60). Using a similar accelerometer, we found a clearly 
weaker correlation of the sub-domain Actual Physical Activity with exercise 
capacity (r = 0.30). This might be explained by different ways of exercising 
performed in the two studies. Higher scores on the accelerometer reflect better 
skills in walking, not necessarily in cycling, and thus correlation with 6-MWD is 
likely to be stronger. We think that maximal physical capacity on a cycle 
ergometer accurately reflects what a person is able to, but does not predict his or 
her pattern of daily activities. Some patients will exceed their limits in physical 
capacities, others avoid most exercise in fear of severe dyspnoea or fatigue or 
because of a more sedentary lifestyle.  Measuring this separate aspect of health 
status thus benefits the diagnostic work-up, because accelerometry indicates 
what a patient really does in daily life, O2 max what a patient can do, and 
Subjective Impairment indicates what a patient believes he can do.
IV relation of O2 max with QoL
Quality of Life refers to satisfaction with life [3;29]. The NIAF sub-domain 
General QoL refers to satisfaction with life in general and emotional wellbeing 
reflected by mood and anxiety. As far as we are aware from searches in the 
literature General QoL has rarely been investigated in relation to exercise 
capacity. In COPD the relation between general QoL and exercise capacity is 
grossly unexplored. Only one study correlated anxiety, depression, mood and 
psychological distress with 6-MWD, revealing no correlations [7]. Our findings 
regarding O2 max (%pred.), however, show weak but significant correlations 
with the sub-domains General QoL and Satisfaction Health (Health-related QoL). 
We would like to explain these two findings as follows. First Satisfaction Health 
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covers physical functioning and confidence in the future. Both Satisfaction 
Health and O2 max  are associated with the decline in exercise capacity during 
the progression of COPD, thus leading to some correlation. Concerning general 
QoL and O2 max we think that some relation is probable, because both 
parameters are connected to the severity of COPD according to the GOLD classes. 
However, from the scarce data on these relationships of course no firm 
conclusions can be drawn. 
Influence of Types of Exercise Limitations on Health Status
From a theoretical point of view, fatigue could be more prominent in patients in 
whom oxygen uptake is the dominant limiting factor, than in ventilatory-limited 
patients. This is supported by clinical experience learning that rapid onset of 
fatigue is common in patients with interstitial lung disease, who frequently 
show disturbed oxygen uptake. Progressive hypoxaemia during exercise, 
however, invariably provokes dyspnoea in patients with COPD. 
In our study no significant differences were found between the four types of 
exercise limitation in sub-domains of HS, except for some in the Physiological 
Functioning domain. No differences in any other sub-domain of HS were found, 
denying the existence of such relations that were postulated prior to the conduct 
of our study.
 In contrast to our findings, one study studying symptoms due to pathophys-
iological impairments during CPET in COPD patients and healthy persons, 
discriminated symptoms between those impaired by poor physical condition 
(more often leg fatigue) and those by ventilatory limitation (more often 
dyspnoea) [30]. However, a substantial amount of overlap existed in the Borg 
scores between these two groups. In addition, our study assessed dyspnoea and 
fatigue in quite a different way, i.e. during daily activities over a considerable 
time span.
Conclusion
This study is the first to evaluate the meaning of O2 max  by a large number of 
HS aspects, which were based on a validated conceptual framework of HS [4]. 
This framework measures many unique aspects of HS covering the domains 
Physiological Functioning, Complaints, Functional Impairment, and QoL. 
Thereby, this framework (NIAF) is to be preferred over usual methods of HS 
assessment.
 The results of this study imply that measuring O2 max helps to quantify the 
maximal workload, and to understand the physiological changes and limitations 
occurring in COPD during exercise. This is of great importance in planning 
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pulmonary rehabilitation or preoperative evaluation. However, CPET performance 
poorly predicts the severity of complaints, functional impairments in daily life, 
or QoL, since it is largely independent of these disease aspects, as proved by 
many low or even absent correlations. This means that in clinical practice, which 
also comprises rehabilitation, all main domains with their sub-domains should 
be assessed in order to obtain a detailed picture, because they represent unique 
aspects of a patient’s HS. Only then HS can be improved by directing therapeutic 
efforts at the most affected sub-domains.
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Appendix   A list of instruments indicating the subscales used for 
measuring main domains and sub-domains of the NIAF HS 
concept is shown
Main domains 
      Sub-domains
Parameters
Physiological 
functioning
     Airflow
     Static lung volumes
     Exercise capacity
     Gas Exchange
     Muscle Force
     Body Composition
FEV1%, MEF50%, VE%
TLC%, RV%
VO2%, TLCO%, BE-Delta, HRmax%
Δ (A-a) DO2
Δ PaCO2
PI max %, PE max %, Leg force %
BMI  kg/m², FFMI  kg/m ²
Instrument Subscale
Complaints
     Subjective Pulmonary
     Complaints
Physical Activity Rating Scale-
Dyspnoea
Dyspnoea Emotions Questionnaire
Quality of Life for Respiratory Illness 
questionnaire
Global activities
Global burden
Specific activities
Dyspnoea 
subjective
Breathing 
problems
     Dyspnoea Emotions Dyspnoea Emotions Questionnaire Frustration
Mood
Anxiety
     Expected Dyspnoea Physical Activity Rating Scale-
Dyspnoea
Expected dyspnoea
functional Impairment
     Actual physical activity Accelerometer 
     Behavioural impairment Sickness impact profile Body care & 
movements 
Home management 
Mobility 
Ambulation 
     Subjective impairment Quality of Life for Respiratory Illness 
questionnaire
Global Impairment
Sickness impact profile
General activities,
Social activities
Total
Burden
Social interaction
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Appendix   Continued.
Main domains 
      Sub-domains
Parameters
Physiological 
functioning
Quality of life
     General QoL Satisfaction With Life Scale
Symptom Checklist
Beck Depression Inventory
Total
Anxiety
Primary care
     Satisfaction Health Satisfaction-Physical
Satisfaction-Future
     Satisfaction Relations Satisfaction-Spouse
Satisfaction-Social
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ABSTrACT
Background and aims: Muscle mass depletion occurring in chronic obstructive 
pulmonary disease still leaves questions regarding its relation with health 
status. How health status should be conceived and assessed is a significant 
obstacle in answering these questions. This study tries to appoint which domains 
of health status are challenged by muscle depletion and evaluates evidence of 
gender difference.
Methods: 135 Patients enrolled in a cohort  study with initial assessment of 
health status  by the Nijmegen Integral Assessment Framework. In here 4 main 
domains and 16 sub-domains are recognized. These sub-domains were correlated 
with fat free mass index using baseline  data. Associations of fat free mass  and 
diffusion parameters with sex were elaborated.
Results: Muscle depletion occurred predominantly in those with low body mass 
index, and did not correlate with sub-domains of 3 main domains: Complaints, 
Functional Impairment and Quality of Life. In Physiological Functioning Hyper-
inflation correlated weakly. Diffusion capacity significantly correlated with fat 
free mass index in separate analyses of  pulmonary function data. Interestingly, 
diffusion capacity was significantly lower in women than in men.
Conclusions: muscle depletion hardly affects health status in COPD. Physiological 
correlations, however, do exist, pointing to severe disease, especially emphysema, 
and female sex as important concomitant factors.
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INTrODuCTION
In patients with chronic obstructive pulmonary disease (COPD) a distinction is 
currently made between local pulmonary and systemic non-pulmonary effects. 
By far the most important systemic effect in COPD is loss of muscle mass (1). 
Other systemic disease manifestations include loss of fat mass and bone mass 
(2,3). Although seen fairly often in persons with advanced disease, these changes 
in body composition are not obligatory, not even for the most severe stage of 
COPD (4). Among the deficiencies of these three tissue compartments, loss of 
muscle mass has achieved most of the research attention during the last two 
decades. 
 It  became evident that loss of muscle mass has significant impact on muscle 
function (5) thereby challenging exercise capacity, and prognosis on survival 
(6-8). This seems to be an independent effect, considering the association of lean 
body mass with risk of exercise limitation and 6-MWD, after correction for age, 
height, race, pulmonary function, smoking history and education level (9). 
Strikingly, the prevalence of muscle mass depletion seems higher in women than 
in men, as several reports have demonstrated for moderate and severe COPD, 
although this has not gained much interest (1,5,10). Studies of the pathophysiolog-
ical mechanism of its development, suggested that low fat free mass (FFM) is 
associated in some way, to the phenotype of COPD, being more prevalent in the 
emphysematous than the bronchitic type (11). This idea is challenging because 
the coincidence of emphysema and pulmonary cachexia could be regarded as a 
more or less distinct disease form within the COPD spectrum. How these data fit 
with each other, however, remains obscure.
 Association of low muscle mass with Health Related Quality of Life (HRQL) 
is another field of interest, yielding some recent clinical reports. Dyspnoea for 
example, presumably is correlated with FFM. But until now, only a handful of 
authors have addressed this issue (10,12-14). Thus far, no sound conclusions can be 
drawn regarding the relationship  between nutritional depletion and aspects of 
health status (HS), usually measured by different instruments including those 
for dyspnoea.  One study showed significant differences between low and normal 
FFM index for Saint Georges Respiratory Questionnaire (SGRQ) subscales 
Activity and Impact and concerning the domain ‘Invalidity’ of another specific 
questionnaire on HRQL (14). However, in a multicenter study of larger scale no 
differences in MRC dyspnoea scale or SGRQ scores were observed between 
depleted and non-depleted patients (10). 
 These inconclusive findings to a certain extent may be attributed to the use 
of a multitude of questionnaires that address only a limited concept of health 
status in studies to date. Our research group developed a validated and well 
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differentiated concept of HS that allows an integral assessment, and introduced 
a clinical instrument for measuring this integral HS (Nijmegen Integral 
Assessment Framework: NIAF).  This proved a worthwhile single HS instrument, 
feasible in clinical practice (15). The hallmark of the NIAF is that it covers four 
independent main domains, Physiological Functioning, Complaints, Functional 
Impairment and Quality of Life,  which could be subdivided into 16 independent 
sub-domains. This HS instrument thus has the potential to meet the objections 
of many instruments for HRQL that we know of today.
 So at present, we can not be quite certain that muscle wasting in COPD has 
no correlation with any aspect of Health Status assessed by this broad concept. 
In addition, there is emerging evidence that gender may play a role in the 
occurrence of muscle wasting in connection to a specific type of COPD.
 This study was planned with the hypothesis that muscle wasting is not 
associated with the non-physiological aspects of health status, and only has 
association with some physiological variables such as diffusion capacity, and 
with gender. Two questions were to be answered: 
 Is FFMI only related to health status in its physiological components, not in 
patient-relevant outcomes, when an integrated HS assessment tool is applied? 
And, if so, what  might be the role of gender in the association of low FFMI with 
the emphysematous type of COPD? 
 We correlated FFMI with all 16 sub-domains of HS, and then evaluated the 
prevalence of low FFMI in both sexes. Also, HS sub-domains were analysed for sex 
differences, and associations of sex with diffusion parameters were investigated.
 
MeTHODS
Patients
Patients with stable COPD were recruited from three different respiratory 
clinics to form a prospective cohort. Patients were recruited on a voluntary 
basis by their respiratory physician in two neighbouring hospitals, or a senior 
staff member (J.M.) of the Department of Respiratory Diseases in the University 
Lung Centre Dekkerswald. The study was approved by the institutional ethical 
committee (Radboud University Nijmegen Medical Centre). All participants gave 
written informed consent to the study protocol. The inclusion– and exclusion 
criteria have been published elsewhere (16). In brief, patients were included if:
1. COPD was ascertained by the GOLD criteria with a FEV1/VC  post broncho-
dilator < 70 %, and current or past smoking, and
2. FEV1 %predicted post-bronchodilatation was > 30 and < 80, presenting a 
sample of GOLD stages II and III, and
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3. patients were in stable clinical condition with no prior exacerbation in the 
last 6 weeks before enrollment, and
4. did not participate within the last 6 months in a pulmonary rehabilitation 
program.
Asthma with persistent airflow obstruction was excluded by review of the 
medical records (J.M.,T.V.). Asthma was defined as a long history of attacks of 
dyspnoea and marked reversibility of the airway obstruction confirmed by 
spirometry, dating from childhood.
All measurements were performed at enroLlment (baseline) and after one year 
(follow up), as part of a prospective study. Here, only baseline measurements are 
reported.
Measurements
Body composition
Body mass index (BMI) was derived from weight divided by square height. Body 
composition was measured by bioelectrical impedance (Bodystat, 1500, 
Douglas, Isle of Man, UK 1997). FFM (kg) was transposed to FFM index (FFMI) 
using the standard formula differentiated by sex. Three weight classes were 
distinguished, partly based on criteria used by others (10,17), underweight: BMI 
≤ 21 kg/m², normal weight: > 21 and ≤ 26 kg/m², and overweight: > 26 kg/m². 
Accordingly, patients were divided into depleted, FFMI < 15 kg/m² (females) and 
FFMI < 16 kg/m² (males), and non-depleted individuals whose FFMI was ≥15 
and ≥16 respectively.
Muscle function
Four different muscle groups were tested for maximal strength: M. Quadriceps, 
handgrip, inspiratory and expiratory muscles. Leg force was tested in sitting 
position with a 90 º knee flexion, asking the patients to extend the leg as hard as 
possible against a fixed resistance, using a Microfet 2 (Biometrics Europe, 
Almere, the Netherlands). Handgrip force was measured by a hand-held 
dynamometer. Respiratory muscle function was determined by mouth pressures 
expressed as Pi max and Pe max at RV and TLC level respectively with a Validyne 
pressure gauge. The best of three acceptable maneuvers was recorded. The 
predicted values published by Wilson were used to calculate Pi max and Pe max 
% predicted (18).
Pulmonary function
Routine spirometry with reversibility testing with a short-acting bronchodilator 
was performed by Masterscreen PFT, 2002, Jaeger Ltd., Würzburg, Germany. 
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Also static lung volumes and diffusion capacity (DLCO s.b.) were measured with 
this instrument, by the Helium dilution technique according to ERS recommen-
dations. Exercise capacity was evaluated at baseline by the use of a maximal 
incremental cycle ergometry (Corival 906900, Lode). During the tests patients 
were connected to the Vmax 29, (Sensormedics, Bilthoven, the Netherlands), for 
measuring gas exchange and ventilation with concurrent electrocardiographic 
and oxymetric monitoring (Datex, Helsinki, Finland). Arterial blood gas samples 
were drawn at rest, at maximum exercise and after 3 minutes rest. 
Health status
Health Status was measured by the recently published NIAF, which captures the 
integral health status of patients with COPD by four main domains and 16 more 
concrete sub-domains (15)  (originally 15 sub-domains were discriminated; later 
on fatigue proved to be a separate sub-domain in main domain Complaints; 
paper by J.B. Peters & J. Vercoulen et al., submitted)(19). Consequently, the 
individual condition is represented in 16 scores, covering the main domains 
Physiological Functioning, Complaints, Functional Impairments and Quality of 
Life. Existing instruments were selected to measure these 16 sub-domains, 
resulting in Sub-domain Total Scores (STS). Higher scores represent worse 
clinical condition, because all test results were mirrored before computing them 
by factor analysis. 
 An overview of the 16 independent sub-domains of HS and its underlying 
parameters and instruments is given in appendix 1.
Statistics
Sex difference of low muscle mass frequencies (i.e. persons with depletion) was 
tested by X² test. Correlations of FFMI with lung function variables were 
calculated by parametric test, since FFMI was normally distributed. Smoking 
status was tested for difference in mean FFMI by T-test. Multiple stepwise 
regression was used to analyse which of the significant variables in bivariate 
correlation matrix (table 3), were independently associated with FFMI. 
Differences in both sexes for parameters of diffusion capacity were examined by 
T-test, as was done for STS values of all 16 sub-domains.
 Pearson correlations were evaluated between FFMI and STS after checking 
for normal distribution of STS. Subsequently, FFMI data were dichotomized in 
depleted and non-depleted patients, and checked for differences in STS by T-test. 
Significance was determined at p value < 0.01, because of multiple comparisons.
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reSuLTS
Characterization of study sample
Of 361 initially selected patients, 135 fulfilled all inclusion criteria. Among them 
were mainly elder people, with longstanding COPD, most of whom were 
ex-smokers. Mean BMI was near the border of overweight, with moderate 
variance, in both sexes, while FFM and FFMI were clearly lower in females. Mean 
FFMI in women tended to be closer to the lower border of normal (15 kg/m²) 
Table 1   Patient characteristics N= 135.
variable mean (SD)
age  64.5 (9.3)
sex M/F 111/24
smoking status
   Current
   Ex-smokers
40
95
BMI  (kg/m²) n=135  25.7 (4.0)
FFM  (kg)
   Males / females    54.7 (6.3) / 41.1   (4.7)
FFMI (kg/m²)
   Males / females  18.0 (1.8) / 15.5   (1.7)
IVC %pred  92.4 (14.8)
FEV1 %pred  51.4 (11.9)
RV %pred  131.0 (34.8)
TLC %pred  103.4 (15.9)
DLCO %pred  66.8 (22.9)
KCO %pred  60.2 (22.0)
PaO2 (kPa) rest  10.9 (1.3)
PaCO2 (kPa)  rest  5.2 (0.5)
Handgripforce %pred  163.8 (41.5)
Pi max  8.3 (2.7)
Pi max %pred  111.6 (34.0)
Pe max  #  9.3 (3.0)
Pe max %pred  79.6 (23.4)
O2  max  % pred  70.8 (18.0)
Legend: # : refers to 133 subjects due to missing values.
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than in men. Handgrip force as percentage predicted was high in the total group. 
Other variables were not remarkable given the selection of GOLD II and III 
classes. These results are presented  in Table 1.
Correlations of muscle mass with HS sub-domains (STS) 
FFMI as continuous variable
Of all STS only Hyperinflation was significantly although weakly correlated 
with FFMI (Table 2). Exercise capacity and Dyspnoea Expected showed a trend 
Table 2   Correlations between fat free mass index (FFMI) and Sub-domain 
Total Scores (STS). In the right column mean STS are displayed for 
both sexes, and tested for differences by T-test. Sub-domains are 
grouped into the 4 main domains of the NIAF, depicted in bold.
Pearson correlation of ffMI with NIAf Sub-domain 
Total Scores and mean values of STS by sex
                                                                                                             
ffMI SeX
        Sub-domain correlation    P STS men STS women P
Physiological Functioning
Airflow - 0.14   0.118 787.49 783.41 0.59
Hyperinflation - 0.25   0.004 ** 150.15 163.14 0.041 *
exercise capacity - 0.19   0.031 * 457.34 477.22 0.036 *
Gas exchange
     Δ (A-a) DO2
     Δ PaCO2
 0.08
 0.11
  0.362
  0.204
- -
- -
Muscle force - 0.17   0.054 205.90 225.32 0.010 *
Body Composition - 0.95 < 0.001 863.24 883.85 0.001 **
Complaints
Subjective Pulmonary
Complaints 
- 0.05   0.577 62.47 65.73 0.486
Dyspnoea emotions   0.02   0.785 39.94 38.02 0.517
Dyspnoea expected - 0.17   0.049 * 2.21 2.77 0.008 **
fatigue - 0.10   0.255 26.29 28.38 0.397
Functional Impairment
Actual Physical Activity - 0.13   0.139 176.98 192.59 0.015 *
Behavioural Impairment - 0.09   0.308 23.85 27.23 0.367
Subjective Impairment - 0.10   0.247 103.68 108.99 0.340
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towards significance with p < 0.05. Correlations were very low however. No 
significant correlations were found between FFMI and sub-domains of Complaints, 
Functional Impairments and Quality of Life.
FFMI as dichotomous variable (depleted vs. non-depleted)
Quite similar results were obtained when these two FFMI groups were tested for 
differences in STS values. Hyperinflation was the only sub-domain that reached 
significance. Muscle Force and Exercise capacity proved not to be significantly 
different (results not shown).
Prevalence of muscle mass depletion and its physiological 
correlates
Low body weight defined as BMI below or equal to 21 kg/m² was present in 18 
patients (13 %). Overweight was found in 51 (38 % of the whole sample). Low fat 
free mass was encountered in 23 (17 %), and in the majority was accompanied 
by low BMI, Table 3. Low FFMI in patients with normal BMI occurred in 8 (12.1%), 
whereas it was absent in those with increased BMI. Frequency distribution of 
low FFMI by sex showed a higher proportion of depletion of muscle mass in 
females compared to males (29.2% vs. 14.4% respectively), although this did not 
reach statistical significance (Chi square test, p= 0.081, results not shown).
 FFMI analysed as an interval variable in relation to pulmonary and muscle 
function parameters showed a variety of significant correlations (Table 4). Low 
but significant correlations with indices of airflow and hyperinflation were 
Table 2   Continued.
Pearson correlation of ffMI with NIAf Sub-domain 
Total Scores and mean values of STS by sex
                                                                                                             
ffMI SeX
        Sub-domain correlation    P STS men STS women P
Quality of Life
General Wellbeing - 0.08   0.379 54.31         58.35 0.133
Satisfaction Health - 0.09   0.317 21.00         21.52 0.794
Satisfaction relations - 0.06   0.526 9.84           9.83 0.997
Legend: NIAF: Nijmegen Integral Assessment Framework. - :  Gas Exchange, a duplex variable 
derived from blood gas samples during cycle ergometry before and at the end of the exercise test, 
was not involved in this supplemental analysis for the revised version; *=p <0.05; **=p <0.01
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noted. Also, a significant but weak correlation was observed with VE max, a 
parameter derived from maximal cycle ergometry. Vital capacity (VC) or 
inspiratory capacity (IC) did not correlate. More remarkable however, were the 
moderate and highly significant correlations with parameters of diffusion 
capacity for carbon monoxide (CO), KCO %predicted in particular. Skeletal and 
respiratory muscle function were also correlated with FFMI, in this sample most 
pronounced with Pe max and handgrip force. These correlations were weak to 
moderate (Table 4).
 Because of the relatively high correlations of FFMI with parameters of 
diffusion, and the alleged association of low muscle mass with the emphysematous 
type of COPD, some further explorations were conducted into this subject.
 Multiple stepwise regression with FFMI as the dependent variable is presented 
in Table 5. Sex appeared the best predictor of low FFMI, followed by diffusion 
capacity (KCO) and Pe max (kPa). The explained variance of FFMI, determined 
by these 3 variables, was 32 %. Female sex appeared more strongly associated 
with low FFMI than male sex. This association was explored in more detail, by 
evaluation of sex differences in diffusion parameters DLCO, DLCO %predicted, 
KCO and KCO %predicted (Table 6, data not shown for KCO and KCO %pred.). All 
these parameters differed significantly, women showing worse diffusion for CO 
than men. Remarkably, sex difference was not observed for FEV1 %predicted 
(51 and 52 %, n.s.), as was tested by T-test. (data not shown).
Table 3   Distribution of BMI categories (underweight, normal and 
overweight) by sex for whole study sample (n=135) and subgroup 
with diminished fat free mass index (n= 23). 
BMI
≤ 21 kg/m² >21 - ≤ 26 kg/m² > 26 kg/m² Total
All patients, N (%)
  females: 24
  males:111
       18 (13)         66 (49)        51 (38) 135 (100)
Patients with low FFMI,
N (% BMI category)       
Total
        females          5 (28)           2 (3)          0   7
        males        10 (56)           6 (9)          0  16
        Total        15 (83)           8 (12)          0  23 (17)
Legend: BMI: body mass index. Low FFMI: fat free mass index defined as < 16 ( ), <15 ( ). 
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 Finally sex differences were evaluated for the 16 sub-domains of HS 
(integrated in table 2: correlations of STS with FFMI) to explore possible gender 
differences in the non-physiological sub-domains of health status. We only found 
one to be significant: Dyspnoea Expected, which showed a worse score in 
females. A trend toward significance was observed for Actual Physical Activity 
with p: 0.015.
Table 4   Pearson bivariate correlation coefficients between FFMI and  
pulmonary and muscle function variables.  N=135.
ffMI
Pearson’s r  p-value
PULMONARY FUNCTION VARIABLES
IVC    L     n.s.
FEV1 L   .27    .001
FEV1 %pred.     n.s.
MEF   .24    .005
TLC %pred.   .26    .003
VE max. L   .27    .002
DLCO   .37 < .001
DLCO %pred.   .37 < .001
KCO   .38 < .001
KCO %pred.   .42 < .001
MUSCLE FUNCTION VARIABLES
Quadriceps force kgF     n.s.
Handgrip force kgF .29    .001
P i max  kPa                 .19    .26
P i max %pred.                            .17    .047
P e max kPa .33 < .001
P e max %pred. .21    .014
Legend:  IVC: inspiratory vital capacity; FEV1: forced expiratory volume in 1 s; MEF: mid- 
expiratory flow; TLC %pred.: total lung capacity as percentage of predicted; VE max: maximal 
ventilation measured during cycle ergometry; DLCO: diffusion capacity for carbon  monoxide; 
DLCO %pred.: DLCO as percentage of predicted;  ; KCO: transfer factor for carbon monoxide 
expressed as DLCO/alveolar volume;  KCO %pred.: KCO as percentage of predicted;  P i max: 
maximal inspiratory mouth pressure;  Pe max: maximal expiratory mouth pressure.
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DISCuSSION
This study provides new findings regarding the relationships of muscle depletion 
with a broad collection of HS aspects. Furthermore, associations were found 
that link female sex, next to low FFMI and pronounced disturbance in CO-diffusion, 
Table 5   Summarized data from multiple stepwise regression with FFMI as 
dependent variable. Independent variables included sex, KCO, KCO 
%pred, DLCO, DLCO %pred, Pe max, Pi max, handgripforce, FEV1 
%pred, PEF, MEF(mid-expiratory flow), VE max en TLC %pred.
factors included in models r² f Standardized 
coefficients
significance
1) sex 0.216 36.03  - 0.464  < .001
2) sex
 Kco
0.300 27.80  - 0.396
 0.298
< .001
< .001
3) sex
  Kco
  Pe max
0.322 20.39  - 0.337
 0.287
 0.161
< .001
< .001
  .003
Legend: R² : explained variance between factor and FFMI; F: ratio of mean squares of regression 
and residual; KCO: transfer factor for carbon monoxide expressed as DLO/alveolar volume 
(DLCO: diffusion capacity of the lung for carbon monoxide); Pe max: maximal expiratory mouth 
pressure.
Table 6   Parameters of diffusion capacity for carbon monoxide by sex. 
Differences between men and women were analysed by T-test.
Diffusion capacity for carbon monoxide
N Mean (SD) Mean difference (CI) p
DLCO  men
            women
111
 24
6.4
4.1
2.27 (1.3-3.2) < 0.001
DLCO % pred.
            men
            women
111
 24
70.0
52.3
17.6  (7.8-27.4)    0.001
Legend: N: number of patients; SD: standard deviation; CI: 95 % confidence interval; DLCO: 
diffusion capacity for carbon  monoxide; DLCO %pred.: DLCO as percentage of predicted; KCO: 
transfer factor for carbon  monoxide expressed as DLCO/alveolar volume; KCO %pred.: KCO as 
percentage of predicted. N=135.
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to the clinical phenotype of COPD, i.e. the emphysematous type. More specifically, 
first, low FFMI had no relationship with the health status of patients with COPD 
in GOLD classes II-III, except for Hyperinflation, a sub-domain of Physiological 
Functioning. Hereby it now seems clearly established that muscle depletion in 
COPD has little to do with the non-physiological aspects of heath status. At least 
this holds true for moderate and severe COPD.
 When examined with single pulmonary function parameters within main 
domain Physiological Functioning, muscle mass depletion appears to be linked 
to indices of severe COPD, more specifically emphysema, such as diminished 
diffusion capacity, low FEV1 (L) and hyperinflation (TLC %pred.).
 Second, beyond confirmation of a higher prevalence of low FFMI in females, 
as reported earlier (1,5,10), (1)(16) this study revealed that the association between 
muscle depletion and diminished diffusion capacity is more pronounced in women. 
In multiple regression, low FFMI proved to be predicted (partly) by diffusion 
capacity, gender and Pe max. The strongest predictor, however, was gender. 
Female sex, eventually, was characterized by significantly lower parameters of 
diffusion capacity. This latter finding has not been reported before.
Correlation of  ffMI and aspects of Health Status assessed by  
the Nijmegen Integral Assessment framework
Correlation with non-physiological aspects of Health Status  
(main domains Complaints, Functional Impairment, Quality of Life)
Former studies invariably used instruments of HRQL which do not account for 
the different components that build a concept of health status that completely 
covers every aspect. The many instruments that exist, meant to illustrate how 
health status is affected by the factors under study, refer to seemingly voluntary 
subsets of health status. Therefore we preferred to evaluate this subject with a 
health status assessment that meets the objections of those commonly used 
instruments. The NIAF has a combined theoretical and empirical basis which is 
solid, and has been validated by recognized statistical methods (15). Its power 
lies in its complete picture that it provides of all relevant aspects of health status 
including the patient relevant outcomes.
 Two ways were used to display the FFMI data before statistical analysis, i.e. 
as continuous and dichotomized variable. With sub-domains beyond the main 
domain Physiological Functioning no significant correlations were found. 
Neither significant differences were found in scores representing these 
sub-domains between depleted and non-depleted patients. This confirms our 
hypothesis that in the main domains Complaints, Functional Impairment and 
Quality of Life FFMI has no relevant associations.
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 Some former reports concerning the question what impact muscle depletion 
might have on HRQL, in majority concluded that these features of COPD are 
unrelated (10,12-14). Only one (14) found a positive association between SGRQ 
Activity and Impact and ‘invalidity’ (a domain score of the Medical Psychological 
Questionnaire for Lung Diseases) and FFMI. Our results are in line with a large 
multicenter study (10) which examined correlations of FFMI with the MRC 
dyspnoea scale and the SGRQ Total and subscale scores. No relation was found 
with either dyspnoea or the SGRQ subscales and Total score. Therefore we 
conclude that FFMI is not associated with non-physiological aspects of HS, when 
assessed in an elaborate manner. At least for COPD within GOLD classes II and III 
we can be pretty sure.
 One can speculate though, whether this holds for GOLD IV too. Despite the 
clear negative correlations between FFMI and health status with respect to non-
physiological aspects, an exception may be necessary for some sub-domains of 
HS in patients with very severe COPD (GOLD IV). Notwithstanding a very weak 
correlation between some sub-domains of Health Status and the GOLD 
classification, found in an earlier study of our group  in GOLD II and III (16), a 
relation between declined muscle mass and some aspects of health status may 
be envisaged in GOLD IV. The established higher risk of mortality and 
exacerbation frequency with lower FFMI (6-8) seem indirect indications that low 
FFMI has important implications in the long run. Also, the course of patients in 
GOLD IV is accompanied more frequently by problems in maintaining functional 
status and in preserving quality of life, which are important components of 
health status. However, because of the large overlap between GOLD II and GOLD 
III HS scores it is hard to predict which sub-domains would correlate when GOLD 
IV would have been included (16). 
Correlation with pathophysiological parameters of Health Status  
(main domain Physiological Functioning)
In contrast to the absence of correlations with non-physiological sub-domains of 
the NIAF, described above, the associations with the main domain Physiological 
Functioning are obvious. Hyperinflation is highly significantly correlated with 
low FFMI, and Exercise capacity and Muscle Force are near significant. In 
addition, several indices of airflow are significantly correlated, as well as 
diffusion capacity and – not unexpected – Pe max and handgrip force. When 
interpreting these findings one should bear in mind that such single indices of 
pulmonary or muscle function are embedded in the referred sub-domains for a 
great deal. For example, diffusion capacity is an element in sub-domain Exercise 
capacity. See also appendix 1. 
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 Beside the fact that women seem more susceptible to developing muscle 
depletion, additional analyses revealed that gender is the strongest predictor of 
FFMI, even stronger then diffusion capacity and respiratory muscle strength. 
After further analysis it became evident that female patients with COPD have 
significantly lower mean diffusion capacity than men. This proved to be a new 
finding, which seems to fit in earlier data regarding the association between low 
fat free mass and the emphysematous subtype of COPD. An early study in this field 
(5) had shown that low FFMI is associated with low parameters of diffusion 
capacity. Low FFMI was shown to be more prevalent in women in some reports 
afterwards (1,4,5,10). The higher prevalence of low FFMI or BMI in the emphysematous 
type of COPD compared to the bronchitic type, discriminated by radiographic data 
and pulmonary function, has been reported only recently (11,19,20). 
 Engelen et al.(5) already speculated on the association of low fat free mass 
with more pronounced emphysema, as diffusion capacity proved to correlate 
with FFMI. They explained this by suggesting that emphysema is more likely 
associated with muscle wasting than the bronchitic type of COPD. The same 
authors supported their view with a nice study, based on the High Resolution-CT 
(HRCT) discrimination between the two subtypes, showing that weight loss 
(49% vs. 22%) and depletion (37% vs. 12%) were indeed more frequent in 
emphysema type than in the bronchitic type (11). 
 Further support came from 2 recent studies (19,20). The former showed that 
the bronchitic type of COPD assessed by HRCT was associated with higher BMI 
and CO-diffusion parameter and less severe hyperinflation than the 
emphysematous type and also than a mixed group. A confounding effect of 
smoking, however, can not be excluded, because the three groups showed 
different numbers of pack years and the well-known relation between smoking, 
metabolism and body weight (21). The latter study confirmed this in 
emphysematous type of COPD by significant correlations with the same variables 
(lower BMI and diffusion capacity, more hyperinflation) (20). Yet another study 
revealed significantly lower BMI in the category with most severe radiographic 
emphysema (22). It also concluded, however, that categories of emphysema 
severity based on HRCT assessment, can not be translated directly into clear 
clinical phenotypes. This is because of wide variation in radiographic emphysema, 
but otherwise  comparable disease stage. 
 All together this is rather strong evidence that there is some relation between 
phenotype and changes in body composition, especially regarding muscle mass.
 The present study confirms all these findings, and adds a link in-between of 
significantly lower parameters of diffusion in females. This effect of gender in 
the development of COPD and more explicitly emphysema, has not been 
mentioned earlier as far as we know. Perhaps the gender difference may be 
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linked to the greater susceptibility of women to the deleterious effect of smoking 
as outlined some years ago (23). The significantly lower values of diffusion 
parameters in women found in our study fits the concept of emphysema being 
more likely to occur in females than in men. On the other hand one could argue 
against this unproven concept, by supposing that women are less trained 
physically, thereby developing less muscle mass. Then the correlation between 
FFMI and female gender would be a coincidence dependent on lifestyle, but 
without connection to the pathophysiological process of emphysema.  In this 
study we did not find evidence that such is the case, for neither a marker of 
physical condition (Actual Physical Activity), nor Exercise capacity were 
significantly different in women.
 Apart from these explanatory considerations, there is the magnitude of the 
finding regarding female preference to develop the emphysema phenotype of 
COPD.  Since only 32 % of the variance in FFMI could be explained by gender, KCO 
and Pe max, more factors must play a role in muscle depletion. One might be 
physical deconditioning, although this study found no evidence. The sub-domain 
covering general physical activity, represented in this study by Actual Physical 
Activity showed no correlation with low FFMI, making it not a strong suspect. 
Other mechanisms such as different levels of systemic inflammation in the two 
phenotypes of COPD, or hormonal differences between men and women, such as 
different concentrations of testosterone, are imaginable, but should be 
investigated in further research.
Restrictions of this study
This study is at relative disadvantage by the small fraction of females (17.7 %), 
thereby somewhat undermining the power of lowered diffusion capacity in 
females and the higher likelihood than males of demonstrating muscle wasting. 
Furthermore, the results may not be extrapolated to patients with COPD in the 
most severe stage of disease. Nevertheless, this is the first study examining 
detailed relationships of muscle depletion with  an extensive series of 
physiological  variables and  the full picture of Health Status.
Conclusions
The results showed that loss of muscle mass is a phenomenon far more connected 
to physiological processes, like diminished CO-diffusion capacity and static 
hyperinflation, than to patient’s appreciation of health status (Complaints, 
Functional Impairment and Quality of life). By this study the issue of muscle 
depletion and its HS impact seems clarified, since an elaborate and comprehensive 
HS instrument was evaluated. This conclusion implies first that causes and 
approaches to restore the loss of muscle mass should be investigated vigorously, 
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because of its known association with decreased survival. Second, that clinicians 
should not worry much about the effects of muscle depletion on patient relevant 
outcomes like dyspnoea and fatigue, subjective impairments and quality of life, 
to mention a few.
 Female sex and characteristics of the emphysema phenotype of COPD appear 
evident correlates of lost muscle mass, since the association of gender, diffusion 
capacity, radiographic emphysema, and hyperinflation with low FFMI is present 
consistently, while co-factors were not encountered in this study. Because 
two-third of its variance is still unexplained, further research is needed to 
unravel additional causes of muscle wasting. Perhaps better strategies then 
come available for treatment of this clinically important disease aspect.
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Appendix 1   List of instruments with indication of subscales used for 
measuring main domains and sub-domains of the NIAF Health 
Status concept.
Main domains (bold text)
      Sub-domains (plain text)
Parameters
Physiological functioning
     Airflow
     Static lung volumes
     Exercise capacity
     Gas Exchange
     Muscle Force
     Body Composition
FEV1%, MEF50%, VE%
TLC%, RV%
VO2%, TLCO%, BE-Delta, HRmax%
Δ (A-a) DO2
Δ PaCO2
PI max %, PE max %, Leg force %
BMI  kg/m², FFMI  kg/m ²
Instrument Subscale
Complaints
     Subjective Pulmonary
     Complaints
Physical Activity Rating Scale-
Dyspnoea
Dyspnoea Emotions Questionnaire
Quality of Life for Respiratory Illness 
questionnaire
global activities
global burden
specific activities
dyspnoea 
subjective
breathing problems
     Dyspnoea Emotions Dyspnoea Emotions Questionnaire frustration
mood
anxiety
     Expected Dyspnoea
     Fatigue 
Physical Activity Rating Scale-
Dyspnoea
Fatigue Checklist Individual Strength
expected dyspnoea
subjective fatigue
functional Impairment
     Actual physical activity Accelerometer 
     Behavioural impairment Sickness impact profile body care & 
movements 
home management 
mobility 
ambulation 
     Subjective impairment Quality of Life for Respiratory Illness 
questionnaire
Global Impairment
Sickness impact profile
general activities
social activities
total
burden
social interaction
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Appendix. Supplementary information
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.clnu.2010.09.013.
Appendix 1   Continued.
Main domains (bold text)
      Sub-domains (plain text)
Parameters
Quality of life
     General QoL Satisfaction With Life Scale
Symptom Checklist
Beck Depression Inventory
total
anxiety
primary care
     Satisfaction Health Satisfaction-Physical
Satisfaction-Future
     Satisfaction Relations Satisfaction-Spouse
Satisfaction-Social
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ABSTrACT
Background: Exacerbations of chronic obstructive pulmonary disease (COPD) 
are held responsible for decline in health status (HS). This may not apply equally 
to all exacerbations, because different definitions are required for quite different 
illnesses. Selection of definition and sensitivity of the HS instrument may affect 
results regarding the impact of exacerbations. Sensitivity of a new HS instrument, 
which covers different and more aspects, has not yet been tested, with respect 
to exacerbations. 
Objectives: Confirmation of the negative HS effect of exacerbations by using a 
highly differentiated instrument, and to evaluate which aspects of HS are 
affected most.
 
Methods: One hundred and sixty-eight ambulatory patients with COPD were 
evaluated prospectively with regard to a wide range of HS aspects, at beginning 
and end of a 1-year follow-up. Recording of symptom changes and treatment on 
monthly diary cards resulted in the identification of event-based exacerbations. 
HS was assessed via a new validated instrument integrating both physiological 
and non-physiological sub-domains. Parametric correlations were calculated 
between exacerbation frequency and HS scores at the end of study. Partial 
correlations were then explored using HS scores at baseline to correct for prior 
HS levels.
Results: Correlations between exacerbation frequency and HS sub-domains 
were found to be frequent, predominantly in non-physiological sub-domains. 
After correction for HS scores at baseline, only 2 sub-domains (belonging to 
main domain Complaints), remained significantly but weakly correlated. 
Conclusion: Exacerbation frequency and HS show weak correlations after a year, 
but most of these disappear after correction for prior HS levels. In such 
exacerbations, aggravated HS probably takes much longer to manifest itself.
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INTrODuCTION
Chronic obstructive pulmonary disease (COPD) is a condition which has documented 
effects on several health aspects, namely ventilatory reserve, mortality, hospital 
admission rate and health-related quality of life (HRQL). Apart from these 
parameters, exacerbations have been studied in the last two decades as an 
additional outcome measure. They form a distinct aspect in the individual 
burden of COPD, require a great deal of expense in medical care and influence 
hard end points. Furthermore they are considered to impose, on their own, a 
negative effect on Health Status (HS) [1- 6]. Although the short term effects are 
particularly striking, negative effects in the long term also have been reported. 
Such effects seem to occur more commonly in frequent exacerbators [3] [7,8].
 Because exacerbations of COPD are defined by highly variable criteria with 
subsequent variation in severity of their course and thus outcome, their effects 
may vary along with their definition. Clearly, those identified by the necessity 
for hospital admission are those most likely to cause deterioration in HS, 
demonstrated by high rates of 1-year mortality after hospital admission for 
exacerbations [9,10]. Recently, a large survey of COPD admissions in the UK 
revealed that severity of exacerbations based upon unexpected radiological 
infiltrates may affect prognosis also in terms other than mortality [11,12]. In 
ambulatory patients for whom a course of corticosteroids and/or antibiotics is 
sufficient treatment for the exacerbations [5] [8] [13], the evidence also supports 
such a deleterious role, albeit with less hazardous outcome. Both types of 
exacerbation are considered to be so-called event-based exacerbations, that 
affecting ambulatory patients occurring more frequently than that associated 
with in-hospital treatment. When a symptom-based definition is used, less 
convincing reports are seen with respect to HS deterioration [6,7]. In fact, 
improvement in Saint George’s Respiratory Questionnaire (SGRQ) scores was 
noted over a 2-year period, with less improvement in frequent exacerbators.
 There is as much variation in methods for assessment of HS as there is in the 
definitions of COPD exacerbations. Establishing a relationship of HS with 
exacerbations may suffer from this lack of standardization. Several instruments 
are available, but a gold standard can not be assigned. Nearly all of them 
encompass only some aspects of HS, since HS is defined as an overall concept 
incorporating physiological functioning, symptoms, functional impairment, and 
quality of life (including HRQL) as main domains [14,15]. Most instruments 
meant to measure HS do not account for all these domains. In this study, we use 
a detailed assessment of HS, covering 4 main domains and consisting of 16 
sub-domains, providing more complete assessment [16]. We evaluated the 
magnitude of effects on HS of those exacerbations seen most frequently in daily 
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practice. A prospective cohort of ambulatory patients was followed up for 1 year, 
measuring HS at the beginning and the end of the study. With these follow-up 
data we examined whether a change in HS scores was attributable to exacerbation 
frequency. The event-based definition for ambulatory patients was chosen 
because of the high prevalence of that type of exacerbation and a relatively 
objective means of establishing this. We postulated that, at least, some HS 
aspects would be negatively affected by exacerbations.
MeTHODS
Design of study
A longitudinal cohort of patients with COPD was followed for 1 year. They were 
recruited from 3 different outpatient departments in urban and suburban areas. 
Patients received the usual care from these medical centres with regular control 
visits in ambulatory wards. They all underwent a detailed assessment of their 
pulmonary function and other aspects of HS, according to the Nijmegen Integral 
Assessment Framework (NIAF) [16], both at baseline and after follow-up. Cardio- 
pulmonary exercise testing (CPET) was conducted only at assessment 1. 
Exacerbations were monitored each month over the 1-year period.
Patients 
For this study, 168 eligible ambulant patients with moderate and severe COPD - 
mostly GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage II-III 
- were included after written informed consent and formed the patient sample at 
baseline. Twelve patients ultimately ended up with GOLD stages I (n=4) or IV 
(n=8) based on their lung function measurement at baseline, in contrast to prior 
pulmonary function in the recruitment phase. The study was approved by the 
ethics committee of the Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands. For detailed information about the recruitment procedure see 
Vercoulen et al. [16]. In summary, inclusion followed if: an established diagnosis 
of COPD was made within GOLD stages II and III (FEV1/FVC < 70 % and 30 % < 
FEV1 < 80% predicted after bronchodilation), and they were in a stable clinical 
condition without exacerbation in the 6 weeks prior to enrolment and they had 
not participated in a pulmonary rehabilitation program within the previous 6 
months.
Exclusion followed if patients had important comorbidity that could interfere 
with the study protocol or evaluation of HS components, likely to be influenced 
by such conditions as cardiac, neurological or oncological disease and diabetes.
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exacerbations 
Once a month over the 1-year period, patients completed structured diary cards, 
and returned these by mail each time. They recorded fatigue and breathlessness, 
and whether a change of cough, sputum production, sputum colour and dyspnoea 
had occurred compared to their normal stable state – for at least 3 days 
consecutively in the preceding month. In addition, extra doses bronchodilating 
inhaler therapy and courses of antibiotics and/or prednisone, administered by 
their general practitioner or chest physician, had to be recorded. Furthermore, 
some questions regarding medical consultations including hospital admission 
had to be answered. The diary card contained 17 questions in total.  During 
follow-up, patients were urged not to visit the clinic for any confirmation or 
treatment of their exacerbations, other than regular visits and in line with usual 
care policy. Patients who completed and returned 10 or more diary cards were 
considered evaluable.
 From the cards, the frequencies of exacerbations per patient were identified. 
We selected an event-based definition, based on the sole criterion of use of an 
antibiotic and/or course of prednisone for increases in symptom severity. 
Health Status measurement
HS was assessed by the NIAF developed by our research group [16]. This provides a 
validated clinical assessment that includes physiological as well as non-physiological 
aspects. It warrants a detailed assessment of HS, covering Physiological Functioning, 
Complaints, Functional Impairments and Quality of Life as main domains. These 
four main domains were subdivided into 16 relatively independent sub-domains 
[16,17], each representing a unique aspect of HS. Each sub-domain is represented 
by a single score, Sub-domain Total Score (STS). Table 1 shows detailed 
information regarding the description of main domains, sub-domains and their 
constituting of instruments as a result of the data handling by the NIAF.
Statistics
Basic analyses were performed to evaluate demographic characteristics and the 
clinical and physiological data of the sample. Total number, range and means of 
exacerbation frequency were calculated. 
 Exacerbation frequency taken as a continuous variable, was correlated with 
the HS STS at follow-up by Pearson correlations. To evaluate whether causal 
relationships exist between exacerbations and HS, partial correlations were 
calculated between exacerbation frequency and HS at follow-up, controlling for 
HS at baseline. p values were set at 0.05.
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Table 1   List of physiological measurements and questionnaires used in the 
NIAF and its specific relation to each sub-domain.
                                                         Parameters
Physiological functioning
     Airflow
     Hyperinflation
     Exercise capacity
     Gas Exchange
     Muscle Force
     Body Composition
FEV1%, MEF50%, VE%
TLC%, RV%
VO2%, TLCO%, Δ BE, HRmax%
Δ (A-a) DO2
Δ PaCO2
Pi  max %, Pe max %, Leg force %
BMI  kg/m², FFMI  kg/m ²
Instrument Subscale
Complaints
     Subjective Pulmonary
     Complaints
Physical activity rating scale-
Dyspnoea
Dyspnoea Emotions Questionnaire
Quality of Life for Respiratory Illness 
questionnaire
global activities
global burden
specific activities
dyspnoea subjective
breathing problems
     Dyspnoea Emotions Dyspnoea Emotions Questionnaire frustration
mood
anxiety
     Expected Dyspnoea
     Fatigue
Physical activity rating scale-
Dyspnoea
Fatigue Checklist Individual Strength
expected dyspnoea
subjective fatigue
functional impairments
     Actual physical activity Accelerometer  
     Behavioural impairments Sickness impact profile body care & 
movements 
home management 
mobility 
ambulation 
     Subjective impairments Quality of Life for Respiratory Illness 
questionnaire
Experienced Burden of Daily 
Activities
Global Impairment
Sickness impact profile
general activities
social activities
total
total
burden
social interaction
Decline of Health Status Sub-domains by exacerbations of COPD | 93
5
reSuLTS
Patient Characteristics
Patient characteristics are presented in Table 2. After recruitment, 168 patients 
were included,  mainly older men, a majority of whom had a clear smoking 
history and had had a diagnosis of COPD for years. They represented moderate 
to severe COPD according to GOLD criteria, with mean BMI just above the upper 
limit of normal, signs of mild hyperinflation and diminished diffusing capacity 
for carbon monoxide. Mean values of partial pressure of oxygen and of carbon 
dioxide in arterial blood (PaO2 and PaCO2) were within normal limits. Mean 
inspiratory muscle strength was slightly above normal. 
 Figure 1 shows details of the inclusion of patients and the subsequent 
number of drop outs (n=22). Ultimately, 116 patients proved evaluable with 
regard to baseline data and the follow-up registration of exacerbations. The 
frequency distribution of exacerbations is listed in Table 3, together with the 
distribution of GOLD stages. Due to missing data concerning HS at assessment 2, 
another 9 patients were excluded from follow-up analyses after a year, leaving 
107 individuals for studying. Sequelae of the sample showed a death rate at 1 
year of 2.9 %. Hospitalization because of exacerbations occurred in 17 of 116 
patients with complete data (14.6 %).
Table 1   Continued.
                                                         Parameters
Quality of life
     General QoL Satisfaction With Life Scale
Symptom Checklist
Beck Depression Inventory
total
anxiety
primary care
     Satisfaction Health Satisfaction With Life Scale Satisfaction-Physical
Satisfaction-Future
     Satisfaction Relations Satisfaction With Life Scale Satisfaction-Spouse
Satisfaction-Social
MEF: maximum expiratory flow; VE%: minute ventilation at maximum exercise in percentage 
predicted; VO2%: maximal oxygen consumption as percentage of predicted; Δ BE: change in base 
excess during maximal cycle exercise test;  HRmax%: maximum heart rate as percentage of 
predicted; Δ (A-a) DO2: change in alveolar-arterial oxygen difference during cycle exercise test. 
Pi  max % : maximal inspiratory mouth pressure percentage predicted; Pe max % : maximal 
expiratory mouth pressure percentage predicted; FFMI: fat-free mass index.
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effect of exacerbation frequency on Health Status
Correlations between exacerbation frequency and HS sub-domains (STS) 
showed 8 of 15 sub-domains to be significant (Table 4). Though 1 sub-domain in 
main domain Physiological Functioning was significant, the non-physiological 
Table 2   Patient characteristics at baseline, comparing  those included 
(complete follow-up measurements and ≥ 10 diary cards) and 
excluded from analyses (drop outs  or incomplete diary cards)
Total 
sample
N=168
Included in
analyses
N=116
excluded from 
analyses
N=52
Age, years 64.5  (9.1) 64.4 (9.4) 64.6 (8.6)
Sex   M/F 131/37 92/24 39/13
Married (n=163) 129  (79.1) 95  (82.6) 34  (70.8)
Smoking history;
n=166 
  Current
  Ex-smokers
  Non-smoker
n=166
45 (27.1)
98 (59.0)
23 (13.9)
n=115
23 (20.0)
78 (67.8)
14 (12.2)
n=51
22 (43.1)
20 (39.2)
  9 (17.7)
Duration of COPD diagnosis (n=161)
    < 1year
    1 – 10 years
    > 10 years
20
64
77
16
45
53
 4
19
24
IVC, L 3.6     (0.90) 3.7     (0.86)  3.5     (1.0)
IVC %pred. 92.7   (15.5) 90.6   (15.6)  93.6   (15.4)
FEV1 p.b, (L.) 1.52   (.48) 1.56   (.48)  1.42   (.48)
FEV1 %pred. 51.6   (13.6) 52.8   (14.1)  48.8   (12.1)
FEV1/IVC, % 42.9   (11.3) 43.5   (11.7)  41.9   (10.5)
TLC (%pred.) 103.1 (16.0) 103.6 (16.3)  101.9 (15.6)
TLCO (%pred.) 68.7   (23.9) 69.9   (24.6)  66.1   (22.0)
PaO2,  (kPa) 10.9   (1.4) 10.9   (1.2)  11.0   (1.7) 
PaCO2,  (kPa) 5.2     (0.5) 5.1     (0.5)   5.2     (0.6) 
BMI  (kg/m2) 25.6   (4.1) 25.9   (4.1)  24.8   (3.9)
Pi max.  (%pred.) 114.0 (34.2) 114.6 (33.0)  112.5 (37.2)
Data presented as mean (SD), or frequency (%). IVC: Inspiratory vital capacity; FEV1 p.b.: forced 
expiratory volume in 1 s after bronchodilation; FEV1 %pred.: FEV1 as % predicted; FEV1/IVC %: 
FEV1 as percentage of IVC; TLC: total lung capacity; TLCO: transfer factor of lung for carbon 
monoxide; Pi max.: maximal inspiratory mouth pressure.
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domains predominately represented the significant correlations; however, 
correlations were weak in every sub-domain.
 To account for the effects of the prior HS condition, partial correlations were 
analysed. Only 2 sub-domains were significantly correlated with exacerbation 
frequency, but very weakly (Table 4). Both were components of a main domain 
Complaints: Subjective Pulmonary Complaints and Expected Dyspnoea.
figure 1   Flow chart of inclusion of patients with subsequent follow-up events, 
numbers of participants and reasons for drop out
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
361  eligible 
45 not willing further study-information  316 informed about study 
168 gave informed consent  
148 did not consent to study protocol 
Measurements at baseline (physiologic & non-physiologic)   
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
D  9 
I 10 
A 11 
R 12 
Y      months 
      
C   
A   
R   
D      
S         
  
22 did not attend 2nd visit: death (5), 
sick (3), pulmonary rehab.(2), various 
reasons (9),  reason unknown (3)  
 
146 attended repeat measurements after 1 
year (physiological & non-physiological)  
 
116 completed ≥10 of 12  
monthly diary cards
analysed for baseline data  
30 completed < 10 monthly diary 
cards 
 
107 with complete 1st & 2nd 
measurements and ≥10 
monthly diary cards
analysed for follow -up data  
9 had substantial missing data in 2nd
measurement 
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Table 3   Frequency distribution of exacerbations in 116 evaluable patients 
with total and mean number, according to GOLD stage.
exacerbation 
frequency a
                                                               
GOLD Stage
distribution
 I II III IV
Total (%)          Number of 
exacerbations
0  0 24  10  1    35    (30.2
1  0 18   7  1      26    (22.4) Total b : 257
2  1  9  6  1 17    (14.7) Mean no./patient: 2.20
3  1  7  8  3 19    (16.4)
≥4
Total
 1 8  9  1
 3 66  40  7 
19    (16.4)
a In patients who completed ≥ 10  diary cards.
b In the study sample during the 12-month follow-up. 
Table 4   Correlations between exacerbation frequency and HS sub-domains 
(STS) measured after follow-up with partial correlations in right 
column, involving correlations with baseline HS (STS baseline).
Main domain with
    sub-domain
   differentiation
Pearson Partial correlation
Physiological functioning
   Airflow 0.161 0.178
   Hyperinflation -0.121 -0.1
   Exercise capacity   a 0.233* 0.154
   Muscle Force 0.036 -0.048
   Body Composition 0.091 0.063
Complaints
   Subjective Pulmonary
   Complaints
0.292** 0.207*
   Dyspnoea Emotions 0.186 0.123
   Expected Dyspnoea 0.258** 0.267**
   Fatigue 0.234* 0.112
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DISCuSSION
Main results of the Study
This study showed that HS effects of exacerbations in ambulatory patients are 
hardly detectable after 1 year of follow-up. To a large extent, the positive 
correlations between exacerbation frequency and HS at a certain moment in the 
course of COPD proved to be accounted for by prior HS condition. This was the 
case for nearly all HS sub-domains.
effects of exacerbations on Subsequent Health Status
Associations of exacerbation frequency and subsequent HS were similar to the 
results of earlier reports [1] [4,5]. It is not clear  from the literature whether all 
exacerbations cause HS impairment. This is because there is such variety in the 
design and methodology of studies, besides varying definitions of exacerbations 
and variability in the assessment of HS itself. It is only with regard to its strong 
association with mortality that there seems to be little doubt, provided 
Table 4   Continued.
Main domain with
    sub-domain
   differentiation
Pearson Partial correlation
functional Impairments
   Actual physical
   activity
0.076 0.088
   Behavioural
   impairments
0.238* 0.094
   Subjective
   impairments
0.315** 0.11
Quality of Life
   General QoL 0.273** 0.091
   Satisfaction Health 0.196* 0.069
   Satisfaction Relations 0.13 0.127
Correlations and partial correlations. *: p < 0.05; ** p < 0.01.
 a Exercise capacity refers to cycle  ergometry conducted at baseline, composed of HR max %pred., 
VO2 max %pred., TLCO %pred and Δ BE. Here,  it is only based on TLCO %pred. measured at 
follow-up. See footnotes to tables 1 and 2 for explanation of abbreviations.
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in-hospital exacerbations are taken into account. However, it is obvious that 
many patients suffer episodes of exacerbation long before they reach terminal 
illness. How these exacerbations relate to HS derangements is less clear. 
Available reports show some evidence that HS declines with exacerbation 
frequency, but HS was measured either shortly after exacerbations [4] [18] or by 
retrospective means [13] [19,20]. Long-term studies with prospective design have 
delivered only indirect or weak evidence for a harmful effect on HS (by 
demonstrating slower recovery months after an exacerbation in those with a 
second exacerbation) [4] [6,7]. These studies recruited ambulatory patients in 
general. Another study, which has often been cited and also provides some 
evidence [8], represents a post hoc analysis, dealing with the effect of inhaled 
corticosteroids upon HRQL. It claims that the corticosteroids exerted a protective 
effect on SGRQ scores by lowering exacerbation frequency.
The exacerbations in our sample of ambulatory patients can be considered to 
represent average severity. They are defined by physician-based clinical 
diagnosis calling for outpatient medical treatment. Only a small number 
necessitated hospital admission and, moreover, 1-year mortality was low, 
indicating that they did not represent the most severe exacerbations and can 
thus be regarded in between ‘very mild’ and ‘more severe’ exacerbations. Care 
was taken to avoid the effects of short-term changes in HS by excluding patients 
with recent exacerbations.
 By taking into account the prior levels of HS represented by the scores at the 
start of follow-up, the possible influence of these variables was eliminated by 
calculating partial correlations. This statistical method provides a correction of 
already existing correlations a priori and makes the true causal role of 
exacerbations more visible. In doing so, it in fact appears that in none of the 16 
sub-domains was a clear effect of foregoing exacerbations detectable. The 
correlations of Dyspnoea Expected and Subjective Pulmonary Complaints are of 
such small magnitude that we are left no other interpretation. Hence, the 
conclusion can be drawn that HS is not affected by moderately severe event-based 
exacerbations in ambulatory patients after a 1-year period. This is against our 
postulate, but not in true contrast to studies of Llor and Miravitlles et al. [6, 7]. 
For they showed that, primarily based on symptom-based exacerbations, SGRQ 
scores actually improved in both groups of exacerbators, the infrequent as well 
as the frequent. Interestingly, the frequent exacerbators had higher, i.e. worse, 
HRQL scores already from the outset, which fits in with findings of significant 
correlations of HS sub-domains with exacerbation frequency at study upon 
entering our study. It also seems to counter the data reported by Spencer et al. 
[8], which estimated a decline in SGRQ total score of somewhere around 2.4-2.9 
units over a 3 year period. Such a rate, however, means that there was no 
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clinically relevant change (a minimum of 4 points), and so a decline, if present, 
can be considered minimal.
 In summary, this study further delineates the existing evidence regarding 
the causal role of exacerbations in the decline of HS. Depending on severity and 
the pre-existing level of HS, within a limited time span of several years, in mild-
to-moderate exacerbations the effects may be nearly absent.
Perspective
Overlooking the studies mentioned above, it seems clear that effects of 
exacerbations on HS are differentiated. The severity of the exacerbations plays 
an important role in the ultimate effects. It is also evident that the definition of 
exacerbations used for any particular study will influence severity to a large 
extent, confounding the results. How can all the different evidence put together 
in perspective?
 Evidence so far seems to reveal that symptom-based exacerbations - 
presumably mild exacerbations, since about half of them remain unreported and 
thus untreated [1] - have no detectable impact on HS within a 2- to 3-year time 
span. If not too frequent, they might even show better HS after some time for as 
of yet unclear reasons, which could be hidden in a bias caused by participating in 
a long-term study. Event-based exacerbations, which rely upon diagnoses by 
involvement of a physician, may have no or only a minor impact on HS, if treated 
predominately out of the hospital. HS aspect scores may fluctuate strongly 
depending on the interval between exacerbation onset and the moment of 
measurement. In the long run, extending this by at least 6 months, frequent 
exacerbators may not fully recover, resulting in a slow worsening of certain HS 
sub-domains. This process appears to take several years to develop. Earlier and 
probably more prominent changes in HS may occur in patients who have been 
admitted for an exacerbation who receive appropriate treatment in hospital 
wards. They might show an accelerated decline of HS.
Strength and Weaknesses
This study is credited by its longitudinal design with considerable length, 2 
consecutive assessments and the use of a well-validated and detailed assessment 
of HS. We are aware of only 3 studies with a comparable or longer follow-up [1, 
6,7]. Some reports which state that exacerbation frequency is associated with 
decline in HS, are cross-sectional or they measured HS only at the end of 
follow-up [1, 13]. The chosen method for assessment of HS (NIAF) has some 
advantage over HS instruments with a longer tradition, such as the SGRQ and the 
CRQ (Chronic Respiratory Disease Questionnaire).  Most instruments measure 
only a few aspects of HS and do not always measure the aspect of HS that they 
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were thought to measure [21]. The NIAF aims to cover all relevant aspects of HS 
[16] and, therefore, is a convenient tool when looking into detail which aspects 
of HS are affected by exacerbations. 
 The exclusion of patients with recent exacerbations renders a relative 
independency of short-term effects on HS sub-domains. Within 6 weeks, most 
symptoms of an exacerbation have subsided, promoting the evaluation of 
long-term effects [22,23]. On the other hand, a 1-year follow-up may be too short 
to develop changes in HS great enough to become significant. Longer follow-up 
studies, however, are more difficult to perform because of the increasing number 
of drop outs or incomplete data. Besides, the mean frequency of exacerbations in 
the present study (2.2) is similar to rates in studies of comparable length, and 
thus seems adequate to exert an effect.
 Another relative weakness is that we used monthly diary cards to identify 
event-based exacerbations by self reporting. Medical records were not checked as 
to whether oral courses of antibiotics and/or prednisone had indeed been given.
Implications
This study, once more, demonstrates the concern with the wide variety of events 
captured by the term exacerbation. It appears that HS decline by home-treated 
exacerbations over a time span of 1 to 2 years is minimal (sub clinical) at most. 
That is why, above all, further studies are required with a particular effort to 
define exacerbations and their severity as clearly as possible. They could  then 
be directed into more binding variables with regard to their consequences, than 
variables with elementary labels like frequency, as it is now. Studies with a long 
follow-up are envisaged for moderately severe and mild exacerbations, in order 
for effects to be detected.
 The repeated finding of clear associations of low HS with exacerbation 
frequency also requires further study, because we do not know how this intricate 
relationship comes about. It can not be excluded that both phenomena mutually 
reinforce each other. It seems worth exploring the notion of low HS being a risk 
factor for developing exacerbations, in order to obtain the tools to intervene and 
prevent exacerbations. As an example, depression has been shown to be a factor 
that predicts exacerbations [24].
Limitations
The patient sub-population in this study contained patients with only minor 
comorbidities. The exclusion of major comorbidity might have changed the 
correlations between HS sub-domains and exacerbation frequencies, with 
respect to their impact on HS. Comorbidity is likely associated independently 
with disability and age, and may affect the trend to introduce medical care, 
thereby indirectly altering the frequency of exacerbation [13,20,25]. 
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Extrapolation of the results to other subpopulations of COPD can not therefore 
be made. 
Conclusion
Exacerbations of COPD, more specifically the ones considered moderately severe 
and occurring in ambulant patients in the majority, do not exert a measurable 
effect on HS as measured by the NIAF in a 1-year follow-up.  The negative effect 
of this type of exacerbation on HS apparently is a slowly developing phenomenon.
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SuMMAry AND  GeNerAL DISCuSSION
INTrODuCTION
The present studies compiled in this thesis have a common focus: the relationship 
of some clinical topics in COPD with a comprehensive model of assessment of 
Health Status. The reason for studying these relationships lies in the acknowl-
edgement that up till now much confusion exists concerning the meaning of the 
concept of health status and the way it should be assessed. Consequently, no 
clear interpretations are possible from studies so far with respect to the topics 
studied. In chapters 2 to 5 these topics are presented. Here the main results will 
be summarized in a concise way. 
The value of the GOLD classification regarding the assessment of 
Health Status
Chapter two describes the meaning of the GOLD classification for discrimination 
in different levels of Health Status. Health Status is defined by the Nijmegen 
Integral Assessment Framework, a recently developed model to assess Health 
Status by means of 4 main domains, divided into 16 (initially 15) sub-domains. 
The GOLD classification was thought to provide comparable patients by division 
into 5 classes of severity and thereby could tailor the treatment and management 
of COPD. This basal viewpoint was doubted however, by reviewing the literature 
on the subject, which made clear that different aspects of health status correlated 
weakly with severity classes of the GOLD division. That gave rise to a study to 
examine the relevance of the GOLD classification system for estimating the 
severity of clinical problems patients may suffer. In a GOLD II and a GOLD III 
group of patients only 5 of 15 tested sub-domains of Health Status proved to be 
significantly different between both classes. The differences were small and, 
moreover, showed substantial overlap, so it was concluded that the GOLD classes 
have no real significance in discriminating health status problems, except 
airflow itself, which represents one of the sub-domains of Health Status. The 
consequences are on the therapeutic side predominately, because identification 
of the sub-domains which are bothersome for patients, should guide the selection 
of treatment options.Taken together, GOLD staging can not help in planning 
which treatment is best suitable for individual patients.
The relationship of maximal exercise capacity and Health Status
Chapter three deals with the question how exercise capacity relates to 
functional status and dyspnoea in patients within the full range of the COPD 
spectrum. Functional status is a poorly defined term, but has to do primarily 
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with the physical performance of the tasks of daily life. More than pure maximal 
physical strength or endurance it concerns the sphere of daily activities. Because 
of its vague meaning it rather is abandoned from use in clinical studies. The 
NIAF HS framework on the contrary, offers concrete measuring tools to assess 
one’s abilities in daily living. Maximal exercise capacity measured by incremental 
cycle ergometry has been evaluated in several studies which stated that it is a 
better measurement of overall Health Status than pulmonary function tests at 
rest. Beside the fact that this may be true, it does not mean that it is a valid 
indicator of Health Status. In fact, if maximal oxygen consumption is taken as the 
parameter of exercise capacity, inconsistent results are found with respect to 
correlations with a variety of HS aspects. This may be caused by a too inaccurate 
definition of HS and/or incomplete HS assessment in those studies. Compared to 
the newly presented Health Status framework, comprising as main domains 
Physiological Functioning, Complaints, Functional impairments and Quality of 
Life with their sub-domains, studies so far seemed to have suffered both defects. 
When GOLD II and III patients were analysed for correlations between VO2 max 
and sub-domains of Health Status many of these showed significant correlations. 
However, all of these correlations were weak. It turned out in further analysis, 
that no differences were noted in sub-domain scores according to the type of 
exercise limitation, which was held responsible for the reached VO2 max, except 
for some in the domain Physiological Functioning. The types of exercise 
limitation that were discerned were: ventilatory limitation (I), limited oxygen 
uptake (II), defined as an enlarged gap in alveolar – arterial Pa O2 at maximal 
exercise with resulting hypoxaemia, cardiocirculatory limitations (III), 
combining cardiovascular disease and impaired physical condition, symptom 
limitation (IV), based on stopping the exercise test for severe symptoms without 
reaching the physiological maximum and combinations (V) of the 1st and 2nd 
type or the 1st and 3rd type. All these results can be summarised by stating that 
VO2 max is not a good index of the many sub-domains of Health Status, 
irrespective the type of exercise limitation. In conclusion, when one aims to 
measure Health Status, maximal exercise capacity is a bad surrogate parameter 
to use. 
Muscle depletion and its relationship with Health Status and the 
COPD phenotype
Chapter four explores the relationship that might exist between muscle 
depletion and a series of health aspects. After it was concluded that the literature 
regarding such relationships was far from conclusive, the question was raised 
which health aspects are under attack by muscle depletion, which is not a rare 
condition in COPD, particularly in progressive cases. Since assessment of Health 
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Status is performed in so many ways, the broad coverage of the NIAF instrument 
was utilized to try to answer this question. A second goal of this study was to 
explore in some detail the role of gender in the development of muscle depletion, 
because women seem to be more prone to develop depletion of muscle mass, and 
this muscular condition in turn is associated with the emphysematous phenotype 
of COPD in some studies. A decreased fat free mass index was the outcome 
parameter to indicate muscle mass depletion. This was correlated to the 16 
sub-domains of the NIAF Health Status and proved not to be associated with 
aspects of HS in domains other than Physiological Functioning (more specifically 
Hyperinflation and Body Composition). This meant that in domains Complaints, 
Functional Impairments and Quality of Life no associations were demonstrated 
with the fat free mass index. It thus seems that low muscle mass has no impact 
on Health Status, excluded the concomitant changes in Physiological Functioning. 
Within this latter area correlations were marked that depicted a relationship 
with more severe disease, specifically in ventilatory parameters, diffusion 
capacity and expiratory muscle force.  
 As regards the significance of female gender with respect to occurrence and 
associations of low muscle mass, a remarkable finding was made. Not only appeared 
low muscle mass to be associated, in separate analyses, with female sex and 
more severe COPD, females showed, in addition, to have lower carbon monoxide 
diffusion capacity. These differences reached high statistical significance in all 
common diffusion parameters. This brougth us to conclude that women have 
greater risk to attract a type of COPD characterized as the emphysematous 
phenotype. A warning sign although, seems appropriate here. Because only 32 
% of the variation of fat free mass index is explained by the 3 variables sex, 
diffusion capacity and Pe max. This indicates that surely not all patients with 
COPD show this association.
exacerbations and their effect on diminished Health Status
Chapter five is a  longitudinal study with assessment of baseline and follow up 
data regarding health status with one year interval. In between these two 
assessments the occurrence of exacerbations was measured by monthly 
questionnaires, and information about medication use, use of rescue inhalations, 
changes in prescriptions and medical consultation or admission to the clinic was 
collected. This design had been chosen to relate the course of Health Status to 
the occurrence of exacerbations. Two kinds of definitions for exacerbations of 
COPD are commonly applied in clinical studies, being symptom-based and 
event-based. Yet, these episodes of clinical worsening are not sharply defined by 
the criteria utilized, especially this holds true for symptom-based exacerbations. 
Both research and clinical practice await better definitions, but for now one has 
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to accept these. In the study of this thesis too, these two definitions were 
incorporated, but in the preparation phase of the study the event-based was 
selected as the most reliable one. From the results it was estimated that the 
supposed severity of the exacerbations encountered, was moderate overall. The 
study tried to confirm the results of previous studies on the subject, leading to 
the idea that exacerbations have a negative impact on Health Status. This effort 
was undertaken in realizing that health status assessment in most earlier 
studies hampers good methodological quality. This viewpoint is based on review 
of the literature on health status measurement, which tells us that most 
instruments are incomplete and/or poorly validated.
 From 168 patients with COPD who were included in the study, sufficient 
data were gathered at the end of follow up in 107. Many of those excluded (52) 
had not succeeded in returning sufficient answers in the 12 consecutive 
questionnaires to the investigator team. The frequency of exacerbations was 
correlated with the scores of all 16 sub-domains of Health Status, that were 
discerned by the Nijmegen Integral Assessment Framework. By subsequent 
calculation of partial correlations, the true effect of exacerbations on Health 
Status was shown more precisely because this method adjusts the results for 
preexisting correlations at the start of the follow up period. Thereby, in the end, 
only two sub-domains, Subjective Pulmonary Complaints and Expected Dyspnoea, 
proved to demonstrate a statistical significant, but very weak correlation. This 
means that a period of one year in which on average 2.2 exacerbations occurred 
per patient, only a very small negative effect is noted in a narrow corner of the 
whole Health Status concept. It was further concluded in this study that it takes 
probably much longer to elicit evident worsening of Health Status than one year, 
provided the same range of severity of exacerbations is present.
Closing remarks
The studies collected in this thesis affirm some ideas in the growing knowledge 
about COPD and comprise some new findings. It also renders the opportunity to 
be more aware of the importance of evaluating a patient‘s health in sufficient 
detail, for which purpose the newly introduced NIAF seems a better tool than 
most other instruments used hitherto.
 First, the very limited value of using the GOLD classification in patient 
management is clearly outlined. Second, the significance of maximal exercise 
capacity in evaluating individual health of patients with COPD is taken back to 
its, mainly physiological, meaning. Making clear that it should not be used as a 
surrogate for Health Status assessment. Third, muscle wasting or loss of muscle 
mass, should be considered as a pure pathophysiological phenomenon. It has no 
associations with non-physiological components of Health Status, representing 
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the domains of Complaints, Functional Impairments and Quality of Life. 
Interestingly,  it turned out that female sex may play an important role in the 
direction the COPD pathology will develop. Here an old but not yet buried issue 
emerges again: the discrimination between blue bloaters and pink puffers. The 
last term was used for long to indicate the emphysematous type of COPD. Finally, 
it became evident that exacerbations of COPD surely do not all exert a negative 
effect on Health Status. In one year no relevant deterioration could be observed 
in moderately severe exacerbations which rarely necessitate hospital admission. 
In general, drawing conclusions regarding this issue is markedly hindered, 
however, because of the great variation in definition and indication of severity of 
exacerbations. The last issue also is involved in this study of exacerbations.
GeNerAL DISCuSSION
INTrODuCTION
In recent years the clinical investigation in patients with COPD has generated a 
growing amount of studies dealing with the evaluation of treatment outcomes 
that refer to the experience patients have of the efficacy. Nowadays clinical trials 
almost invariably include some quality of life measurement. It is part of a wide 
recognition that attention has to be paid to treatment effects that are meaningful 
to patients and should not be limited to pathophysiological parameters. Studies 
dealing with such outcome parameters affirmed the notion that there is large 
discrepancy between lung function parameters and scores indicating quality of 
life. A finding already demonstrated for dyspnoea scores compared to FEV1. 
Apparently dyspnoea is quite another concept than airflow limitation, and not 
surprisingly, most studies of quality of life parameters showed weak to moderate 
correlations with pathophysiological impairment (12) (11) (23) (24) (25) (1) 
(26) (27). Gradually this accumulating information emerged into worldwide 
awareness that ultimately has penetrated into international guidelines on 
diagnosis and treatment. The GOLD guideline on COPD, is a paradigm in this 
regard. Soon after its coming of age however, it was realized that this global 
initiative would not solve clinical and research questions quickly. One objective 
of GOLD was to enhance comparability of patient populations included in 
scientific papers worldwide, by housing them into one system of severity classes, 
based on FEV1 %predicted, known as the GOLD-classification. Because the 
clinical spectrum of patients with COPD is fairly extended, it is not surprising 
that several aspects relating to health status do not parallel the degree of airflow 
limitation. It had been shown already that, for example, anxiety or depression 
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are relatively frequent problems for patients, but they proved not to correlate 
well with airflow limitation. The same holds true for fatigue or scores reflecting 
the extent of impairment reported by patients themselves (24) (12) (23) (11) 
also confirmed recently concerning fatigue using the same health status 
framework as in this thesis (28). Also, disease characteristics  such as bullous 
changes in the parenchyma can vary widely without a clear association with the 
GOLD classes. Nevertheless, after evaluations of patient relevant outcomes 
designated with terms as QoL or HRQL, had come to daylight and were related to 
the GOLD severity classes, a rather confusing picture emerged. Disagreement 
was reported whether the GOLD classification was a useful discriminator of 
other health aspects of COPD beyond FEV1 %predicted (12) (29) (30). The next 
paragraph will deal with this issue in particular.
The value of GOLD classes regarding differences in HS impairment
In chapter two results are presented of a study which aimed to show how 
inadequately GOLD-classes distinguish HS when divided in detailed sub-domains. 
It had to be concluded that GOLD stages do not distinguish patients with 
problems of their health status, or only in a very limited way. It is regarded an 
advantage of this study design (chapter two), by using an extended well-validated 
HS instrument, that such a firm conclusion is allowed. In somewhat different 
terms this conclusion was already drawn in 1999 by Hajiro et al. (11) who 
indicated that severity stages of COPD (ATS criteria for FEV1%predicted cut-offs) 
discriminate HRQL less accurate than classes of dyspnoea severity. It was not 
tested whether the results (chapter two) apply for GOLD classes 1 and 4. A study 
containing all 4 stages had demonstrated already that HS aspects were not 
significantly different between I and II, and between III and IV (12). Thus, the 
conclusion with respect to the limited value of the GOLD classes (chapter two) 
probably can be extrapolated towards the whole range of GOLD stages.
 By this conclusion, it may be recognized more easily by physicians in 
respiratory medicine, that effective treatment planning should go beyond GOLD 
classification. In its place a broad assessment of HS is mandatory that does 
justice to the clinical relevance for the patient. It is strongly recommended that 
it becomes standard policy to evaluate patients with COPD in a way similar to 
the NIAF instrument. This ensures a full diagnostic overview of physiological 
and non-physiological derangements. It has to be implemented not only in 
pulmonary rehabilitation programs, but, in daily clinical practice too.
 For reasons of reproducibility and general apllicability it is advocated that 
the NIAF Health Status assessment will be evaluated in future studies for its 
discriminating properties in other COPD populations; these preferably would 
contain also GOLD stages I and IV. 
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The recognition of the importance of disease burden and the 
road to health status assessment 
A common background of the separate studies of this thesis is the inconsistent 
manner in which health status is being assessed in studies so far. In most former 
studies originating in the 6th and 7th decade of the 20 th century attention was 
paid to pathophysiological mechanisms, possible interventions and their effects 
on physiological abnormalities. This was the era of great expansion of the 
knowledge of COPD. Innumerate studies were published highlighting topics on 
epidemiology, immunology, environmental factors, imaging and bronchologic 
investigations in an attempt to understand this complex disease with its many 
appearances. After many years it became evident however, that in spite of so 
much scientific harvest, little could be done in the physicians office to help the 
patients. A fatalism nearly emerged - to which many clinicians resided - hanged 
on the recognition that COPD was an untractable illness, possibly only 
ameliorated if one quitted smoking. About the same time, attempts were made 
to focus on what all therapies really meant for the patients, i.e. their complaints, 
abilities and quality of life (QoL).  Since that time scientific reports began to 
mention outcomes of QoL, and studies were undertaken to evaluate what were 
the effects of different medications in terms of these outcomes. Generally, these 
were advocated to use permanently despite little knowledge of their true 
efficacy in the long run. Efficacy in terms of QoL, functional improvement and 
similar aspects representing health was largely unknown, so it appeared. 
Readily, a variety of instruments was met, developed  – on site -  in health care 
centres, that prompted a method of health assessment. When reviewing the 
studies introducing ever new questionnaires that tell something regarding one’s 
health condition, one is struck by the seemingly boundless expansion of 
examples. For instance there has been reported the Seattle Obstructive Lung 
Questionnaire (31) including emotional function and coping skills. All kinds of 
mental and mood conditions, together with functional and dyspnoea indices 
have been reported from the 80-ies onwards of the last century. After some time, 
a certain delineation became apparent, favouring the use of instruments that 
are meant to assess health related quality of life, in order to concentrate on 
issues relevant for the discrimination between different health states. Further, 
the more disease specific they were constituted, the more useful they were 
thougth for evaluation of health. Consequently, disease specific instruments 
were gradually preferred over generic HRQL instruments. From that time 
onwards instruments, promising to offer such disease specific measurements, 
enjoyed growing popularity. The Chronic Respiratory Disease Questionaire 
(CRQ) and the St. George’s Respiratory Questonnaire (SGRQ) (32) are good 
examples of this preference.  Noteworthy to mention here, is the concurrent 
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frequent use of specific dyspnoea indices because dyspnoea is a good predictor 
not only of exercise capacity and mortality, but of some other HS aspects too (33) 
(34). Baseline Dyspnoea index (BDI), and Transition Dyspnoea Index (TDI), with 
a multidimensional structure, and also the unidimensional scale, the Medical 
Research Counsil (MRC) scale can be mentioned here. Nonetheless, still other 
instruments are developed at different places, that mean to improve validation 
and feasibility of assessing health status. The Dutch Clinical COPD Questionnaire 
(CCQ) may be mentioned in this respect, a 10-item simple questionnaire  (35).  
 When all attempts to measure patient relevant outcomes are overlooked 
(chapter two, three, four and five), it is concluded that the key problems with 
these are: 
• too much overlap of health domains
• too frequent incompleteness of the instrument with respect to the relevant 
domains to get a sufficient picture of one’s health status
• too little efforts to fundamentally validate the proposed instruments
The insufficient delineation of the terms quality of life, health related quality of 
life and health status is the inevitable result of these shortcomings (chapter 
three). This notion was at the entrance of the studies on health status in COPD 
in this thesis.
Maximal exercise capacity and health status; two distinct 
components in COPD
The significance of maximal exercise capacity for other HS aspects
The value of the NIAF was further explored in other clinical manifestations of 
COPD. The first study in line is described in chapter three,  exploring the clinical 
value of exercise capacity with respect to the other components of the NIAF 
health assessment. Often, a test of cardio-pulmonary exercise capacity, is 
considered a definite assessment of a patient’s disease state and preserved 
fitness. Because of its multiple integrating physiological variables it is  considered 
as a sort of gold standard of functional evaluation. But its significance  should 
not be overrated. Probably it is overestimated when exercise capacity is 
proposed as a means of estimating one’s total health status. Some reports 
suggested that HRQL could be established  by measuring the maximal oxygen 
consumption or incremental shuttle walking test (ISWT) (5) (6). Reviewing the 
literature it was concluded that measures of exercise capacity probably do not 
hold qualities of health status other then biologic and physiological ones. It 
seemed worth while then, to re-explore the relationship between maximal 
exercise capacity and a range of HS aspects, making use of the NIAF. Our study 
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aimed to reappraise the value of maximal exercise capacity as a measure of 
overall health status in COPD.
Measuring exercise capacity
For purposes of evaluation of exercise capacity several methods are available. 
The maximal cycle ergometry is commonly used to test patients (or healthy 
persons) for their physical fitness. Ventilatory and cardiovascular parameters 
are applied to analyse causes of limited exercise tolerance in detail. Beside cycle 
ergometry, the treadmill provides another way to test cardio-pulmonary fitness, 
suited for those people that are able to run. 
 Functional tests such as 6-Minute Walk Distance (6-MWD) or 12 min. (12-MWD) 
and the shuttle walk test (SWT) are simple to perform, provide fewer patho-
physiological parameters, but reflect functional capacity in a more natural way 
with greater relevance for daily activities. The greater effort is demanded by 
such tests, the higher is the correlation with maximal oxygen consumption, 
measured in a maximal incremental cycle ergometry  (from about 0.50 in 
12-MWT up to 0.88 for the SWT; (36). Correlations with the level of daily 
activities in patients with COPD have been reported as well, suggesting that they 
may have predictive value for HS domain functional impairment. Finally, 
endurance tests are available but little is known about their discriminatory 
quality regarding HS evaluation. 
 In this thesis cardio-pulmonary exercise testing (CPET) by incremental 
cycle ergometry was used (chapter three), mainly because it offers the best 
opportunity to collect all data of exercise physiology. In the NIAF developmental 
phase, CPET was preferred because of this characteristic and its frequent use. 
Weak correlation between maximal oxygen consumption and  
Health Status
VO2 max%predicted proved to correlate with most of the 16 sub-domains of HS 
according to the NIAF assessment. But only weakly correlations were  found (up 
to a maximum of r: 0,36), indicating that maximal exercise capacity on cycle 
ergometer is a different measuring concept than e.g. aspects within the main 
domain Complaints (chapter three). Or aspects such as Subjective or Behavioural 
Impairments.  Sub-domains of quality of life also showed some significant 
correlations, but these proved to be weak again  (till 0.31, for Satisfaction with 
Health). Berry et al. laid emphasis upon the additional value of measuring peak 
oxygen consumption relative to FEV1 measurement not only in predicting 
physical performance and functional status, but they stated its value in 
predicting HRQL as well (5). This conclusion can not be supported by the findings 
in chapter three, because of the low correlations with sub-domains regarding 
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Complaints, Functional Impairments and Quality of Life. Probably, this difference 
may be attributed to the limited number of health aspects (2 of 4 dimensions of 
the Chronic Respiratory Disease Questionnaire) that proved significant in their 
study. Also, their conclusion seems rather premature since the size of the 
improved prediction of HRQL in the two dimensions was distinctly low 
(explained variance rose from 3,5 to 9,7 %).  So it should be denied that VO2 
max%predicted can be considered an overall measure of HS. Evidence that 
maximal exercise capacity and overall HS are different concepts comes from a 
few other studies also (37).  No further studies can be found that have studied 
the correlation of maximal oxygen uptake with a comparable broad spectrum of 
HS aspects. One study that approximates the one in chapter three contains 
fatigue, dyspnoea and anxiety as non-physiological variables of HS, which – 
partly - determine functional performance. But these 3 variables accounted for 
only less than 36 % of the variance in functional performance, implicating that 
this surrogate parameter of exercise capacity represents a different construct 
than fatigue, dyspnoea and anxiety, aspects of health that are also comprised in 
the NIAF HS model (34).  
 Maximal oxygen consumption, after all, appears to take the position that it 
originally was assigned: as an objective means to determine exercise capacity, 
as an invaluable contribution to understanding exercise limitation in physiological 
terms and in planning training programs. So, assessment of exercise capacity is 
an essential part of the estimation of one’s total health status, but can not 
adequately replace assessment of HS. 
Loss of muscle mass;  relation with physiological, but not with non-
physiological HS aspects
From the former study, in which exercise capacity was the angle of incidence, it 
was a small step toward muscle mass to explore in detail. In chapter four the 
question is answered whether muscle wasting has indeed no consequences for 
non-physiological health status aspects.
Brief overview of muscle wasting in COPD
Studies so far had demonstrated that muscle wasting is associated with chance 
of survival (38), exercise capacity and risk of exacerbations. It seemed reasonable 
to assume at forehand that muscle wasting would impact on experienced 
impairments and resulting disabilities, both important aspects of Health Status.
From studies on the metabolic and morphological changes of skeletal muscles in 
COPD it had been demonstrated that stable patients with COPD show an 
enhanced level of protein breakdown and protein synthesis compared to healthy 
people. Diminished proportions and numbers of certain fibre types in these 
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muscles can occur simultaneously. The consequences are less endurance, but 
relative preservation of shortly sustained muscle actions.  As a consequence, a 
disturbed equilibrium in protein metabolism and a shift in fibre type 
composition, may affect the functional performance and subsequently, the 
degree of dyspnoea generation and experienced impairments. Besides, quite an 
other factor may be involved in the mechanism of muscle wasting. That is disuse 
of skeletal muscle resulting in atrophy by inactivity.
Muscle wasting and Health Status
In this thesis the scientific focus was specifically on the clinical consequences of 
muscle wasting, patient’s health status in particular. Decrease in muscle 
strength and exercise capacity are unequivocal signs caused by muscle depletion 
(39) (40). But how about aspects of HS with respect to non-physiological 
domains such as Complaints, Functional Impairments or Quality of Life?
 Recently no association was demonstrated between low fat free mass and 
rate of dyspnoea or SGRQ scores (41) in 400 patients with COPD distributed over 
39 clinics. This study is the only large scale study investigating the association 
of low fat free mass with parameters of health status up till now. Patients 
belonged to GOLD classes 2 and 3, like in the study presented in chapter four, 
and the study was also conducted in the Netherlands. It therefore is deemed a 
valuable reference study. In that study only handgrip strength correlated with 
low fat free mass index (FFMI) while dyspnoea, FEV1 %predicted and SGRQ 
scores did not, indicating to some degree that low muscle mass has no impact on 
other than selected physiological HS aspects. In contrast to the study of 
Vermeeren et al. (41) a broader HS assessment was used (chapter four) to 
examine whether this finding held true for many other non-physiological HS 
aspects as well. This method of HS assessment includes several sub-domains 
within the main domain of Impairments, and expands the sub-domains 
Complaints and Quality of Life compared to the MRC dyspnoea scale and the 
SGRQ scales in the multi-centre study.
Lack of associations between muscle depletion and HS aspects.  
How is it explained?
This study confirmed that muscle depletion is seen more frequent in women than 
in men (chapter four), and is not associated with non-physiological aspects of 
HS. After two rather large numbered studies with similar results, it seems 
ascertained that low FFMI is not correlated with HS in the non-physiological 
domains, but it is not yet clear how this might be explained. In fact, FFMI is weakly 
associated with Hyperinflation and moderately with diffusion capacity (chapter 
four), both distinct indices of the pathophysiological process. But It seems hard 
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to imagine that FFMI, which has association with mortality and with exacerbation 
rate (42) (43) (44), is totally independent of HS aspects which represent disease 
burden.  As yet no explanation has been put forward by  previous investigators 
(41) (45). Based on the study findings (chapter four) only a speculative 
explanation can be put forward, which needs to be tested yet.  Adaptation to the 
physiological limitations could be an explanatory factor. Adaptation to alterations 
in muscle function ensues by reduced rate of physical activities or avoiding the 
effort of sustained activities. This would clarify why no associations were found 
with for instance Fatigue, Subjective Pulmonary Complaints and Subjective 
Impairments.  Although this seems a possible factor in the lack of associations, it 
can not be supported by the present study (chapter four) due to the method of 
investigation. Adaptation can not be adequately derived from sub-domains Daily 
Physical Activities and/or Behavioural Impairments, the 2 components of the 
NIAF most indicative of aspects of physical behaviour. Daily Physical Activities 
was assessed by an accelerometer (also named Aktometer) which registers the 
total time of being in motion (chapter four), but not the pace of these activities. 
So, this does not account for the intensity of activities of daily living, by which the 
degree of physical effort is determined.
 Insufficient adaptation may result in performing beyond or below one’s 
actual physical capacities, as can be observed from pulmonary rehabilitation 
participants. If the actual capacities are exceeded one can expect excessive 
dyspnoea and fatiquebility. In contrast, if one performs below his or her true 
capacities, enhanced levels of Behavioural Impairments combined with low 
Subjective Impairments, Fatique and Subjective Pulmonary Complaints are 
envisaged. A further study seems worth wile to attempt to explore these two 
modes of misadaptation.
role of gender in COPD with muscle wasting; a modest contribution to 
understanding the pathophysiological associations of muscle depletion?
The role of gender in the prevalence of muscle depletion was addressed because 
some studies had found a higher prevalence of low fat free mass in females (39) 
(41). Also, because low FFMI showed only positive correlations with Physiological 
Functioning (chapter four) and because some studies had reported associations 
with parameters of COPD severity and phenotypic features. This, of course, is a 
challenging issue, appealing new studies to try to explain this finding. Also of 
interest, some studies had found that muscle depletion is seen more prominently 
in those with roentgenologic emphysema according to high resolution CT scans, 
as contrasted with bronchitics (46) (47) (48). The same studies showed that still 
another determinant of emphysema, diffusion capacity, was significantly lower 
in these patients (KCO 50 versus 89 %predicted in the study of van Engelen (46); 
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and 51 versus 85 %predicted DLCO values in that of Kitaguchi (47). This led us 
to examine the interrelationship between gender, fat free mass index and 
diffusion capacity. When diffusion capacity was compared in men and women, it 
appeared that women had lower diffusion capacity than men. Moreover, if FFMI 
was analysed by logistic regression, female sex was shown to be the strongest 
predictor among diffusion capacity KCO and maximal expiratory pressure 
(chapter four). So, it seemed that a new gender difference in COPD had been 
found. Already dyspnoea and QoL parameters were demonstrated to be different 
between the sexes. But this may not be an exclusive feature for patients with 
COPD (personal communication J.H. Vercoulen, 2006). Taking together all the 
evidence, including that from chapter four, we are able to point to a specific 
phenotype of COPD, the emphysematous subtype, being associated partly with 
female sex, low muscle mass and diminished diffusion capacity (chapter four). 
Gender therefore has a moderate effect on the development of COPD, i.e. whether 
it takes the pathophysiological pathway of pure emphysema or COPD with 
bronchitic features.  In future studies attention has to be paid as to what the 
other factor(s) are, determining who develops the emphysematous type, and 
who the bronchitic type.
explanatory considerations
The possible mechanism of the gender difference in developping a certain 
phenotype in COPD, by and large, is unclear. Women  being more susceptible for 
the harmful effects of cigarette smoking in comparison with men, is one 
proposed explanation. This was based on a selected subpopulation, however 
(49). This research question has been picked up by several investigators since 
that study, but very few reports can be find as yet, evaluating the differentiation 
in emphysematous type versus bronchitic type based on HRCT scanning.  Only 
one showed men to have more frequent airway reversibility than women, 
suggesting that women were more likely to attract the emphysematous type 
(50). On radiologic evaluation, however, women showed to have less degree of 
overall emphysema than men! Evidently, these conflicting results require more 
scientific effort to get clarified.
exacerbations of COPD, clinical relations with regard to impact
General remarks upon impact on health
In chapter five a study was set up to unravel which relationship exists between 
exacerbations of COPD and Health Status according to the NIAF HS concept. 
 Exacerbations are of special interest in clinical studies during the last fifteen 
years, when it was acknowledged that these might be the mechanism by which 
the steady disease state is disrupted, causing an accelerated deterioration. 
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Studies were performed demonstrating that exacerbations indeed have significant 
impact on survival (51) (52). Also impact on lung function decline has been 
proposed (53) (54) (55), but  proof  regarding a causal role seems indirect at 
most and may only regard intermittent and continuous smokers (56) (57).
 Beside the question whether exacerbations exert an effect on ventilatory 
impairment, scientific interest was focussed upon an effect on HRQL and health 
status.  At forehand one is inclined to think that exacerbations cause lower HS 
after some time, certainly when kept in mind that mortality is high after 
exacerbations for which hospital admission was necessary  (51) (52). A British 
study (58) provided some evidence that exacerbations exert a negative effect on 
health status. In subsequent years most studies seem to suggest a causative role 
for exacerbations in developing worse health status, although one study  (59) 
brought up the opposite view.
Minimal effects of exacerbations on Health Status
In chapter five a prospective study is presented, showing that exacerbations 
hardly have an influence on the Health Status when a conceptually broad HS 
assessment is applied. HS was measured twice with a one year interval. 
Exacerbation frequency correlated significantly with  several HS sub-domain 
scores of the follow up measurement, most of them in the non-physiological 
domains (chapter five). To check whether these findings were robust, 
correlations were adjusted for correlations with the baseline scores of sub- 
domains. So called partial correlations ensure that events, arising within a 
certain time frame, are less influenced by the situation at baseline. It then 
appeared that only two weakly significant correlations were left: Subjective 
Pulmonary Complaints and Expected Dyspnoea (chapter five). It had to be 
concluded therefore that exacerbation frequency – with an event-based 
definition – did not exert a relevant change in health status during one year.  
Depending factors of HS outcome after exacerbations
The findings in chapter five seem to contrast with many studies on the subject 
up till now  (58) (16) (60) (20), but the effect size of HS changes over a 6, 12 or 36 
months period, reported in most of these studies, should be taken with care. 
Frequently, they do not rise beyond the clinical relevant changes, designated for 
the selected HS instrument. Only if cumulative changes are accounted over 3 
consecutive years this criterion was fulfilled (60). Such fulfillment was obtained 
in only one study  for SGRQ symptoms, but not for the other subscales or the 
results of CRQ measurement. Only for frequent exacerbators (≥ 2/year), a change 
little above the clinically relevant threshold was found in the 3 SGRQ, and most 
of the CRQ subscales (20). Clearly, the frequency with which exacerbations occur 
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has its influence on the subsequent effects on HS. The conclusion in chapter five 
can be further commented by realizing the relative mild severity of exacerbations 
that were recorded. Only a small minority of them needed hospital admission 
(14.6 %). This will surely contrast with patients who need more intensive 
treatment in the hospital (19) (51) (61). So, conclusions of this study can not be 
extrapolated to all kinds of event-based exacerbations. The dependence of 
outcome in HS of the severity of the exacerbations deserves more attention in 
designing future studies. In summary, it is concluded that effects of exacerbations 
on HS depend on frequency, and still more important, the severity of such events.
Methodological difficulties
Some more critical remarks on this subject should be made. These regard the 
lack of standardization in measuring health status, and lack of a standard 
definition of exacerbations. And lastly, the rather weak methodological design of 
a number of studies. To begin with this last criticism. Most studies did not assess 
HS at both the beginning and the end of follow up, weakening the evidence for a 
negative effect on HS. This seems a relevant issue since differences in HS scores 
frequently do exist already at baseline, making it difficult to draw conclusions. 
Most studies use the difference between frequent and infrequent or non-exacer-
bators as evidence for their conclusion. The conclusion of chapter five was 
based on a another approach: partial correlations, to account for preexisting 
differences in HS scores at the start of the study. Furthermore, several studies 
had a retrospective design, which certainly has drawbacks with reference to 
reliability of data collection. Longitudinal studies had durations of study which 
varied quite widely, ranging from 6 weeks, the average time of recovery from an 
exacerbation, to 2 and even 3 years. Such fundamental differences make studies 
uncomparable. Another difficulty is encountered by studies in which the follow 
up starts immediately from the onset of an exacerbation, with variable time 
frames afterwards to collect data. Different outcome objectives are met which 
should well be discerned in interpreting results with respect to long term changes. 
 The problem of bad standardization of health status assessment is a 
recurrent issue in this thesis (chapter two to five). Throughout the 4 studies 
roughly the same set of health status instruments is used, so it can be noticed 
when overlooking the literature with regard to the 4 subjects. They do not assess 
health completely, in the way as is achieved by the NIAF and their use seems 
rather at random. With the NIAF as a new and broader HS concept expectations 
were tested whether it would enhance the understanding of relationsships with 
exacerbation frequency.
 With respect to the choice of the definition of exacerbations many remarks 
can be made. Still there is a call for a standard definition, advocated at regular 
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times (62). A brief explanation of commonly used definitions in the literature is 
summed up here. Grossly this deals with three types of definition. One of the 
oldest is that proposed by Anthonisen  (21) in order to register episodes of 
worsened symptoms, and analyze their remission under antibiotic treatment. 
Accordingly, this way of defining has been called a ‘symptom-based‘ definition, 
expanded with several modifications later on. Major criteria include enhanced 
dyspnoea, phlegm quantity and purulence of phlegm, known as the Anthonisen 
type I exacerbation. In addition, an event-based definition was proposed, with 
large variation in severity if not further specified. Most studies using this 
event-based definition required the criteria of worsened symptoms during 3 
consecutive days, apart from day to day variations, with the necessity of the use 
of a corticosteroid or antibiotic course or both. Of course, physicians may decide 
that admission to the emergency department, ward or even ICU is needed 
because of severity of the condition. All these different events can be met in 
research articles by the covering term ‘event-based’ definition. Obviously 
severity and aetiology of such an array of events vary greatly, and with these 
also outcome parameters (63) (64).  The effect of interventions influenced 
exacerbation frequency, and the frequency itself was affected too by differing 
definitions. Finally, there is the laboratory approach to identify exacerbations by 
assessing markers of inflammation, but the lack of sensitivity and specificity of 
any test repelled such definition from clinical trials (65). 
 When a selection of these definitions had to be made at the planning of the 
study of chapter five, considerations arose with respect to the objectivity of the 
symptom-based and the event-based definition. Because only subjective criteria, 
on which is reflected by the patient himself, affect the decision of a symptom-based 
definition, the event-based definition was favoured. Exacerbations with an 
event-based definition are dependent mainly on the physician ’s diagnostic 
considerations. It is recommended that diagnostic criteria for exacerbations are 
made more specific, doing justice to severity differences, and if possible, 
aetiology too, so we can leave behind the opinion they should not be incorporated 
in the definition (53).
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reCOMMeNDATIONS
1. The GOLD classification into 5 categories of severity should not be used for 
purposes of individual HS assessment. Better instruments exist, among 
these the Nijmegen Integral Assessment Framework (NIAF). 
2. Evaluation of all patients with COPD should comprise assessment of specific 
components of all 4 domains of Health Status, Physiological Function, 
Complaints, Functional Impairment and Quality of Life. This must be 
incorporated in standard clinical practice.
3. Functional status should be abandoned from communications in clinical 
studies and practice. Instead specific components of the main domain 
Functional impairments, can provide more accurate information on the 
capability to keep up one’s daily tasks.
4. It is strongly advocated to try to abandon symptom-based definitions in 
studies of impact of exacerbations on Health Status or their pathophysiolog-
ic changes. 
5. In searching answers to questions with respect to the meaning of exacerbations 
in the course of COPD, definitions must be sougth that delineate both 
aetiology and severity. Current descriptive criteria completely lack elements 
of these two aspects.
6. The role of female sex in developing more often muscle depletion and the 
emphysematous type of COPD deserves further study. Also, attention has to 
be paid as to what the other factor(s) are that explain who develops the 
emphysematous type, and who the bronchitic type. 
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SAMeNVATTING eN DISCuSSIe
INLeIDING
In dit proefschrift komt een aantal studies ter sprake met als gemeenschappelijk 
element, een nieuw instrument om de gezondheidstoestand (Engels: Health 
Status *) te bepalen van patiënten met Chronic Obstructive Pulmonary Disease 
(COPD). Het wetenschappelijk onderzoek naar de gevolgen voor de gezondheid 
van deze patiënten en naar behandelvormen ter verbetering ervan, heeft de afgelopen 
paar decennia een opvallende ontwikkeling doorgemaakt. In hoofdstuk een 
wordt een inleiding gegeven op deze ontwikkeling, de achtergronden van het 
ontstaan alsmede de methodologische valkuilen, waarmee de pas ontwikkelde 
instrumenten ons confronteren. Die ontwikkeling ligt vooral op het gebied van 
de meting van effecten van allerhande therapieen, zowel op medicamenteus als 
op niet-medicamenteus gebied, gericht op de Health Status (HS), waaronder de 
Kwaliteit van Leven. Oppervlakkig bezien, zou kunnen worden geconcludeerd 
dat het meten van ziektegevolgen van COPD voor de gehele persoon, - als aanvulling 
op meten van gevolgen van de stoornis op louter orgaan niveau - zich tot een 
gevestigde methodiek heeft opgewerkt, echter, bij nadere beschouwing blijkt 
dat de uitkomsten nog veel aan interpretatieverschillen overlaten. Dat wordt 
met name veroorzaakt door de veelheid aan verschillende instrumenten. Elk 
bezit een zekere psychometrische kwaliteit, die onderling kan verschillen, en 
ook detaillering en keuze van te meten gezondheidsdomeinen verschilt per 
instrument, dat wordt ingezet. Kortom, er is een groot gebrek aan eenduidigheid 
en standaardisatie in het bepalen en kwantificeren van de Health Status. De nog 
jonge ontwikkeling van het bepalen van Health Status en het ontbreken van een 
gouden standaard daarvoor, rechtvaardigt twijfels aan de validering van de 
bedoelde HS instrumenten. Het blijkt dan bij kritischer beschouwing, dat er weinig 
harde conclusies zijn te trekken omtrent voor de patiënt relevante uitkomsten. 
Nadat tevoren in ons researchprogramma een nieuw concept van Health Status 
was uitgewerkt en op zijn psychometrische kwaliteiten was getoetst, zijn 
vervolgens diverse klinische thema’s aan nieuw onderzoek onderworpen, in zake 
effecten op, en verbanden met de Health Status bij COPD. De totstandkoming van 
dit nieuwe concept is elders uitvoerig beschreven. Alleen zij op deze plaats 
vermeld, dat het ontstaan een gedeeltelijk theoretische achtergrond bezit, maar 
vooral een empirische benadering heeft gehad, ontwikkeld vanuit meerdere 
disciplines, betrokken bij het researchprogramma en de praktijk van de long-
*  hier wordt de Engelse term gehandhaafd, omdat de Nederlandse als aanduiding minder 
bekend is.
132 | Chapter 7
revalidatie in een academisch centrum. Tenslotte is het uiteindelijke model 
uitvoerig statistisch getest op zijn kwaliteiten, en sufficient bevonden. De 4 
studies (hoofdstuk twee t/m vijf) welke hier zijn bijeengebracht, zijn gebaseerd 
op dat Health Status concept en vormen de kern van dit proefschrift.
De waarde van de GOLD classificatie voor het bepalen van 
de Health Status
In hoofdstuk twee wordt een studie gepresenteerd, die tot doel had de relatieve 
waarde van de Global initiative of Obstructive Lung Disease (GOLD) classificatie 
voor het inschatten van de Health Status, inzichtelijk te maken en duidelijk naar 
voren te brengen. Health Status wordt in dit onderzoek gemeten met behulp van het 
nieuw ontwikkelde instrument, het Nijmegen Integral Assessment Framework, 
NIAF. Kern van dit concept is het onderscheid tussen 4 hoofddomeinen, elk 
onderverdeeld in sub-domeinen, met in totaal 16 (aanvankelijk 15) sub-domeinen. 
Deze 4 zijn achtereenvolgens Physiologisch Functioneren (Eng. Physiological 
Functioning), Klachten (Eng. Complaints), Functionele Beperkingen (Eng. 
Functional Impairments) en Kwaliteit van Leven (Eng. Quality of Life).
 De GOLD indeling in verschillende ernst klassen zou moeten helpen om tot 
snellere resultaten te komen in wetenschappelijk onderzoek naar effectieve 
therapieen. De grote spreiding van klinische presentaties noopte immers tot 
enige differentiatie, zodat beter vergelijkbare patiënten populaties konden 
worden onderworpen aan (meta)analyses. De vooraf beschikbare literatuur gaf 
echter al aan dat de GOLD indeling, of voorlopers daarvan, weinig verband hield 
met de mate waarin problemen met de gezondheid werden ervaren door 
patiënten. Of te wel, de Health Status correleert slecht met de oplopende ernst 
klassen van de GOLD systematiek. Dit is de meest logische gevolgtrekking, de 
conclusies van sommige wetenschappelijke artikelen ten spijt.
 In het onderzoek, uitgevoerd bij 135 patiënten, 70 in GOLD klasse 2, en 65 in 
klasse 3, bleken er van de toen gehanteerde 15 sub-domeinen slechts 5 significant 
te verschillen tussen GOLD 2 en GOLD 3. Gelet op de spreiding van de scores in 
die 5 sub-domeinen, aangegeven in box plots, moest worden besloten tot een 
verwaarloosbaar verschil in HS tussen beide GOLD klassen. De conclusie van 
deze studie luidde dan ook, dat de GOLD-indeling niet kan helpen bij het plannen 
van een goed op de patiënt toegesneden therapeutisch plan. Dit heeft vanzelf-
sprekend gevolgen voor de behandelpraktijk. Juist de gedetailleerde diagnostiek, 
zowel in engere zin op pathofysiologisch gebied, als op de gezondheidsbeleving 
als geheel, biedt de mogelijkheid de specifieke (sub)domeinen van HS te 
identificeren, waar de patiënt het meeste hinder van ondervindt. Het meten van 
de Health Status met behulp van het NIAF is daartoe een zeer geschikt middel.
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Het verband tussen maximaal inspanningsvermogen en Health Status
Het verband tussen de maximale inspanningscapaciteit en Health Status is het 
onderwerp van hoofdstuk drie. De waarde van het meten van maximale 
inspanningscapaciteit bij patiënten met COPD werd in voorbije jaren ook 
geevalueerd ten opzichte van de betekenis die het heeft voor inschatting van de 
gezondheidstoestand, Health Status (HS). Met name om de vraag te beantwoorden 
of het verband houdt met de functionele status en met de mate van dyspnoea. 
Functionele status is een slecht gedefinieerd begrip en heeft te maken met de 
fysieke gesteldheid om activiteiten te kunnen ontplooien horende bij het 
dagelijks leven. Niet gedefinieerd is hoe veel lichamelijke inspanning die 
activiteiten kosten. Iedere patiënt zal een ander patroon van activiteiten hebben, 
met navenant grote verschillen in inspanningsniveau, dat daarvoor nodig is. 
Dyspnoea is iets beter gedefinieerd, maar er bestaan veel methodes om die te 
kwantificeren. Hoewel niet valt te ontkennen dat een maximale inspanningstest 
beter verband houdt met de algemene gezondheidstoestand dan de uitkomst 
van een longfunctie meting in rust, kan niet worden gesteld dat maximale in-
spanningscapaciteit (bijv. gemeten als VO2 max) een voospeller is van Health 
Status, zoals gesuggereerd door enkele auteurs. Dit was reden om in hoofdstuk 
drie na te gaan wat de correlaties waren tussen VO2 max en de sub-domeinen 
van HS van het NIAF. 129 patiënten werden voor deze studie geselecteerd, allen 
met een goed uitgevoerde maximale fietsproef met meting van de maximale 
zuurstofopname. Vele van de 16 sub-domeinen van HS toonden een significante 
correlatie met de VO2 max. Echter, de correlaties waren allen zwak, maximaal 
0.36 (Subjective Impairments), hetgeen erop duidt dat de sub-domeinen van 
HS iets anders betekenen dan inspanningsvermogen. Met andere woorden, 
inspanningsvermogen is een tamelijk uniek aspect van HS. Dat geldt evenzo 
voor functionele beperkingen, hoofddomein Functional Impairments, en voor 
dyspnoea klachten, vervat in hoofddomein Complaints. Om na te gaan of 
misschien wel een duidelijke correlatie bestond bij een bepaald type van inspan-
ningsbeperking met aspecten van HS werd een aanvullende analyse verricht. 
Daarbij werden verschillende typen van inspanningsbeperking (reden om de 
fietsproef te stoppen c.q. fysiologische verklaring voor het niet meer kunnen 
inspannen)  gecorreleerd met de genoemde sub-domeinen.   Voor dit doel werden 
de fietstesten beoordeeld door een klein panel van de onderzoekers, waarbij 5 
categorien werden onderscheiden: ventilatoire beperking (I), zuurstof opname 
beperking (II), cardiocirculatoire beperking, hetzij door een cardiovasculaire 
aandoening, dan wel door gebrekkige lichamelijke conditie (III), beperking door 
symptomen, zonder fysiologische grenzen te bereiken bij maximale inspanning 
(IV) en een menggroep met zowel fatoren van I als van II, of van I en III (V). 
Alleen in hoofddomein Physiological Functioning werden enkele significante 
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verschillen gevonden, maar niet bij sub-domeinen van de 3 andere hoofddomeinen, 
Complaints, Functional Impairments en Quality of Life. Dit onderstreept  de 
conclusie dat maximaal inspanningsvermogen weinig of niets zegt over de mate 
van problemen in de drie laatst genoemde HS aspecten. Het meten van de 
maximale zuurstofopname tijdens een fietstest heeft dus vooral zijn waarde in 
het objectief vastleggen van de inspanningscapaciteit, het identificeren van de 
fysiologische beperking van een verminderde capaciteit tot inspanning en een 
instrument om trainingsprogramma’s bij revalidanten te selecteren. Maar het 
kan het bepalen van de Health Status geenszins vervangen.
Spiermassa verlies, het verband met HS aspecten, geslacht en het 
phenotype van COPD
In hoofstuk vier werd de vraag gesteld of verlies van spiermassa, een regelmatig 
waargenomen fenomeen bij patiënten met COPD, een relatie heeft met afname 
van HS. Daarbij bestond met name nieuwsgierigheid ten aanzien van de vraag 
welke HS aspecten van het NIAF het meest door spiermassa verlies zouden zijn 
aangedaan. Uit de literatuur was een onduidelijk beeld te destilleren ter zake. 
Zowel positieve correlaties met verminderde Health Related Quality of Life als 
afwezige correlaties worden in klinische studies vermeld. Omdat uit deze studies 
naar voren kwam dat spiermassa verlies vaker bij vrouwen voorkwam, en een 
sterkere associatie toonde met emphysemateuze afwijkingen in het longparenchym, 
werd ook nagegaan of geslacht een bepaalde rol speelde in het voorkomen van 
spiermassa verlies. Het onderzoek (hoofdstuk vier) betrof 135 patiënten. 
Spiermassa werd uitgedrukt in de maat vet vrije massa index (of fat free mass 
index, Eng. (FFMI)), een getal dat is gecorrigeerd voor lengte. Deze index werd 
gecorreleerd met de 16 sub-domeinen van HS welke in het NIAF worden 
onderscheiden. Als resultaat werd gevonden dat FFMI alleen met enkele 
sub-domeinen uit het domein Physiological Functioning significante correlaties 
heeft, en niet met aspecten van zogenaamde niet-fysiologische sub-domeinen. 
Nadere beschouwing leerde dat een lage FFMI waarde, als uiting van spiermassa 
verlies, opvalllenderwijs was geassocieerd met de longfunctieparameters, welke 
een ernstiger vorm van COPD aanduiden, zoals FEV1, TLC %pred., diffusie 
capaciteit voor koolmonoxide en exspiratoire spierkracht. Deze parameters 
werden onderzocht op verschillen tussen mannen en vrouwen vanwege het 
verschil in prevalentie van spiermassa verlies. Hierbij bleek diffusie capaciteit 
voor koolmonoxide bij vrouwen significant lager te zijn, en wel in alle gebruikelijke 
parameters. Zowel DLCO als KCO, als absoluut getal en ook uitgedrukt als 
percentage van voorspeld, waren duidelijk verschillend tussen de sexen. Hiermee 
werd, voor het eerst, een link gelegd tussen vrouwelijk geslacht en spiermassa 
verlies en een bepaald type van COPD phenotype, het emphysemateuze type. Dit 
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in tegenstelling tot patiënten die het bronchitische type vertegenwoordigen. 
Hoewel geslacht de voornaamste voorspeller was van een lage FFMI, wordt 
hierbij aangetekend dat de verklaarde variantie in FFMI slecht 32 % is, wanneer 
geslacht met diffusie capaciteit en exspiratoire spierkracht wordt gecombineerd.
exacerbaties van COPD en hun effect op vermindering van  
Health Status
In hoofdstuk vijf tenslotte, wordt beschreven welke nadelige invloed exacerbaties 
van COPD hebben op parameters van Health Status. Uit de literatuur aangaande 
de invloed van exacerbaties op het beloop van de ziekte, in het bijzonder de 
Health Status, zijn de laatste 2 decennia enkele studies verschenen die tot zo’n 
negatieve invloed concludeerden. Net als bij de beschouwing van de literatuur 
bij voorgaande artikelen van dit proefschrift, werd ook hier bemerkt, dat een 
gebrek aan standaardisatie in methode en veelal onvolledige HS meting door de 
keus van de instrumenten tot onduidelijke bevindingen hadden geleid. Voor deze 
studie werden weer de 16 sub-domeinen van het NIAF gehanteerd voor correlaties 
met exacerbatiefrequentie in het voorafgaande jaar. Die was prospectief gemeten 
middels maandelijkse vragenlijsten, welke informatie gaven over toename van 
klachten van dyspnoea, sputum kleur en hoeveelheid gedurende minstens 3 
opeenvolgende dagen. Tevens werd gevraagd aan de patiënten, die normaal 
poliklinisch werden gevolgd bij hun longarts en /of huisarts, of zij extra 
behandeling hadden gekregen in de vorm van een kuur corticosteroïden en/of 
antibiotica, in de afgelopen maand. Op basis van de antwoorden kon een exacerbatie 
worden geidentificeerd. Indien gebaseerd op een wijziging in therapie, spreekt 
men van een ‘event-based’ exacerbatie. Deze komt iets objectiever tot stand dan 
een zogenaamde ‘symptom-based’ exacerbatie, op grond van klachtentoename. 
Om deze reden werd aan die eerste de voorkeur gegeven. De studie was 
gebaseerd op de hypothese dat exacerbaties tot slechtere Health Status leiden, 
en de vraagstelling luidde dan ook: kan de verslechtering in HS door exacerbaties 
worden bevestigd indien van een gedetailleerd en zorgvuldig ontworpen HS 
instrument (het NIAF) wordt gebruik gemaakt.
 Van 168 patiënten met COPD werden alle benodigde metingen en onderzoeken 
gedaan ten behoeve van het bepalen van de HS conform het NIAF, zowel aan het 
begin als na een jaar  follow up. Wegens het niet voldoende vaak invullen van de 
vragenlijsten vielen er 52 personen af, en nog eens 9 personen hadden meerdere 
testen van de 2e HS meting niet volbracht. Zodoende bleven er 107 personen over 
voor de geplande analyses. De correlaties tussen exacerbatie frequentie en de 
sub-domein scores van de eindmeting werden bepaald, waarna deze werden 
herberekend door aanpassing met de correlaties die waren verkregen met de 
scores van de 1e HS meting. Deze techniek staat bekend onder de naam partiele 
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correlaties. Het geeft een betere inschatting van ware effecten van de onafhankelijke 
variabele, in dit geval excerbatiefrequentie, doordat gecorrigeerd wordt voor 
reeds bestaande verbanden aan het begin van de onderzoekstermijn. Slechts 
twee sub-domeinen bleken een significante correlatie te vertonen, Subjective 
Pulmonary Complaints en Expected Dyspnoea, zij het een erg zwakke. Dit 
betekent dat in het verloop van een jaar, waarin gemiddeld 2.2 exacerbaties 
per patiënt optraden, slechts een minimaal effect kon worden gevonden ten 
nadele van de HS. Het overgrote deel van de HS aspecten bleef onveranderd. 
De conclusie van deze studie was dat het waarschijnlijk veel langer dan een jaar 
duurt eer exacerbaties van vergelijkbare ernst (met 14,6 % ziekenhuis opname 
wegens exacerbatie in deze studie, beschouwd als matig ernstig) een meetbare 
verslechtering van de HS veroorzaken.
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DANKWOOrD
Het verrichten van wetenschappelijk onderzoek ten behoeve van een promotie 
en het publiceren van de uitkomsten is geen korte termijn werk, ook al zou iedere 
promovendus en promotor dat wel willen. Ook dit traject heeft een langdurig en 
intens beroep gedaan op meerdere mensen. Voor het werk, verricht aan dit 
proefschrift in de periode 2004 tot 2013, wil ik de volgende personen mijn er-
kentelijkheid betonen voor hun steun, hulp en vertrouwen.
Prof. Dr P.N.r. Dekhuijzen, mijn promotor 
Beste Richard, allereerst wil ik je danken voor de kans die je me hebt gegeven om 
enkele jaren op jouw afdeling te komen werken en daarbij wetenschappelijk 
actief te zijn. Dat was geen vanzelfsprekendheid! Mede daarom heb ik het erg fijn 
gevonden om een drukke, op produktie gerichte praktijk te kunnen verruilen 
voor werk op een academische afdeling, het ULC Dekkerswald.
 Ook jij had de ambitie, net als ik, om het promotietraject op een snelle wijze 
uit te voeren en tot een goed einde te brengen. Ik herinner me als de dag van 
gisteren, dat je mij bij een van de eerste besprekingen over de opzet van het 
onderzoek aanvuurde om in het vinden van korte en snelle combinaties, de bal 
direct naar het doelgebied te dirigeren. Deze voortvarendheid sprak mij 
bijzonder aan, hoewel ik tegelijkertijd proefde dat je enigszins twijfelde aan mijn 
doelgerichtheid. Kennelijk bezit je zoveel mensenkennis, dat je mij al op voorhand 
wilde behoeden voor het af en toe verlaten van de hoofdlijn. Ik dank je voor dat 
juiste inzicht, en voor het advies  - zonder omhaal gegeven - om, als het even kon, 
de bocht af te snijden. Ik heb me vanaf dat moment voorgenomen niet alleen goed 
wetenschappelijk te werk te gaan, maar ook pragmatisch te blijven, om tot het 
uiteindelijke doel te komen: artikelen en een promotie.
 De fase die tot het eerste artikel moest leiden was voor mij nog behoorlijk 
nieuw en dat was te merken in de reacties daarop van jouw kant: te weinig 
structuur. Vooral door jouw goede aanwijzingen  werden volgenden versies 
langzaamaan beter. Ook verder in het traject heb je nog regelmatig geholpen om 
mijn schrijven te verbeteren, en het vooral eenvoudig te houden. Je hebt me 
daarmee geleerd wat objectief wetenschap bedrijven is. Mijn schrijven werd 
geleidelijk iets makkelijker.
 Ik dank je ook met name voor jouw niet aflatende stimulansen om volgende 
stappen te zetten, en jouw initiatieven om weer voortgang in het proces te 
brengen indien nodig. Jij was voor mij een ideale procesbewaker, en zeer kundig 
op dat terrein. De wijze van ons contact waarop wij over resultaten of concept 
artikelen  overlegden mag wel uniek worden genoemd, is mijn ervaring na 8 jaar 
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gezamenlijke inspanningen. Nooit werd een mailtje van mij niet prompt beantwoord 
door jou, vrijwel altijd direct voorzien van adviezen, die de marsroute helder 
schetsten, en dat in een minimum aan woorden of tekens (je efficientie in deze is 
onovertroffen; hier van zinnen te spreken zou zeker misplaatst zijn). Daarbij 
maakte het zelfs niet uit of ’t weekend was of – nog bijzonderder – jij met vakantie 
was. Ik kan niet anders zeggen: ik heb dat bijzonder gewaardeerd en prettig 
gevonden en wil je ook daarvoor van harte bedanken.
 Snel is het desalniettemin niet gegaan, deze promotie. Ik had in mijn 
ongeduldig enthousiasme aanvankelijk eind 2007 in mijn hoofd geprent. Het is 
een stuk opgeschoven in de tijd. Enfin, nu het gereed is,  telt feitelijk alleen het 
resultaat.
Dr. J.H. Vercoulen, copromotor
Beste Jan, jij was het die mij verwelkomde direct bij mijn kennismaking met jou 
op ULC 3 als longarts op de longrevalidatie en opvolger van Johan. Maar, 
kenmerkend voor een gedreven wetenschapper als jij, stelde je wel een 
voorwaarde. Die was het doen van wetenschappelijk onderzoek. Je bofte, en ik in 
feite ook, omdat ik mijn algemene praktijk in Almere had verlaten om meer met 
de medische inhoud van de longgeneeskunde bezig te zijn en om wat theoretische 
verdieping op te zoeken. Zodoende was ik bij de academische longafdeling van 
de Radboud universiteit terechtgekomen. Het bleek een toevalstreffer: jij zocht 
iemand om in jouw juist begonnen research activiteit deel te nemen, ik zocht de 
uitdaging van wetenschappelijk werk. Ik was erg blij met onze ontmoeting 
derhalve. De eerste 2 researchbesprekingen, toen nog met Hans Folgering erbij, 
waren voor mij een verademing. Dit ging over iets nieuws, complex en toch met 
evidente verbinding naar de longartspraktijk! Een wetenschappelijke uitdaging 
werd het zeker, aangezien het gepubliceerd krijgen van jouw basis concept, het 
NIAF, niet van een leien dakje ging. Maar toen het eerste schaap eenmaal over de 
dam was, kwam het vervolg gestaag op gang met diverse artikelen, waaronder 
ook de eerste van mij. Jij trad daarin op als stuurman en coach, hetgeen al gauw 
uitmondde in een wekelijkse researchbespreking op jouw kamer op donderdag 
met Leonie en Jeanette, en later ook Lonneke, een treffen waar ik heel leuke en 
vaak leerzame herinneringen aan heb. Je hebt me de ingewikkelde achtergronden 
van het Health Status model met zijn hoofddomeinen en subdomeinen telkens 
goed kunnen verhelderen, waaruit je kwaliteiten als docent goed naar voren 
kwamen.
 Je hebt  altijd een rotsvast geloof gehad in de kwaliteit van het NIAF concept, 
jouw geesteskind, als een innovatie in de pulmonologische literatuur. Zelf had ik 
er ook direct een heel ‘ goed gevoel’ bij, maar dat is geen waarborg voor succes. 
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Het doordringen in de pulmonologische literatuur viel ons in eerste instantie 
niet mee: het roeien tegen de stroom op, en het naar de kroon steken van gevierde 
auteurs met hun gevestigde begrippen als SGRQ en CRQ, is geen sinecure. Door 
jouw groot vertrouwen en realisme heb ik zelf nooit getwijfeld of mijn verlate 
roeping misschien geen haalbare kaart zou zijn. Ik dank je oprecht voor je 
vasthoudende geloof in de waarde van het NIAF en het daarop gebaseerde 
project waaraan ik me verpand had. Zonder dat had ik dit project vast niet met 
succes voltooid! In de fase na de statistische bewerkingen en analyses kwam het 
aan op het schrijven van wetenschappelijke artikelen. Dat viel in het begin niet 
mee, maar telkens hielp je mij de vele concept teksten beter gestroomlijnd te 
krijgen en er een strak en afgemeten betoog van te maken, zonder onnodige 
franje. Ik ben je veel dank verschuldigd voor de serieuze manier waarop je daar 
iedere keer weer tijd in stak, en op vele plekken nuttige suggesties aanleverde. Je 
was soms een zeer kritisch lezer van mijn drafts, maar ik moet zeggen: je 
aanmerkingen zorgden er wel steeds voor dat het concept artikel er beter door 
werd, en maakten mij scherper bewust van de verschillende betekenissen van 
veel gebruikte termen rond het begrip Health Status. Jan, dank voor je weten-
schappelijke voorbeeldfunctie, je was een inspirerende co-promotor.
Dr. y.f. Heijdra, longarts, associate Professor, copromotor
Beste Yvonne, jouw aandeel in de artikelen die we met elkaar gepubliceerd 
kregen was groot. Dus alvast hier mijn bijzondere dank aan jou voor een zeer 
belangrijk en gedegen inbreng in het rijp maken van mijn concepten voor 
submission. Jouw betrokkenheid kwam niet al ten tonele vanaf scratch, de eerste 
bespreking over een eventueel promotie traject met Richard, Jan, Johan en mij in 
mei 2004. Het was echter slechts een kwestie van weken, dat jij bij alle volgende 
besprekingen aanwezig was, en sindsdien heb je een onvervangbare rol gespeeld 
bij alle artikelen, en in het bijzonder bij het 2e artikel over HS en inspanningsver-
mogen. Door jouw scherpe analyse van de resultaten en deskundigheid op het 
gebied van de inspannings(patho)fysiologie bij longaandoeningen waren we in 
staat een boeiend artikel te presenteren aan het tijdschrift Respiration. Samen 
met Hanneke hebben we, en vooral jij, nog een sloot tijd besteed aan het 
herbeoordelen van zo’n 135 fietsergometrie testen van de onderzoeksgroep om 
tot een goed hanteerbare typologie van inspanningbeperking te komen, d.w.z. 
de oorzaak daarvan. Leuk werk, waar ik nog veel extra’s van heb opgestoken. 
Het liet zien, dat jij je rol als begeleider in wetenschappelijk onderzoek heel 
serieus neemt, en dat heb ik zeer gewaardeerd.
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Johan Molema, collega, medeauteur
Beste Johan, jij was vanaf het eerste begin zeer nauw betrokken bij het idee om 
het pas uit het ei gekomen NIAF te laten (in)filtreren in de wetenschappelijke 
literatuur van ons vakgebied. Je hebt me wel eens gezegd dat het NIAF – het hele 
idee achter het bepalen van gezondheid van COPD patienten vanuit holistisch 
perspectief – een lang gekoesterde wens van jou in vervulling deed gaan. 
Begrijpelijk, gezien jouw intense affiniteit met de longrevalidatie. En daarom 
ook niet verrassend dat jij een enorm aandeel hebt genomen in het leggen van de 
meest essentiele basis voor wetenschappelijk onderzoek: het opzetten van een 
betrouwbare database. Door vooral jouw inspanningen is het gelukt zo’n grote 
en complete set onderzoeksgegevens bijeen te krijgen. Ruim 360 personen 
werden benaderd, maar liefst 168 van hen namen deel aan het onderzoek met 2 
uitgebreide test sessies, met een jaar tussenpoos, en nog maandelijkse 
verstrekking van gegevens over het beloop in dat tussenliggende jaar. Een 
bijzondere prestatie! Toen ik in Nijmegen was aangeschoven bij julie research 
besprekingen, besefte ik me maar al te goed, welke buitenkans hier voor mij lag. 
De onderzoeksresultaten lagen immers voor het oprapen, kant en klaar in SPSS 
format. Ik ben met name jou hiervoor schatplichtig, en daarom deel jij onverkort 
in het gezamenlijk succes. Een en ander leidde bij mij wel tot een zekere hoogmoed 
met betrekking tot de benodigde tijd om op dit materiaal te promoveren, maar 
die inschattingsfout is geheel voor mijn disconto.
 Naast deze conditio sine qua non voor mijn promotietraject, heb je ook steeds 
door de jaren heen belangrijke adviezen gegeven over het duidelijk en goed 
neerzetten van de boodschap die in de uitkomsten van de studies en het 
onderliggende HS model opgesloten zat. Ik bedank je oprecht voor die zeer 
nuttige en unieke bijdragen, die de uiteindelijke artikelen mede hebben gevormd. 
En dat was veel meer dan de vaak pakkende titels, waarmee jij kwam aandragen. 
Het was tevens stimulerend te merken dat jij enthousiast reageerde op de uitge-
kristalliseerde resultaten, waarnaar je al lang had zitten uitkijken. Het gaf mij 
energie om het plan te volbrengen.
Leonie Daudey, medeauteur en mede-promovend(us) -a
Beste Leonie, jou ken ik vanaf mijn komst naar Dekkerswald, waar ik al vlug 
betrokken raakte bij het onderzoeksproject NIAF, waar jij als jonge psychologe 
samen met Jan, Johan en anderen de eerste resultaten met elkaar evalueerden. In 
de vergaderruimte van ULCD overlegde jij sheets met voorlopige resultaten van 
de 1e fase van jouw promotietraject. Ik keek en luisterde met nieuwsgierige 
aandacht naar jullie werk. Het was boeiend. Aangezien jij al wat langer met de 
materie aan het werk was, en ik nog moest opstarten met een onderzoeksplan, 
had jij een flinke voorsprong op mij waar ’t gaat om vaardigheden met het 
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hanteren van de SPSS database. Heel veel praktische hulp heb ik van jou gehad, 
om wegwijs te worden met zo’n krachtige data machine. Alles was gecodeerd, en 
niet onmiddelijk herleidbaar tot bekende parameters. Zonder jouw frequente 
hulp en instructies, ook t.a.v. sommige statistische bewerkingen had ik het niet 
gered. Heel veel dank daarvoor.
 Eenmaal met het bewerken van de data meer vertrouwd, hadden we 
regelmatig contact tijdens en buiten de researchbesprekingen met Jan om, 
waarbij van allerlei aan de orde kwam. De onzekerheden omtrent voortgang en 
succes met ons beider onderzoek, de onzekerheid omtrent verlenging van jouw 
aanstelling bij de vakgroep medische psychologie en zo meer. Onze gemeen-
schappelijke ambitie was een sterk bindende factor, en in die hoedanigheid ben 
ik je als persoon ook erg gaan waarderen. Ik herinner me nog goed dat we samen 
een serie patienten uit het bestand kritisch hebben geevalueerd vanwege 
vermoeden op chronisch astma met gefixeerde bronchusobstructie, die voor 
mijn eerste paar artikelen geëxcludeerd moesten worden. Bij die gelegenheid 
kon ik door mijn kennis op het gebied van astma, COPD en longfunctiemetingen 
jou wat achtergrondinformatie geven die jij weer goed kon gebruiken. Ik vond 
het prettig om wat terug te kunnen doen voor jou.  Ook als medeauteur heb je een 
goede bijdrage geleverd. Toen ik al een tijdje weg was uit Dekkerswald, en jij 
voor je werk ook naar elders ging, hebben we met tussenpozen via de mail 
contact gehouden, soms nog om onderzoekgegevens te controleren, of namen 
van sub-domeinen te verifieren, maar vooral om ieders voortgang te horen. Ik 
voel nog steeds die band die toen is ontstaan, en leef erg mee met jouw prestaties. 
Vanzelfsprekend heb ik je onlangs gevraagd om paranimf te zijn bij mijn 
promotie.
Jeannette Jacobs-Peters, medeauteur en mede-promovend(us) -a
Beste Jeanette, bijna net als met Leonie, leerde ik jou kennen als promovenda in 
het research clubje rond Jan. Ik meen dat jij iets later toetrad dan ik, maar dat 
was eigenlijk niet zo van betekenis. Jij deed ook mee, vanaf 2005?, in een project 
dat zeker 3 promoties moest gaan opleveren. Jij en Leonie, beiden psycholoog, 
werden al snel onafscheidelijk, deden voor de patienten min of meer dezelfde 
testen, en onze 3 onderzoeksactiviteiten werden in een adem doorgesproken 
tijdens de wekelijkse sessies. Ik kon altijd met plezier gadeslaan hoe jij met grote 
nuchterheid en inwendig plezier Jan van repliek diende als die weer een ‘goed’ 
idee had bedacht. Dat ging ongeveer zo: “Ja Jan, dat zou wel mooi zijn, maar hoe 
dacht je aan die gegevens te komen”? Jan: “ Ja, Jeannette, goeie vraag  . . . . ; bedenk 
jij daarvoor eens een plan”. Of het die handige tactiek van Jan was of jouw eigen 
inventiviteit weet ik niet precies, maar je hebt met bijv. de ontwikkeling van het 
NCSI en de grafische weergave van patient scores in elk geval indruk gemaakt. 
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Het was duidelijk dat jij in wetenschappelijk onderzoek wel je creativiteit kon 
etaleren. Ook van jou kreeg ik meermalen handige instructies ten aanzien van 
het gebruik van trucs met SPSS of excel, die mijn semi-digibeet-zijn een tijdje 
onzichtbaar konden houden. Ik ben je dankbaar voor je grote vaardigheid op dat 
gebied, en je optimistische natuur. Het was een groot plezier om samen zo op te 
trekken.
 Ook jij hebt een aandeel in mijn productie gehad, het 2e artikel, en daarom 
ook als medeauteur mijn dank voor je hulp en advies bij het tot stand komen van 
de definitieve versie. Ook aan jou heb ik al langere tijd terug gedacht als mijn 
paranimf als ’t zover zou zijn. Eind 2012 kwam daarom als het mooie moment 
voor mij, om jou daarvoor te benaderen. En bijzonder leuk was je reactie: je vond 
het een hele eer! 
Lonneke Boer, medeauteur en mede-promovend(us) -a
Beste Lonneke, jij hebt een zeer wezenlijk deel van het werk gedaan, door vanaf 
het allereerste moment mee te denken in de aanpak van de studie van de 
exacerbaties, wat een complexe zaak bleek. Keuzes van definities moesten 
worden gemaakt – Anthonisen I, II en event-based exacerbation etc. – aan de 
hand van de beschikbare antwoorden uit de vragenlijst van de follow up studie, 
tussen Voor- en Nameting. Als promovenda van Jan, de vierde in volgorde voor 
zover ik weet, kwam jij een jaartje later in ons research team, maar al snel 
draaide je mee alsof dat de gewoonste zaak van de wereld was.  Je viel op door je 
onafhankelijke kijk op methodologische vragen, hetgeen erg waardevol was 
juist bij de studie die wij tweeen gingen uitwerken. Jouw kennis van statistiek 
maakte dat ik vol vertrouwen alle analyses voor die studie aan jou kon overlaten, 
een mooie tijdsbesparing voor mij! Veel dank voor al dat werk (en de ettelijke 
herhalingen die de analyses nog kregen). Jij hebt ook veel geduld moeten 
opbrengen om de acceptatie van ons exacerbatie artikel te kunnen begroeten, 
maar na langdurig voorbereidend werk en diverse submission pogingen is het 
uiteindelijk toch fraai gelukt. Samen met Jan heb jij er nog extra overleg met de 
statisticus van de Radboud aan gespendeerd. Na zo’n 6 jaar was ’t dan tenslotte 
zo ver! Dank voor al je inzet en inbreng Lonneke.  
Hanneke van Helvoort, hoofd Longfunctie laboratorium uCCZ
Beste Hanneke, jij hebt in de bewerking van het tweede artikel over maximaal 
inspanningsvermogen en Health Status een grote rol gespeeld. Wij kenden 
elkaar van de gemeenschappelijke werkzaamheden op Dekkerswald, waar jij 
kort voor je promotie als hoofd Longfunctie laboratorium was komen werken. 
Via de patientenzorg en de frequente refereerbijeenkomsten hadden we heel 
regelmatig contact. In 2006 toen mijn opzet voor het inspaningsartikel, samen 
Dankwoord | 147
met Jan en Yvonne, zo’n beetje zijn vorm had gekregen, kreeg jij als vanzelfspre-
kend een belangrijke taak in het herbeoordelen van talloze fietstesten, die ten 
aanzien van de fysiologische reden om de inspanning te staken opnieuw moesten 
worden geinterpreteerd. Ruim over 100, dus ga er maar aan staan! Jij en Yvonne, 
hebben daarin het voortouw genomen, ik deed er mijn deeltje nog aan mee, en 
voerde de nieuwe data in de database in. Toch was het een klus, en dat was het 
stellig, die vlot door jullie werd afgerond. Hulde voor dat belangrijke karwei, het 
heeft de waarde van ons gezamenlijke artikel er behoorlijk mee verhoogd. bijna 
onnodig te zeggen dat je ook bij de concepten van het artikel een hele 
gewaardeerde inbreng hebt gehad, en het geheel ook kritisch hebt doorgelezen. 
Hanneke, veel dank voor die belangrijke hulp en inbreng.
Andre Hijmans, senior longfunctie analist, longfunctie laboratorium uLCD
Beste Andre, zowel tijdens mijn actieve periode als longarts, als in mijn 
hoedanigheid van onderzoeker in het Adaptatie project kreeg ik altijd een 
welwillende Andre te spreken, die mij snel en adequaat kon helpen om gegevens 
te checken in de originele longfunctie rapporten. Ten behoeve van mijn 
onderzoek heb je me meermalen gegevens aangeleverd, die nodig bleken voor 
precieze beschrijving van de meetmethodieken op het longfunctie laboratorium. 
Ook nog 3 jaar na mijn vertrek van het ULCD heb ik je nog om informatie moeten 
vragen over de spierkrachtmetingen in het kader van het reviseren van mijn 3e 
artikel. Ik kreeg vlot de vele detailgegevens van jouw gemaild inclusief litera-
tuurverwijzingen! Bijzondere dank aan jou dat je zo belangeloos hebt bijgedragen. 
Tot slot: bedank ik enkele mensen die wat verder van het Nijmeegse afstonden de 
afgelopen jaren, hoewel, niet voor een ieder gaat dat laatste op.
 In algemenere zin waren velen van mijn vrienden en familiekring op gezette 
tijden zeer belangstellend hoe het vorderde. Ook oude en nieuwe collega’s 
(longartsen resp. specialisten ouderengeneeskunde) hoorden daartoe. Vaak heb 
ik verzucht dat het nog wel vooruitgang boekte, maar toch wel erg langzaam. 
Hoeveel hoop op een feestelijke afronding ik toen bij hen de bodem heb ingeslagen 
hebben mijn dierbaren mij, god zij dank, nooit laten blijken. Soms hoorde ik het 
vertrouwde cliché dat het toch nergens voor hoefde, m.a.w. dat ik er dus ook net 
zo goed mee kon stoppen. Volkomen waar, maar toch . . Ik deed het niet voor mijn 
carrière, die in die periode al een switch had genomen, noch voor volk of 
vaderland. In feite alleen maar voor mijn gevoel van trots, dat ik een promotie 
traject, met veel plezier begonnen, deze keer wel zou afmaken. In vroeger dagen 
van mijn loopbaan had ik een minder prettige afloop meegemaakt - zoiets sterkt 
een mens in zijn drijfveren. Voor mij was het stimulerend om regelmatig belang-
stellende vragen over het verloop van het werk te krijgen.
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 Koos, jou wil ik hier even apart noemen, als goede vriend en tevens een 
tijdlang collega in Nijmegen, ieder met heel eigen taken overigens. Maar met jou 
kon ik, juist gezien jouw hoge positie in het academische wereldje, dingen 
bespreken aangaande mijn wetenschappelijke activiteiten, die geen ander 
zonder enige drempel met mij kon delen. Het was altijd nuttig en tegelijk prettig 
relativerend om de ins en outs van het moeizame proces met elkaar even door te 
nemen op onze avondjes bij jou of mij thuis of tijdens zeilweekends in Friesland. 
Dank voor je steun en stabiele kompas door de jaren heen.
Dan nog meer in de persoonlijke sfeer een woord van dank. Ten eerste aan mijn 
twee zoons, Maarten en Otto. Jongens, ik weet dat het jullie ook altijd een soort 
eer is geweest dat iemand van ons zo’n karwei ging klaren. Zou een van jullie het 
zijn geweest, mijn bewondering zou groot zijn. Ieder van jullie heeft inmiddels al 
bewonderenswaardige bergen verzet, en die verdienen misschien wel veel meer 
respect. Nu deze prestatie zijn voltooing nadert, voel ik het als een natuurlijke 
zaak, dat wij daar alledrie blij en trots op zijn. Jullie hebben ook altijd meegeleefd 
met mijn geploeter, en de spaarzame successen die er te vermelden waren. Dank 
voor jullie oprechte interesse.
 Tenslotte, mijn lieve partner en echtgenoot. Lily, jij bent van grote steun 
geweest in alle jaren die ik al met werk en onderzoek bezig ben. Je hebt je achter 
mijn wens en plan geschaard om nog een tweede keer een promotietraject in te 
gaan; voorwaar, een gedurfde onderneming, na een mislukte poging jaren 
geleden! Dat je je opnieuw een periode met spanning ging aanhalen, maar daar 
desondanks niet voor bent geweken, is misschien wel de belangrijkste succes 
factor geweest van mijn promotie avontuur. Daarvoor heel veel dank. Je vond, en 
vindt, het fijn voor mij dat het nu gaat lukken. 
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CurrICuLuM VITAe
Tewe Laurens Verhage is geboren op 16 mei 1951 te Gorssel, en deed Gymnasium 
beta aan het Stedelijk Lyceum te Zutphen. Hij studeerde van 1969 tot 1977 aan 
de universiteit van Utrecht, studierichting medicijnen. Na het behalen van het 
artsexamen (met genoegen) vervulde hij diverse arts asstentschappen, o.a. in 
het Juliana ziekenhuis te Veenendaal (1978-1980). Vanaf 1981 volgt hij de 
specialisatie tot longarts in het Sint Antonius ziekenhuis te Utrecht en Nieuwegein. 
Hij werkte als longarts in het AMC, Amsterdam, van 1988 tot 1990, en vervolgens 
gedurende ruim 10 jaar in Almere, in het Flevo Ziekenhuis. In 2004 vervolgde 
hij zijn loopbaan in het Universitair Long Centrum Dekkerswald (ULCD), als 
academisch staflid, met aandachtsgebied longrevalidatie. In deze periode werden 
de eerste initiatieven ontplooid voor een wetenschappelijk onderzoek, hetwelk 
zou uitmonden in een proefschrift. Na de werkzaamheden bij het ULCD, koos hij 
in 2007 voor de opleiding tot specialist ouderengeneeskunde. Het theoretische 
gedeelte van de opleiding werd gevolgd bij Gerion, het opleidingsinstituut van de 
Vrije Universiteit, Amsterdam. Het praktische gedeelte werd doorlopen bij de 
stichting Coloriet in Lelystad. De specialisatie ouderengeneeskunde werd voltooid 
in september 2009.
 Sindsdien is hij werkzaam als specialist ouderengeneeskunde bij Coloriet, 
met name ten behoeve van de vestiging in Dronten. Het werk omvat het vak  ouderen- 
 geneeskunde met een all round takenpakket, met medische eindverantwoord-
lijkheid voor ruim 100 bewoners. Daarnaast neemt hij deel aan het Advies 
Behandel Centrum Coloriet ten behoeve van voornamelijk cognitieve diagnostiek 
en zorg advisering. Hij was tot begin 2012 betrokken bij de voorbereidingen van 
een COPD revalidatieprogramma in het verpleeghuis, vestiging Lelystad.  Tewe 
Verhage bereidt zich thans voor op deelname aan het landelijk en regionaal 
Parkinson netwerk, als onderdeel van de ontwikkeling van specialisaties binnen 
de medische vakgroep. Tewe Verhage is getrouwd en woont in Bussum.
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 1) Het meten van Health Status met een methode die zowel fysiologische, als ook 
aspecten van klachten, functionele beperkingen en kwaliteit van leven in 
 aanmerking neemt, biedt veel voordelen als diagnostisch instrument boven het 
toepassen van longfunctie gegevens en een quality of life (QoL) instrument  
(dit proefschrift).
 2)  Het maximale zuurstofopname vermogen wat gemeten wordt (VO2 max)  
tijdens fietsergometrie is een fysiologische maat die veel functies  integreert. 
Desalniettemin kan het niet dienen als maat voor de gezondheid (Eng. health 
status), welke nog minstens drie andere hoofddomeinen omvat (dit proefschrift).
 3)  Pulmonale cachexia, het optreden van spiermassa verlies door COPD, treedt 
vaker bij vrouwen dan bij mannen op (dit proefschrift).
 4) De bevinding dat vrouwen met COPD een lagere CO diffusie capaciteit hebben 
en vaker spiermassa verlies vertonen dan mannelijke patiënten, en dat deze 
twee factoren gepaard gaan met meer uitgesproken radiologisch emphyseem, 
voedt de hypothese dat bij vrouwen de pathologie meer neigt naar het fenotype 
emphyseem dan naar het fenotype chronische (obstructieve) bronchitis  
(dit proefschrift).
 5)  De nadelige invloed van matig ernstige exacerbaties van COPD op de Health 
Status van patiënten is gering. Het vergt diverse jaren met regelmatig optredende 
matig ernstige exacerbaties voordat de Health Status meetbaar verslechtert  
(dit proefschrift).
 6)  Met de invoering van een instrument als het NIAF om de diagnostiek van 
patiënten met COPD aan te vullen met het bepalen van de Health Status, wordt 
recht gedaan aan de werkelijke behoefte van de patiënt: een holistische 
 benadering van zijn/haar klacht (dit proefschrift).
 7)  In weerwil van bijna onbegrensde medische technologie, valt de mortaliteit  
van COPD begin van de 21 e eeuw beter te voorspellen met een even simpel als 
subjectief gegeven dan welke longfunctie parameter ook: de dyspnoea index 
(Nishimura, Chest 2002).
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 8)  Het bewijs voor een (systemische) inflammatoire oorzaak van spiermassa 
 verlies bij COPD is nog niet geleverd. Vrijwel alle kenmerken van skeletspier­
dysfunctie worden ook aangetroffen bij  lichamelijk inactieven (Wagner, 
Respirology 2006).
 9)  Obesitas is ook een vorm van energieverspilling, omdat er een sterke correlatie 
bestaat tussen energieverbruik in een samenleving, waarin  apparaten 
 lichamelijke arbeid vervangen, en het percentage obese mensen. Rantsoenering 
van energieverbruik in huishoudens, niet van calorieën, zal het probleem 
 kunnen oplossen (ontleend aan Armaroli e.a. Angew. Chem. Int. Ed. 2007).
 10) Er is niets wat door statines (cholesterol verlagende middelen) qua hoogte  
zo goed in stand gehouden wordt als de winst op de recepten voor de 
 farmaceutische bedrijven, (NRC Handelsblad, Wetenschap 23­01­2011).
 11) Wat de wetenschap aan kennis voortbrengt moet wel ingepast worden in de 
grotere werkelijkheid van ons bestaan; want “logic does not exist in the real 
world”, (ontleend aan I. Mc Gilchrist, The Master and his Emissary, 2010).  
Tewe L. Verhage, 2 juli 2013
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